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A B S T R A C T
Background
Antipsychotic agents are often used to treat neuropsychiatric symptoms (NPS) in people with dementia although there is uncertainty
about the effectiveness of their long-term use for this indication and concern that they may cause harm, including higher mortality.
When behavioural strategies have failed and treatment with antipsychotic drugs is instituted, regular attempts to withdraw them have
been recommended in guidelines. Physicians, nurses and families of older people with dementia may be reluctant to stop antipsychotics,
fearing deterioration of NPS.
This is an update of a Cochrane Review published in 2013.
Objectives
To evaluate whether withdrawal of antipsychotic agents is successful in older people with dementia and NPS in primary care or nursing
home settings, to list the different strategies for withdrawal of antipsychotic agents in older participants with dementia and NPS, and
to measure the effects of withdrawal of antipsychotic agents on participants’ behaviour and assess safety.
Search methods
We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), theCochrane Library,
MEDLINE, Embase, PsycINFO, CINAHL, LILACS, clinical trials registries and grey literature sources up to 11 January 2018.
Selection criteria
We included all randomised, controlled trials comparing an antipsychotic withdrawal strategy to continuation of antipsychotics in
people with dementia who had been treated with an antipsychotic drug for at least three months.
Data collection and analysis
We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the
quality of evidence for each outcome using the GRADE approach.
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Main results
We included 10 studies involving 632 participants. One new trial (19 participants) was added for this update.
One trial was conducted in a community setting, eight in nursing homes and one in both settings. Different types of antipsychotics
at varying doses were discontinued in the studies. Both abrupt and gradual withdrawal schedules were used. Reported data were
predominantly from studies at low or unclear risk of bias.
We included nine trials with 575 randomised participants that used a proxy outcome for overall success of antipsychotic withdrawal.
Pooling data was not possible due to heterogeneity of outcome measures used. Based on assessment of seven studies, discontinuation
may make little or no difference to whether or not participants complete the study (low-quality evidence).
Two trials included only participants with psychosis, agitation or aggression who had responded to antipsychotic treatment. In these
two trials, stopping antipsychotics was associated with a higher risk of leaving the study early due to symptomatic relapse or a shorter
time to symptomatic relapse.
We found low-quality evidence that discontinuation may make little or no difference to overall NPS, measured using various scales (7
trials, 519 participants). There was some evidence from subgroup analyses in two trials that discontinuation may reduce agitation for
participants with less severe NPS at baseline, but may be associated with a worsening of NPS in participants with more severe NPS at
baseline.
None of the studies assessed withdrawal symptoms. Adverse effects of antipsychotics (such as falls) were not systematically assessed.
Low-quality evidence showed that discontinuation may have little or no effect on adverse events (5 trials, 381 participants), quality of
life (2 trials, 119 participants), or cognitive function (5 trials, 365 participants).
There were insufficient data to determine whether discontinuation of antipsychotics has any effect on mortality (very low-quality
evidence).
Authors’ conclusions
There is low-quality evidence that antipsychotics may be successfully discontinued in older people with dementia and NPS who have
been taking antipsychotics for at least three months, and that discontinuation may have little or no important effect on behavioural
and psychological symptoms. This is consistent with the observation that most behavioural complications of dementia are intermittent
and often do not persist for longer than three months. Discontinuation may have little or no effect on overall cognitive function.
Discontinuation may make no difference to adverse events and quality of life. Based on the trials in this review, we are uncertain whether
discontinuation of antipsychotics leads to a decrease in mortality.
People with psychosis, aggression or agitation who responded well to long-term antipsychotic drug use, or those with more severe NPS
at baseline, may benefit behaviourally from continuation of antipsychotics. Discontinuation may reduce agitation for people with mild
NPS at baseline. However, these conclusions are based on few studies or small subgroups and further evidence of benefits and harms
associated with withdrawal of antipsychotic is required in people with dementia and mild and severe NPS.
The overall conclusions of the review have not changed since 2013 and the number of available trials remains low.
P L A I N L A N G U A G E S U M M A R Y
Stopping or continuing long-term antipsychotic drug use for behavioural and psychological symptoms in older people with
dementia
Review question
We investigated the effects of stopping antipsychotic drugs in older people with dementia who had been taking them for three months
or longer.
Background
People with dementia may have symptoms and behavioural problems that can be distressing and difficult for carers to manage. Such
symptoms (often described as neuropsychiatric symptoms, or NPS) include anxiety, apathy, depression, psychosis (hallucinations and
delusions), wandering, repeating words or sounds, shouting, and behaving in agitated or aggressive ways, or both.
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Antipsychotic drugs are often prescribed with the aim of controlling these symptoms and behaviours, although most current guidance
suggests these drugs should only be used for short periods of time for the most challenging behaviours. This is largely because these
drugs are thought to have risks of side effects (including some that are serious), and because many behavioural problems improve
without treatment. However, many people with dementia continue to take antipsychotic drugs over long periods of time.
This review investigated whether it is feasible for older people with dementia and NPS to stop antipsychotic drugs which they have
been taking for at least three months. This is an update of a Cochrane Review published in 2013.
Methods
We searched up to 11 January 2018 for any study that randomly allocated some people with dementia who were taking antipsychotic
drugs to continue this treatment and others to stop taking antipsychotic drugs. Study participants were followed up over a period of
time to see what happened.
Results
We included 10 studies with a total of 632 participants in our review. We added one new study with 19 participants for this update.
Most participants lived in nursing homes. The studies varied considerably with regard to the people they included, the methods they
used and the outcomes they measured.
Because the studies were so diverse, it was not possible to combine all the data numerically. We found low-quality evidence that older
people with dementia may be able to stop long-term antipsychotics without their behavioural problems getting worse. However, in some
people who had psychosis, agitation or aggression and who had improved significantly when they first started antipsychotic treatment,
we found that stopping the drugs may increase the risk of the behavioural problems getting worse again. On the other hand, agitation
decreased after stopping the drugs in some participants whose NPS at the beginning of the studies was relatively mild.
We did not find enough evidence to know whether stopping antipsychotics has beneficial effects on quality of life, thinking and
remembering, or the ability to carry out daily tasks, nor if the risk of harmful events - such as falls - is reduced. We are uncertain whether
stopping antipsychotics leads to people living longer.
Quality of the evidence
Overall, evidence was low- or very low-quality. This means we have limited or little confidence in the results, and that it is possible
that other similar research could find something different. The main reasons for this assessment were that there were few studies that
included few people, and a risk that results were not fully reported. All included studies had problems recruiting enough participants,
making it more difficult for them to detect effects of stopping antipsychotics.
Conclusions
Limited evidence suggests that stopping long-term antipsychotic drug use in older people with dementia and NPSmay be done without
making their behaviour worse. There may be benefits especially for those with milder NPS. There may be people with more severe
symptoms who benefit from continuing treatment, but more research in people with both milder and more severe NPS is needed to
be sure about this. The overall conclusions have not changed since the last version of this review and the number of included trials is
still low.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Discontinuation compared to continuation of antipsychotic medication for behavioural and psychological symptoms in older participants with dementia
Patient or population: older people with dementia who had been taking an ant ipsychot ic drug for at least 3 months
Setting: any sett ing
Intervention: discont inuat ion of long-term antipsychot ic drug use
Comparison: cont inuat ion of long-term antipsychot ic drug use
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk
Continuation
antipsychotics
Corresponding risk
Discontinuation antipsy-
chotics
Success of withdrawal
from antipsychotics
Measured with a variety
of outcomes related to
failure to complete the
study
Follow-up: 1 to 8
months
In 7 studies there was no overall dif f erence in the outcomes reported for
success of withdrawal
In two studies of part icipants with psychosis, aggression or agitat ion who
had responded to ant ipsychot ic treatment, discont inuat ion accelerated
symptomatic relapse without af fect ing the number of part icipants expe-
riencing a relapse in one study and was associated with a higher rate of
symptomatic relapse in the other study
In one small study a high proport ion of the part icipants in the discont inu-
at ion group failed to complete the study
575 (9 RCTs) ⊕⊕©©
LOWab
Our intended primary
outcome, success of
withdrawal def ined as
the ability to complete
the study in the allo-
cated study group, i.e.
no failure due to wors-
ening of NPS or relapse
to ant ipsychot ic drug
use, was not reported
in any study. We used
the dif ference between
groups in the number of
non-completers of the
study as a proxy for our
primary outcome. How-
ever, data could not be
pooled due to variability
in outcome measures
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Behavioural and psy-
chological symptoms
Assessed with various
scales.
Follow up: 1 to 8
months
In 2 pooled studies there was no dif ference in NPI scores between the
cont inuat ion and discont inuat ion groups (see Data and analyses and
Figure 1).
In f ive non-pooled studies, there was no dif ference in the outcomes on
scales measuring overall behaviour and psychological symptoms between
groups
519 (7 RCTs) ⊕⊕©©
LOW©b©c
Data could only be
pooled for 2 studies
due to variability in out-
come measures
The two pooled stud-
ies performed sub-
group analyses accord-
ing to baseline NPI-
score (≤ 14 or > 14)
. In one study, some
part icipants with milder
symptoms at baseline
were less agitated at
three months in the dis-
cont inuat ion group. In
both studies, discont in-
uat ion led to worsening
of NPS in some part ici-
pants with more severe
baseline NPS
Adverse events
Assessed with various
scales.
Follow-up: 1 to 8
months
In 5 studies, there was no evidence of a dif ference between groups in
adverse events
381 (5 RCTs) ⊕⊕©©
LOWab
Data could not be
pooled due to variability
in outcome measures.
Adverse events of an-
t ipsychot ics were not
systematically reported
Quality of life (QoL)
Assessed with DCM or
QoL-AD.
Follow-up: 3 months to
25 weeks
In 2 studies, there was no evidence of an ef fect on quality of lif e 119 (2 RCTs) ⊕⊕©©
LOWbc
Data could not be
pooled due to variability
in outcome measures
There was no dif fer-
ence between discon-
t inuat ion and cont inua-
t ion group in the overall
cohort or in subgroups
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with baseline NPI score
above or below the me-
dian (14)
Cognitive function
Assessed with various
scales.
Follow-up: 1 to 8
months
In 5 studies, there was no evidence of an impact on scales measuring
overall cognit ive funct ion
In one of these trials, discont inuat ion improved a measure of verbal
f luency
365 (5 RCTs) ⊕⊕©©
LOWbc
Data could not be
pooled due to variability
in outcome measures
Use of physical re-
straint
Follow-up: 1 month
In one study there was no ef fect on the use of physical restraint 36 (1 RCT) ⊕©©©
VERY LOWcd
Conclusion made by the
authors but not sup-
ported by data.
Mortality
Assessed with various
scales.
Follow-up: 4 to 12
months
In two studies there was no evidence of an ef fect on mortality 275 (2 RCTs) ⊕©©©
VERY LOWcd
Data could not be
pooled due to clinical
heterogeneity.
In a long-term follow-
up of 36 months af -
ter the 12 months
randomised discont in-
uat ion trial (Devanand
2012), we were uncer-
tain whether discont in-
uat ion decreased mor-
tality
* The basis for the assumed risk (e.g. the median control group risk across the studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High-quality evidence: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-quality evidence: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that
it is substant ially dif f erent.
Low-quality evidence: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-quality evidence: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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a Downgraded one level for indirectness.
b Downgraded one level for risk of bias.
c Downgraded one level for imprecision due to a small number of part icipants.
d Downgraded two level for risk of bias.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Figure 1. Forest plot of comparison: 1 Discontinuation versus continuation of long-term antipsychotic drug
use: continuous data, analysis method: mean difference, outcome: 1.1 Behavioural assessment by using
Neuropsychiatric Inventory (NPI) measuring neuropsychiatric symptoms (NPS) at 3 months (Ballard 2004 and
Ballard DART-AD) (Analysis 1.1).
B A C K G R O U N D
Description of the condition
According to the World Health Organization (WHO), the need
for healthcare services for older people with dementia will increase
significantly over coming years (Ferri 2005). Today, nearly 50 mil-
lion people worldwide have dementia (Livingston 2017). By 2030,
it is estimated that more than 75 million people will be living with
dementia, and the number is expected to increase to more than
131 million by 2050, as populations age. (Prince 2016). The risk
of dementia rises sharply with age, with an estimated 25% to 30%
of people aged 85 years or over having some degree of cognitive
decline (WHO 2015).
Although cognitive deficits are the clinical hallmark of demen-
tia, non-cognitive symptoms are common and can dominate the
disease presentation. These symptoms include a wide range of
neuropsychiatric symptoms (NPS), such as agitation, aggression,
psychosis (hallucinations and delusions), anxiety, apathy, depres-
sion, wandering, repetitive vocalisations, shouting andmany other
symptoms. These NPS have been observed in 60% to 98% of
people with dementia, especially in later stages of the disease. The
reported prevalence of each type of NPS varies considerably, from
3% to 54% for delusions, 1% to 39% for hallucinations, 8% to
74% for depressed mood, 7% to 69% for anxiety, 17% to 84%
for apathy, 48% to 82% for aggression or agitation, and 11% to
44% for physical aggression (Zuidema 2007). Some NPS may be
more likely than chance to occur together and different ’clusters’
have been described. Petrovic 2007 reports four behavioural syn-
dromes: a cluster with predominantly psychotic symptoms (hal-
lucinations, irritability, agitation and anxiety); a cluster with pre-
dominantly mood symptoms (disinhibition, elation and depres-
sive symptoms); a cluster with predominantly psychomotor symp-
toms (aberrantmotor behaviour) and a clusterwith predominantly
instinctual symptoms (appetite disturbance, sleep disturbance and
apathy). Clusters may differ in prevalence, course over time, bi-
ological correlates, psychosocial determinants and treatment re-
sponse. There is probably overlap between clusters. In general,
NPS follow a fluctuating course and high placebo response rates
have been reported.
NPS can lead to significant carer stress and cause considerable
emotional discomfort. They are associated with higher mortality,
higher use of physical restraints, increased length of hospitalisa-
tion, and often precipitate admission into a nursing home (Gilley
2000). Up to 30% of the costs of caring for people with demen-
tia are directly attributed to the management of NPS (Herrmann
2006).
The treatment of NPS includes non-pharmacologic and pharma-
cologic therapies. Non-pharmacologic therapy is recommended
as first-line treatment of NPS and pharmacologic therapy can be
used when non-pharmacologic therapy fails (NICE 2016).
A wide variety of pharmacological agents are used in the man-
agement of neuropsychiatric symptoms but results of individual
RCTs on the efficacy and safety of these agents conflict, and most
trials investigating the efficacy of drug treatment are only short
term (Ballard 2011).
Antipsychotics are often first-choice drugs for agitation in demen-
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tia, however these drugs have low efficacy for managing agitation
in dementia. Risperidone has the best evidence for improving agi-
tation and psychotic symptoms, particularly when aggression was
the target symptom, but only for 12 weeks. Haloperidol has ef-
fects on quelling aggression, although not on other symptoms of
agitation. Olanzapine and quetiapine do not improve psychosis,
aggression, or agitation, but aripiprazole may improve agitation
(Livingston 2017)
Drugs for cognition, such as cholinesterase inhibitors, including
donepezil andmemantine, have not been shown tobe useful for ag-
itationwhen agitation is the target symptom.Rivastigmine appears
to be beneficial in rate of decline of cognitive function and activi-
ties of daily living for people with mild to moderate Alzheimers’s
disease, although the effects were small and of uncertain clinical
importance and have poor safety outcomes with increased risk of
adverse events (Wang 2015).
Evidence for carbamazepine inmanaging behavioural and psycho-
logical symptoms of dementia, is very limited with an increased
risk of adverse effects (NICE 2016)
A Cochrane Review reported that the selective serotonin reuptake
inhibitors (SSRIs) sertraline and citalopram were associated with
moderate reduction in symptoms of agitation when compared to
placebo in two studies (Seitz 2011). Citalopram in higher doses
than recommended, may have benefits, especially in individuals
with milder Alzheimer’s disease andmilder agitation, but has some
important adverse effects (Porsteinsson 2014). NICE guidelines
did not recommend using SSRIs as treatment for NPS (NICE
2016).
The use of benzodiazepines in the treatment ofNPS in older people
with dementia is not evidence-based and should be discouraged
because of the risk of dependence and falls (CADTH 2010).
A major concern about the use of antipsychotics to treat be-
havioural symptoms in people with dementia is increased risk of
mortality and stroke (Schneider 2005; Schneider 2006). Product
side effect and hazard warnings have been issued for atypical an-
tipsychotics (FDA 2005), and for the older typical or first-gener-
ation antipsychotics in the treatment of psychotic symptoms in
older people with dementia. In the UK, Banerjee 2009 concluded
it was “time for action” in his report to the Minister of State and
recommended using antipsychotics only “when they really need
it” and that more attention should go to training and non-phar-
macological interventions. The literature review by Banerjee 2009
of antipsychotic treatment in older people with dementia revealed
that while improvement in behavioural disturbance was minimal
after 6 to 12 weeks of treatment (estimated effect size 0.1 to 0.2),
there was an increase in absolute mortality risk of approximately
1%.
Description of the intervention
Withdrawal from antipsychotic agents can be either abrupt (im-
mediate cessation of the active drug) or tapered (gradual with-
drawal according to a predefined dosing schedule or following
clinical response). In this review, we appraised RCTs investigat-
ing interventions aimed at assisting older people with dementia to
withdraw from antipsychotics, either by stopping abruptly or by
tapering.
How the intervention might work
Withdrawal of antipsychotic agents from older, often frail, people
with dementia and NPS might improve cognitive function, qual-
ity of life (QoL) of people with dementia and their carers, and
decrease mortality and adverse events (e.g. falls and extrapyrami-
dal symptoms). However, drug withdrawal may also cause a recur-
rence or worsening of the original NPS with a negative impact on
QoL, and may cause a temporary withdrawal syndrome.
Why it is important to do this review
Carers looking after people who are agitated and taking drugs that
may be suppressing NPS are sometimes understandably reluctant
to consider withdrawal of the drug. However, the episodic nature
of such symptoms and the harms associatedwith antipsychotic use,
are lesswell appreciated. Antipsychotic drugs remain inwidespread
use in this population. An update of our 2013 Cochrane Review
(Declercq 2013) of the risks and benefits associated with antipsy-
chotic withdrawal was therefore needed.
O B J E C T I V E S
To evaluate whether withdrawal of antipsychotic agents is feasible
in older people with dementia and NPS in primary care or nursing
home settings; to list the different strategies for withdrawal of
antipsychotic agents in older people with dementia and NPS; and
to measure the effects of the withdrawal of antipsychotic agents
on peoples’ behaviour and assess safety issues such as mortality,
adverse effects or withdrawal symptoms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials. Withdrawal trials that
were not placebo-controlled were included only if the outcome
assessors were blinded to treatment allocation. No language re-
strictions were applied.
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Types of participants
Older participants with dementia living in the community or in
nursing homes and taking an antipsychotic drug.
Older participants were defined as 65 years or over without upper
age limit.
Dementia was defined as an acquired organic mental disorder
with loss of intellectual abilities of sufficient severity to interfere
with social or occupational functioning. The dysfunction is mul-
tifaceted and involves memory, behaviour, personality, judgment,
attention, spatial relations, language, abstract thought, and other
executive functions. The intellectual decline is usually progressive,
and initially spares the level of consciousness. We accepted studies
for inclusion if the reports stated that participants had dementia or
any subtype of dementia. If there was any doubt about this diag-
nosis, first authors of studies were asked to provide further infor-
mation. All grades of dementia severity were included, regardless
of the method of diagnosis. Participants with schizophrenia were
excluded if this was reported in the trial.
Nursing homes are defined as institutions in which long-term
care is provided by professional care workers for three or more
unrelated, frail, older individuals.
Types of interventions
We included studies in which the intervention was withdrawal
of antipsychotic drugs prescribed long-term for neuropsychiatric
symptoms (NPS) in older participants with dementia.
Long-term antipsychotic drug use is defined as use of at least three
months of any antipsychotic agent, either typical (first generation)
or atypical (second generation) at a fixed dosage. Although there is
no good definition of the subgroup of atypical antipsychotic drugs,
we prefer this term to ’new’ or ’second generation’ antipsychotics.
The antipsychotic agents are listed according to the Anatomical
Therapeutic Chemical (ATC) classification. Names of drug classes
and individual drugs are presented in Table 1 and Table 2, respec-
tively; atypical antipsychotic agents are labelled with an asterisk.
Antipsychotic agents should be used in a stable dose, and within
the therapeutic range specified in the drug product information
insert. Defined daily doses (per os), as mentioned in the ATC clas-
sification, are also listed in Table 2. Chlorpromazine is considered
to be the reference drug. Baseline dosage regimen is classified as
very low, low or high for each antipsychotic agent, according to
the dosage table proposed by Ballard 2008 (e.g. for risperidone a
dose of 0.5 mg once daily is very low, 0.5 mg twice daily is low and
1 mg twice daily is high; for haloperidol 0.75 mg once daily is very
low, 0.75 mg twice daily is low and 1.5 mg twice daily is high; for
the referent molecule chlorpromazine 12.5 mg once daily is very
low, 12.5 mg twice daily is low and 25 mg twice daily is high).
Types of outcome measures
Primary outcomes
1. Success of withdrawal from antipsychotics over short-term
(four weeks or less) and long-term (more than four weeks)
follow-up. Success is defined as the ability to complete the study
in the allocated study group, i.e. no dropout due to worsening of
NPS, or no relapse to antipsychotic drug during the trial.
2. Behavioural and psychological symptoms (especially
agitation, aggression and psychotic symptoms) measured with
appropriate scales (e.g. Neuropsychiatric Inventory score (NPI),
Neuropsychiatric Questionnaire score (NPI-Q)).
3. Presence or absence of withdrawal symptoms or withdrawal
syndrome in the first four weeks.
i) Withdrawal symptoms or withdrawal syndrome
include autonomic and behavioural symptoms such as nausea,
vomiting, anorexia, rhinorrhoea, diarrhoea, diaphoresis, myalgia,
paraesthesia, anxiety, as well as movement disorders, such as
withdrawal emergent parkinsonism, withdrawal dyskinesia and
covert dyskinesia.
ii) Agitation, insomnia and restlessness have also been
reported during withdrawal, although it is possible these
symptoms occur due to rebound phenomenon. It is impossible
to discriminate between these aetiological phenomena.
iii) A withdrawal neuroleptic malignant syndrome is a
very rare but extremely severe condition that can complicate
abrupt antipsychotic discontinuation.
4. Adverse events attributable to antipsychotics (e.g. falls,
extrapyramidal symptoms, cardiovascular events and diabetes.
Secondary outcomes
1. Cognitive function (general or domain-specific, e.g. short-
term memory, frontal executive function, language) measured
with appropriate scales (e.g. Severe Impairment Battery (SIB)
score, Standardised Mini-Mental State Examination (SMMSE),
FAS verbal fluency test, Sheffield Test for Acquired Language
Disorder (STALD receptive and STALD expressive skill).
2. Quality of life of participants, carers, family of participants
or a combination of these, measured with appropriate scales (e.g.
Dementia Care Mapping (DCM) and Quality of life-Alzheimer
Disease (QoL-AD)).
3. Time, in days, until prescription of any psychotropic or any
antipsychotic agent.
4. Use of physical restraint.
5. Mortality.
6. Other secondary outcomes reported in the primary papers
(e.g. global functioning, sleep, clinical global impression)
measured with appropriate scales.
Search methods for identification of studies
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Electronic searches
We searched ALOIS, the Cochrane Dementia and Cognitive Im-
provement SpecializedRegister to 10 January 2018.We performed
an interim search on 3 March 2017. Searches for the previous
version of this review were performed in February 2009, March
2011, June 2011, November 2011, August 2012, and November
2012 (Declercq 2013).
ALOIS is maintained by the Cochrane Dementia and Cognitive
Improvement Group’s Information Specialists and contains stud-
ies in the areas of dementia prevention, dementia treatment and
cognitive enhancement in healthy. Studies are identified from:
1. MEDLINE, Embase, CINAHL, PsycINFO and LILACS;
2. trial registers: ISRCTN, UMIN (Japan’s Trial Register), the
World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (which covers ClinicalTrials.gov,
ISRCTN, the Chinese Clinical Trials Register, the German
Clinical Trials Register, the Iranian Registry of Clinical Trials,
and the Netherlands National Trials Register, among others);
3. the Cochrane Library’s Central Register of Controlled Trials
(CENTRAL); and
4. grey literature sources: ISI Web of Knowledge Conference
Proceedings, Index to Theses, Australasian Digital Theses.
Aee About ALOIS for all sources searched.
Details of the search strategies used to retrieve reports of trials from
healthcare databases, CENTRAL and conference proceedings can
be viewed in the ’methods used in reviews’ section in editorial infor-
mation about the Dementia and Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above to cover the timeframe from the last searches performed for
ALOIS to ensure that the search for the review was as up-to-date
and as comprehensive as possible. Search strategies are presented
in Appendix 1, Appendix 2 and Appendix 3.
Appendix 4 lists abbreviations used in this review.
Searching other resources
We reviewed reference lists of included and excluded studies to
identify any additional studies.
Data collection and analysis
Presentation of results and ’Summary of findings’
tables
We included a ’Summary of findings’ table, which included
seven outcomes, prepared using GRADEpro GDT. We used the
GRADE approach to assess evidence quality for all outcomes. Ev-
idence was assessed as high-, moderate-, low-, or very low-qual-
ity, depending on the seriousness of concern about risk of bias,
imprecision, inconsistency, indirectness, and publication bias. For
each outcome in the ’Summary of findings’ table we presented a
summary of the available data, the magnitude of the effect size,
and the quality of the evidence. We justified all decisions to down-
grade the quality of evidence in the footnotes of the ’Summary of
findings’ table.
Selection of studies
For this update, two review authors (EVL, MP) independently
screened study titles and abstracts retrieved from the search for
their relevance. We removed obviously irrelevant reports and du-
plicated reports of the same study.We obtained full-text versions of
potentially relevant reports. We examined these independently to
assess compliance with the predefined eligibility criteria. Two re-
view authors independently decided which trials met the inclusion
criteria. Differences between authors were resolved by discussion
and by consulting other review authors (MVD, TC). We entered
all search results intoRevMan5 (ReviewManager 2014).We listed
excluded studies and reasons for exclusion in the Characteristics
of excluded studies tables.
Data extraction and management
Three review authors (TD, MA, EVL) independently extracted
data from included studies using a predefineddata extraction form.
Differences between authors were resolved by discussion and by
consulting the review authors (MVD, TC). We extracted the fol-
lowing data:
• first author, publication year, journal;
• number, age and gender distribution of the participants
included in the trial;
• withdrawal method (e.g. abruptly versus tapered
withdrawal);
• baseline severity of NPS (e.g. NPI-score), agitation (e.g.
Cohen-Mansfield Agitation Inventory (CMAI) scale or psychotic
symptoms (hallucinations, delusions);
• baseline severity of dementia as determined by the MMSE
score (e.g. mild: 19 to 16; moderate: 15 to 10; severe: 9 to
untestable), or other appropriate scales;
• baseline dose of antipsychotic agent (very low, low, high)
and type of antipsychotic agents (typical or atypical); and
• results (primary and secondary outcomes).
If a paper did not provide sufficient information about either study
details or results, we contacted the study authors where possible.
Assessment of risk of bias in included studies
Three review authors (TD, EVL, MVD) independently assessed
each included study using the Cochrane’s tool for assessing risk of
bias, described in Chapter 8 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We resolved disagree-
ments by discussion with co-authors (MP, TC). We assessed:
• random sequence generation;
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• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessors;
• incomplete outcome data;
• dropout/selective outcome reporting; and
• other potential sources of bias.
We judged each potential source of bias as high, low or unclear and
provided a quote from the study report together with justification
for our judgement in ’Risk of bias’ tables. We summarised the risk
of bias judgements across different studies for each of the domains
listed. We reported the risk of bias using the ’Risk of bias’ tool
from theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
In this update, we assessed bias related to blinding of participants
and personnel separately from bias related to blinding of outcome
assessment (Higgins 2016).
Measures of treatment effect
We entered data into RevMan 5 software for data analysis (Review
Manager 2014). For continuous data, we calculated the mean dif-
ference (MD) if the same scale was used, or a standardised mean
difference (SMD), which is the absolute mean difference divided
by the pooled SD, if different scales were used to measure the
same construct. We calculated a 95% confidence interval (CI) for
each estimate. Dichotomous outcomes were reported as odds ra-
tios (ORs). We pooled data reported as mean differences by using
the inverse variance method as described in the Cochrane Hand-
book for systematic Reviews of Interventions (Higgins 2011).
Unit of analysis issues
Participants in randomised controlled trials (RCTs) was the unit
of analysis.
Cross-over trials were included using the results from paired anal-
yses, which adjust for within-individual comparisons (Elbourne
2002). The unit of analysis in Cohen-Mansfield 1999 was paired
data for drug versus placebo at the end of intervention period 1 and
intervention period 2. Different analysis for assessment of within-
subject variable and between-subject variable were performed.
Dealing with missing data
We reported where data were missing from published reports. We
contacted the original investigators to requestmissing data. If these
data remained unavailable we analysed the available data. We used
intention-to-treat (ITT) analyses where possible. Any statistical
method used by the study authors (e.g. multiple imputation anal-
ysis, last observation carried forward) to deal with not-missing-at-
random data was reported. If study authors reported outcomes for
participants who completed the study, as well as carried forward
or otherwise imputed data, we used the latter data for pooling.
Assessment of heterogeneity
We assessed heterogeneity in two ways. First, we explored the
presence of heterogeneity at face value by comparing population
groups, interventions or outcomes across studies. In the case of
clear face value heterogeneity, we reported the outcomes of the
studies narratively and did not pool the results. Meta-analysis was
only performed when studies were sufficiently homogeneous in
terms of participants, interventions, and outcomes. If there was no
obvious clinical heterogeneity we used statistical tests such as the
CochranChi² (Q) test and the I² statistic to determine the presence
and level of statistical heterogeneity for each outcome. An I² value
of 50% or higher was considered as significantly heterogeneous
(Higgins 2011; Review Manager 2014).
Assessment of reporting biases
To minimise risk of publication bias, a comprehensive search was
performed in multiple databases, including searching for unpub-
lished studies. If more than 10 RCTs were identified, we planned
to assess the existence of publication bias by constructing a funnel
plot (Higgins 2011).
Data synthesis
Trials that did not report comparable outcomes were considered
clinically heterogeneous and results were not pooled in meta-anal-
ysis. In this case, we performed critical interpretive synthesis of
data from individual studies.
The duration of follow-up in trials varied considerably. If the range
of follow-up was considered too large to pool results for meta-
analysis, the data were divided into smaller time periods and sep-
arate meta-analyses were conducted for each period. The overall
estimate was calculated using a fixed-effect model in the absence
of statistical heterogeneity. In the presence of substantial statistical
heterogeneity (I² value of 50% or higher), a random-effects model
was used (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We conducted only one meta-analysis including two trials. We
were therefore unable to analyse subgroups.We reported the results
of subgroup analyses in the included studies.
Sensitivity analysis
We conducted no sensitivity analyses.
R E S U L T S
12Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with
dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; and Table 3.
Results of the search
Searches for this update identified 101 records after a de-dupli-
action and first assessment performed by CDCIG information
specialists; an ongoing study identified in the 2013 review was
also assessed for inclusion. We removed 13 duplicate records (n
= 89 records). We excluded 76 records following assessment of
title and abstract (n = 13 full-text reports). Following assessment,
we excluded 12 full-text articles that did not meet inclusion cri-
teria (see Characteristics of excluded studies). We included one
additional randomised controlled trial (RCT) involving 19 par-
ticipants (Bergh 2011) for this update (Figure 2).
Figure 2. Inclusions of trials of study flow diagram 2018
Included studies
The 2013 review (Declercq 2013) included nine studies (Ballard
2004; Ballard 2008; Bridges-Parlet 1997; Cohen-Mansfield 1999;
Devanand 2011; Devanand 2012; Findlay 1989; Ruths 2008; van
Reekum 2002). One additional study was added for this update
(Bergh 2011). The 10 included studies involved a total of 632
participants (Characteristics of included studies; Table 3).
Overview
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The included trials were very diverse in terms of study participants
(such as the case definition applied and the severity of dementia
of the participants), types and dosages of antipsychotics used be-
fore withdrawal, exclusion criteria, interventions (i.e. method of
discontinuation), outcomes, and times of assessment.
Design
Nine studies were parallel-group RCTs. One study was a cross-
over RCT (Cohen-Mansfield 1999).
Sample size
All 10 studies included small numbers of participants. Seven stud-
ies included fewer than 100 participants; three studies included
between 100 and 200 participants (Ballard 2004; Ballard 2008;
Devanand 2012).
Study setting
Eight studies included participants in nursing homes. One pi-
lot study included participants with Alzheimer’s disease and psy-
chosis, agitation or aggression who were living in the commu-
nity (Devanand 2011). One study included participants with
Alzheimer’s disease andpsychosis, agitation or aggressionwhowere
living in the community or were residents of assisted-living facili-
ties or nursing homes (Devanand 2012).
Participants
Clinical characteristics at baseline
See Characteristics of included studies
1. Age status at baseline
Participants’ average age was 80 years or over in most studies.
2. Sex status at baseline
Most studies included higher proportions of female participants.
Findlay 1989 recruited only female participants.
3. Dementia status at baseline
Different methods were used to diagnose dementia.
• Ballard 2004 and Ballard 2008 included only participants
with Alzheimer’s disease who fulfilled the National Institute of
Neurological and Communicative Diseases and Stroke/
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria for possible or probable
Alzheimer’s disease.
• Bergh 2011 included participants with dementia due to
Alzheimer’s disease or vascular type or mixed type according to
ICD-10 clinical criteria.
• Bridges-Parlet 1997 included residents with diagnoses of
dementia or possible or probable dementia.
• Cohen-Mansfield 1999 had no explicit diagnostic standard
for dementia; the study included nursing home residents aged
over 70 years receiving haloperidol, thioridazine, and lorazepam.
The study author confirmed by email that the residents
participating in the study met the inclusion criteria dementia
(Declerck 2009a [pers comm]).
• Devanand 2011 and Devanand 2012 included participants
with diagnoses of dementia using DSM-IV and probably
Alzheimer’s Disease by National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-ADRDA)
criteria.
• Findlay 1989 included participants with Alzheimer’s disease
classified according to ICD-9 criteria, assessed by a consultant
psychiatrist and based on medical history.
• Ruths 2008 included participants with diagnoses of
dementia according to ICD-10 clinical criteria.
• van Reekum 2002 included participants with all forms of
dementia based on chart review.
4. Cognitive status at baseline
At baseline, participants in most of the studies were described as
having moderate to severe dementia. A variety of methods were
used to measure baseline cognitive severity. Several studies had
inclusion criteria based on cognitive severity at baseline.
• Ballard 2008 included participants with a Standardised
Mini-Mental State Examination (SMMSE) score of 6 or a Severe
Impairment Battery (SIB) score > 30.
• In Devanand 2011, study participants had SMMSE scores
ranging from 5 to 26.
• Participants living in the community in the Devanand
2012 study had SMMSE scores of 5 to 26; participants residing
in nursing homes had scores between 2 to 26.
• Cohen-Mansfield 1999 used the Brief Cognitive Rating
Scale (BCRS) at baseline to determine participants’ cognitive
function without criteria.
• Findlay 1989 used the Cognitive Assessment Scale (CAS)
for measuring cognitive status without criteria.
• There were no clear cut-off values reported to indicate the
severity of cognitive status severity in seven studies (Ballard
2004; Bergh 2011; Bridges-Parlet 1997; Cohen-Mansfield 1999;
Findlay 1989; Ruths 2008; van Reekum 2002.
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5. Behavioural status at baseline
Several trials applied inclusion criteria based on severity of be-
havioural problems at baseline. This was not an inclusion criterion
for this review.
• Ballard 2004 included participants with individual scores
on the Neuropsychiatric Inventory (NPI) that were not higher
than 7 at the time of evaluation.
• In Bridges-Parlet 1997, participants were selected by nurse
supervisors who identified physically aggressive participants with
dementia treated with antipsychotics.
• In the Devanand 2011 pilot trial, participants needed to
have signs of psychosis, agitation or aggression or both to be
included in the study. Psychosis was identified using the
Columbia University Scale for Psychopathology in Alzheimer’s
Disease (CUSPAD) and the Brief Psychiatric Rating Scale
(BPRS) (psychosis factor of at least 4). Agitation and aggression
was measured on the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) Behavioural Rating Scale for
Dementia (score > 3 and present for at least 10 days per month,
on one or more of the items for agitation, purposeless
wandering, verbal aggression or physical aggression).
• Participants in the Devanand 2012 trial had scores on the
NPI of 4 or more at both screening and baseline on the delusions
or hallucinations subscale (psychosis score) or the agitation and
aggression subscale (agitation/aggression score) (with scores on
NPI subscales ranging from 0 to 12).
• Ruths 2008 included all potential participants regardless of
individual neuropsychiatric symptoms (absent = 0, mild = 1,
moderate = 2, severe = 3), providing a NPI-Q sum score ranging
from 0 to 36.
• In van Reekum 2002, participants were included if they
had “stable” behaviour.
Four studies (Ballard 2008; Bergh 2011; Cohen-Mansfield 1999;
Findlay 1989) did not use severity of behaviour problems as a
criterion for inclusion.
6. Global status at baseline
Several studies specified global functional status at time of inclu-
sion in the study.
• In Ballard 2004, participants had Clinical Dementia Rating
(CDR) Scale severity of stage 1 or greater.
• In Bergh 2011, inclusion was limited to Dementia Rating
1, 2 or 3 without further specification.
• van Reekum 2002 used the Clinical Global Impression
scale (CGI) without further specifications.
No other studies reported measurements of global functioning at
baseline.
Intervention
Antipsychotic treatments to be withdrawn and withdrawal
schedules
The included studies used different antipsychotics at different
dosages. Antipsychotics used were thioridazine, chlorpromazine,
haloperidol, trifluoperazine (classified as ’typical antipsychotics’)
and risperidone or olanzapine (classified as ’atypical antipsy-
chotics’).
Three studies used an abrupt withdrawal schedule (Ballard 2004;
Ballard 2008; Ruths 2008).
Two studies (Bridges-Parlet 1997; Devanand 2012) withdrew
most participants abruptly from antipsychotic drugs, but used a
tapering schedule when the baseline dose exceeded the equiva-
lent of 50 mg of chlorpromazine. Bridges-Parlet 1997 did this by
halving the baseline antipsychotic dose during week one and dis-
continuing the antipsychotic drug completely at the beginning of
week two. In Devanand 2012, when the baseline dose was 2 mg
risperidone or more daily, one-week tapering was used by means
of a sequential double-blind placebo substitution (e.g. one 2 mg
tablet of risperidone was switched to one 1 mg tablet and then to
one placebo tablet).
The other studies used a tapering schedule.
• Most participants in Ballard 2008 were taking risperidone
or haloperidol at variable dosages: participants were taking at
least 10 mg chlorpromazine equivalents of a typical neuroleptic
or at least 0.5 mg daily of risperidone. Dosages were defined as
high, low, or very low:
◦ very low: risperidone 0.5 mg daily, chlorpromazine
12.5 mg once daily, trifluoperazine 0.5 mg once daily;
haloperidol 0.75 mg once daily;
◦ low: risperidone 0.5 mg twice daily, chlorpromazine
12.5 mg twice daily, trifluoperazine 0.5 mg twice daily;
haloperidol 0.75 mg twice daily; and
◦ high: risperidone 1 mg twice daily; chlorpromazine 25
mg twice daily; trifluoperazine 1 mg twice daily; haloperidol 1.5
mg twice daily.
• Most participants in Ballard 2004 took risperidone or
thioridazine at variable dosages. Participants used (mean ± SD
dose): risperidone 1.3 mg ± 0.7 mg, thioridazine 38.0 mg ± 26.2
mg, haloperidol 0.9 mg ± 0.4 mg, trifluoperazine 3.0 mg ± 1.4
mg or chlorpromazine 20 mg (no SD value for chlorpromazine
as there was only one person taking this drug).
• In Cohen-Mansfield 1999, participants took haloperidol,
thioridazine and lorazepam at variable dosages (mean dosage
haloperidol 1.34 mg, thioridazine 27.0 mg and lorazepam 0.94
mg, no SD given). The cross-over design of this trial led to a
three-week dose-tapering period followed by seven weeks of
placebo. After this placebo period, the placebo group was titrated
back to the original dose and groups were switched for the
procedure. Participants were withdrawn from antipsychotics
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(haloperidol and thioridazine), and also from lorazepam, which
is a benzodiazepine. Because of the dual drug cross-over design,
it was difficult to interpret the results of this study.
• In Devanand 2011, participants in a community setting
with Alzheimer’s disease and symptoms of psychosis, agitation or
aggression were included and treated with haloperidol in phase
A. In phase B (discontinuation trial) only participants who
responded well to haloperidol in phase A were included. Criteria
for clinical response were minimum 50% reduction from
baseline in the sum score of the three most prominent symptoms
of psychosis, agitation or aggression, a sum score of 6 or less on
these three items (range 0 to 18), and minimal or greater
improvement on the Clinical Global Impression scale (CGI-C)
rated only for symptoms of psychosis, agitation and aggression.
Doses of haloperidol used in phase B varied (4 mg daily, 2 mg to
3 mg daily, 0.5 mg to 1 mg daily). According to these different
dosages there was a two-week tapering period (4 mg daily
switched to 2 mg daily for one week, 1 mg daily for the next
week and then to placebo; participants on 2 mg to 3 mg daily
switched to 1 mg daily for two weeks and then to placebo, and
participants who received 0.5 mg or 1 mg daily were switched
directly to placebo without a tapering period).
• In Devanand 2012, phase A participants were given
flexible-dose risperidone for 16 weeks: risperidone therapy was
initiated at a dose of 0.25 mg to 0.5 mg daily and could be
increased to 3 mg daily, depending on the response and side
effects. Participants who had a response in phase A entered phase
B of the study (discontinuation trial with three regimens:
continued risperidone therapy for 32 weeks (group 1),
risperidone therapy for 16 weeks followed by placebo for 16
weeks (group 2) or placebo for 32 weeks (group 3)).
• Findlay 1989 used a half-dose reduction during the first
week and a total placebo substitution over the next week.
Original dosages that participants had been receiving were stable
dosages between 10 mg and 100 mg thioridazine for at least two
months.
• van Reekum 2002 did not define antipsychotic drug classes
and included residents who had been taking typical or atypical
antipsychotics for at least six months. In this study, all
participants received a standard order for lorazepam (0.5 mg to
1.0 mg) on an as-needed basis for agitation. The study used a
tapering schedule of two weeks in which original medication was
halved for the first week and the remaining dose halved during
the second week followed by a six-month study period.
• In Ruths 2008, participants were taking risperidone 1.0 mg
(median; range 0.5 mg to 2.0 mg), olanzapine 5.0 mg (2.5 mg to
5.0 mg), and haloperidol 1.0 mg (0.5 mg to 1.5 mg).
• In Bergh 2011, all participants were taking risperidone at
inclusion. The doses of the continuation group was determined
by the participant’s dose of antipsychotics prior to recruitment to
the study. The study used a tapering schedule over one week for
the discontinuation group. Participants received 50% of their
original medication dose on day 1, reduced to 25% on day 4 and
12.5% on day 6 and fully discontinued on day 7. The mean dose
at inclusion was risperidone 0.92 mg/day.
Outcome measures
Outcome measures were very diverse across included studies and
therefore difficult to compare. We could not calculate a standard-
isedmean difference (SMD) for any outcomewhen different scales
were used, because we did not consider the scales to be measuring
identical constructs.
Four studies reported outcomes as mean differences with SDs (
Ballard 2004; Ballard 2008; Bergh 2011; Ruths 2008). Five studies
(Bridges-Parlet 1997; Cohen-Mansfield 1999; Devanand 2011;
Devanand 2012; van Reekum 2002) reported outcomes as means,
but only three also reported SDs (Bridges-Parlet 1997; Devanand
2011;Devanand 2012). Findlay 1989 reported outcomes asmeans
with a range and number of observations.
Primary outcomes
1. Success of withdrawal from antipsychotics in the short-term
(4 weeks or less) and long-term (more than 4 weeks)
We defined successful withdrawal as ability to complete the study
in the allocated study group (i.e. no withdrawal due to worsening
of neuropsychiatric symptoms (NPS), or no relapse to antipsy-
chotic drug use during the trial).
• Ballard 2004 and Ballard 2008 reported the participant
flow in results sections and reasons for withdrawal from the
study, for example, withdrawal because of behavioural
deterioration. Unfortunately, relapse to antipsychotic drug use
was not mentioned.
• Bridges-Parlet 1997 reported participants completing the
study and relapse to antipsychotic drug use after completion of
the trial.
• Cohen-Mansfield 1999 reported the participant flow in the
results section and reasons why participants discontinued before
study completion.
• Devanand 2011: phase B reported relapse using criteria of
50% worsening of the three target symptoms of psychosis,
agitation and aggression, and a severity score ≥ 6 on these three
items (range 0 to 18), and minimal or greater worsening on the
Clinical Global Impression scale (CGI-C) (rated for psychosis,
agitation and aggression). Time to relapse was also measured in
Devanand 2011 phase B.
• Devanand 2012: phase B reported relapse using criteria of
increase in the Neuropsychiatric Inventory (NPI) core score of
30% or more, or a 5-point increase from the score at the end of
phase A, and a score of 6 (much worse) or 7 (very much worse)
on the CGI-C scale. The NPI-core score is the sum of the
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subscale scores for agitation-aggression, hallucinations and
delusions. The CGI-C scale ranged from 1 to 7, with higher
scores indicating less improvement for overall psychosis,
agitation or aggression.
• Findlay 1989 did not report withdrawal from the study in
the text, but results can be extracted from the table.
• van Reekum 2002 reported early withdrawals from the
study, but did not mention relapse to antipsychotic drugs.
• Ruths 2008 mentioned relapse of antipsychotic drug use
after withdrawal from antipsychotic drugs.
• Bergh 2011 reported participant flow in the results section
and reasons for withdrawal from the study, but relapse to
antipsychotic drug use was not mentioned.
2. Behavioural and psychological symptoms (especially
agitation, aggression and psychotic symptoms)
Behavioural and psychological symptoms (especially agitation, ag-
gression and psychotic symptoms) were assessed by different scales
across included studies:
• Behavioural and psychological symptoms measured with
NPI and NPI-Q
Two trials using the Neuropsychiatric Inventory (NPI) or Neu-
ropsychiatric Inventory Questionnaire (NPI-Q) score as a primary
outcome performed NPI-subscore analysis (Ballard 2004; Ballard
2008).
Ruths 2008 assessed agitation as a subscore of the NPI-Q and
Ballard 2004 assessed agitation as subscore of Neuropsychiatric
Inventory (NPI) total score.
Only Devanand 2012 reported the effect on the NPI core score,
that is, the sum of the NPI-subscale for agitation and aggression,
hallucinations, and delusions.
The NPI covers 12 domains of behavioural and neurovegetative
symptoms to assess outcome. Each subscore is rated on a 12-point
scale, assessing severity (0 to 3) and frequency (0 to 4) of a domain,
with a theoretical maximum of 144 (i.e. 12 x 12) (range 1 to 144).
The NPI-Q (Neuropsychiatric Inventory Questionnaire) assesses
only the severity of each of the same 12 domains (theoretically
maximum of 36, range 0 to 36) and can be considered as a shorter
version of the NPI.
Bergh 2011 used the primary endpoint changes in the Neuropsy-
chiatric Inventory (NPI-10). The authors reported NPI-10, this
assesses 10 items out of 12 NPI domains (no sleep/night time be-
haviour changes and no appetite/eating changes).
• Behavioural and psychological symptoms measured with
other scales
Bergh 2011 used also the primary endpoint changes in Cornell
Scale for Depression inDementia (CSDD) (minimum score 0 and
maximum score 38) assesses depressive symptoms of the partici-
pants with dementia. A score of 8 points and above is regarded
as a sign of a depressive disorder, while a score of 13 and above is
regarded as a sign of a severe depressive disorder. The CSDD was
divided into two subscales, mood (sadness, anxiety, pessimism,
suicidal thoughts, poor self esteem and delusion) and non-mood
(remaining 13 symptoms).
Bridges-Parlet 1997 used the physically aggressive behaviour scale
(PAB) as the main outcome measure. The PAB scale assesses ag-
gressive behaviour identified by type (coded by a barcode system).
Five different types of behaviour are identified: hitting, biting,
scratching, kicking and pushing. The study authors also assessed
verbal aggressiveness, defined as an instance of speaking in an an-
gry tone of voice, swearing or yelling in anger.
Cohen-Mansfield 1999 used behaviour and agitation measured
by different scales. The primary outcome Brief Psychiatric Rating
Scale (BPRS) assesses somatic concern, anxiety, emotional with-
drawal, conceptual disorganisation, guilt feelings, tension, man-
nerisms andposturing, grandiosity, depressivemood, hostility, sus-
piciousness, hallucinatory behaviour, motor retardation, uncoop-
erativeness, unusual thought content, and blunted effect (scale 1 =
not present to 7 = extremely severe). Agitation was measured with
the Cohen-Mansfield Agitation Inventory scale (CMAI). This
nurse-rated questionnaire consists of 29 agitated behaviours, each
rated on a 7-point scale of frequency.
van Reekum 2002 used behavioural, cognitive, functional and ex-
trapyramidal signs as outcome measures, but reported the BE-
HAVE-AD (Behavioural Pathology in Alzheimer’s disease Rating
Scale) measurements only in a figure (no means or SDs reported).
Aggression was assessed by the ROAS scale (Retrospective Overt
Aggression scale).
3. Presence or absence of withdrawal symptoms in the first
four weeks after withdrawal
None of the studies assessed these specific outcomes although it is
not easy to distinguish between a withdrawal phenomenon and a
relapse of NPS.
4. Adverse events of antipsychotics
Total adverse events likely to be related to antipsychotic use,
such as falls, extrapyramidal symptoms, cognitive dysfunction,
metabolic changes (including weight gain and diabetes), cardio-
vascular events and others were not systematically reported in the
included studies.
• Ballard 2008 measured parkinsonism using the Modified
Unified Parkinson’s Disease Rating Scale (M-UPDRS).
• Bridges-Parlet 1997 gave some attention to observations of
tardive dyskinesia but no measurement scales were used. The
entire study was based on direct observations by experienced
personnel who were blinded to the assigned treatment.
• Cohen-Mansfield 1999 reported adverse events as
secondary outcomes in a table (without reporting an SD), using
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the Abnormal Involuntary Movement Scale (AIMS): assessment
of neurological and physical side effects associated with
psychotropic drug use (9 items: e.g. movement of the face and
oral cavity, extremities and trunk, global judgements of abnormal
movements). A list of adverse effects (sedation, extrapyramidal
reactions, orthostatic hypotension and anticholinergic effects)
was provided to the nursing staff, who indicated frequency of
occurrence. Nurse managers checked lists of psychomotor adverse
effects, including 13 items describing pseudoparkinsonism,
akathisia, acute dystonic reaction, and tardive dyskinesia.
• Devanand 2011 assessed somatic side effects with the
Treatment Emergent Symptom Scale (TESS; range from 0 to 26,
with higher scores indicating more somatic symptoms),
extrapyramidal signs using the Unified Parkinson’s Disease
Rating Scale (UPDRS) and tardive dyskinesia with the Rockland
Tardive Dyskinesia scale. No data were reported for the
discontinuation trial.
• Devanand 2012 assessed extrapyramidal signs using the
Simpson-Angus scale (range from 0 to 40, with higher scores
indicating more extrapyramidal signs); tardive dyskinesia using
the AIMS (range from 0 to 35, with higher scores indicating
more severe symptoms) and general somatic symptoms
developing during treatment using the TESS.
• Findlay 1989 provided additional information on mobility,
range of mobility, transferring, response to chest pushing and
balance and position sense, vibration sense, reading of a sway for
participants standing with eyes open, systolic and diastolic blood
pressure, and heart rate. Findlay 1989 reported lying and
standing blood pressure and heart rate, the sum of the mobility
outcomes, balance while standing, balance on turning head,
balance on turning whole body through 360 °.
• van Reekum 2002 assessed extrapyramidal signs using the
Extrapyramidal Symptom Rating Scale (ESRS).
• Bergh 2011 measured extrapyramidal adverse effects after
prescription of antipsychotics using the M-UPDRS but these
results were not reported.
2. Secondary outcomes
1. Cognitive function (e.g. short-term memory, frontal
executive function, language)
• Ballard 2008 measured cognition using the SMMSE and
the SIB, which was the main outcome for this trial. Frontal
executive function was assessed by the FAS verbal fluency test,
assessing phonemic verbal fluency. Language was assessed by
using the Sheffield Test for Acquired Language Disorder
(STALD receptive and STALD expressive skill).
• Cohen-Mansfield 1999, Devanand 2011 and Devanand
2012 assessed cognitive function using the MMSE. Devanand
2012 also used the Alzheimer’s Disease Assessment Scale -
cognitive score (ADAS-cog, range from 0 to 70, with higher
scores indicating worse cognition).
• Findlay 1989 assessed cognitive function with the
Cognitive Assessment Scale (CAS) scored by a psychiatrist.
• van Reekum 2002 assessed cognitive function with the
MMSE and the Mattis Dementia Rating Scale (MDRS).
2. Quality of life (QoL) of participants, carers, family of
participants, or a combination
• Ballard 2004 scored QoL using Dementia Care Mapping
(DCM) as a measure of participants’ well-being. The method
quantifies activity category codes, which are recorded every five
minutes over a six hour period of observation during one day.
• Bergh 2011 assessed changes after 25 weeks on the Quality
of Life - Alzheimer disease (QoL-AD) scale. The QoL-AD scale
evaluates the quality of life of the patient using 13 items which
are scored on a 4-point scale from ’bad’ to ’excellent’.
3. Time, in days, until prescription of any psychotropic agent
Time, in days, until repeat prescription of any psychotropic agent
with the exception of antipsychotics was not reported systemat-
ically. Only Ruths 2008 reported medication changes in a sub-
group analysis.
4. Use of physical restraint
Only Bridges-Parlet 1997 reported use of physical restraint.
5. Mortality
Only Ballard 2008 and Devanand 2012 reported mortality. Mor-
tality data in one of the two papers describing Ballard 2008 were
reported at 12, 24 and 36 months follow-up after randomisation.
Devanand 2012 assessed mortality at 16 weeks (4 months) and 32
weeks (8 months).
6. Other secondary outcomes
6.1. Global functioning
• Ballard 2008 reported global functioning with the BADLS
(Bristol Activities of Daily Living Scale) and FAST (Functional
Assessment Staging).
• Cohen-Mansfield 1999 reported residents’ functioning as
secondary outcomes by rating levels of activity and positive
mood.
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• Devanand 2011 assessed impairment in activities of daily
living using the modified Blessed Functional Activity Scale
(BFAS).
• Devanand 2012 assessed physical function with the use of
the Physical Self-Maintenance Scale (PSMS; range from 1 to 30,
with higher scores indicating worse functioning).
• van Reekum 2002 assessed functional outcome with the
Blessed Dementia Scale (BDS).
6.2. Sleep
• Ruths 2008 (and subgroup analysis in Ruths 2004) and
Bridges-Parlet 1997 reported effects on sleep.
• Cohen-Mansfield 1999 reported the effect on sleep and
activity level (daytime sleep, time to fall asleep and activity level).
Daytime sleep was an average of the items “How often does the
resident appear drowsy or sleepy during the day?” and “How
frequently does the resident actually sleep during the day?“ Both
items were rated on a frequency scale ranging from 1 (never) to 7
(several times an hour). Time to fall asleep was measured by “On
the average, how long did it take the resident to fall asleep at
night (from the time he/she went to bed until the time the
resident fell asleep)?” and rated on a scale ranging from 1 (falls
asleep immediately) to 6 (nearly never sleeps at night). Activity
level was an average of 2 items: “How often did the resident
participate in social activities ?” and “How frequently was the
resident involved in activities which is meaningful for his/her
level of functioning? and rated on a frequency scale ranging from
1 (never) to 6 (several times a day).
6.3 Clinical global impression
• Ballard 2008 reported clinical global impression using
CGI-C (Clinical Global Impression-Change).
• Cohen-Mansfield 1999 reported clinical global impressions
as secondary outcomes using the CGI-C scale.
• Findlay 1989 reported a psychiatric assessment using the
Sandoz Clinical Assessment Geriatric Scale (SCAGS)
• In Devanand 2012, relapse was reported as a predefined
deterioration on the NPI and the CGI-C. The CGI-C was also
measured at different time points, but was not reported in the
paper.
Co-variables
Only Ballard 2008 conducted a post hoc subgroup analysis by type
of antipsychotic drug (typical versus atypical).
Time of assessment of outcome measurements
Outcomes were assessed at different times.
• Ballard 2004 assessed outcomes at three months.
• Ballard 2008 assessed outcomes in a first paper at 1, 3, 6
and 12 months: only the data assessed at six months were
reported. Analysis at 12 months was limited to the two main
outcomes: cognitive function and neuropsychiatric features. In a
second paper, Ballard assessed the outcome mortality at 12, 24
and 36 months (Ballard 2011). To pool the NPI data we asked
Professor Ballard to provide data from the DART-AD study
assessed at three months (Declerck 2009c [pers comm]). These
data were extracted from the DART-AD database by Ly-Mee Yu
from the Oxford Centre for Statistics in Medicine.
• Bridges-Parlet 1997 reported outcomes at one, two and
four weeks.
• Cohen-Mansfield 1999, a cross-over study, reported that
participants were assessed at five time points: one week after start
of dosage tapering (week 1), phase one tapering (week 3), phase
one end point (week 10), phase two tapering (week 13) and
phase two end point (week 20). Results were reported as paired
data for time points three and five (comparison of assessments of
each phase in the cross-over study).
• Devanand 2011 assessed outcomes in phase B at 0, 2, 4, 8,
12, 16, 20 and 24 weeks.
• Devanand 2012: phase B assessed outcomes at 16 weeks (4
months) and 32 weeks (8 months).
• Findlay 1989 reported outcomes at two and four weeks.
• Ruths 2008 assessed outcomes at four weeks (1 month).
• van Reekum 2002 reported outcomes only in a figure from
visit 1 (baseline) to visit 15 (6 months).
• Bergh 2011 reported outcomes at baseline and after 25
weeks.
Excluded studies
We excluded 12 studies for this update. Of these, eight were
commentaries (Devanand 2013; Garner 2015; Gill 2013; Gnjidic
2013; Ling 2013; Lolk 2014; Power 2013; Renard 2014). Two
studies did not investigate interventions that were relevant for this
review (discontinuation of memantine (Ballard 2015) and discon-
tinuation of antidepressants (Bergh 2012). Patel 2017 was not
a randomised controlled trial (presented a post hoc analysis of
Devanand 2012). Azermai 2013 did not use a suitable control in-
tervention (it was a pilot study without a control group).
Five studies were excluded in the review 2013 (Other published
versions of this review). Horwitz 1995; Westbury 2011; Wessels
2010 were excluded because these were not randomised controlled
discontinuation trials. One trial was excluded because it analysed
the Findlay 1989 cohort for outcomes that are not relevant to
our review (McLennan 1992). Another study was excluded as it
seems to be the registration of a not (yet) published (and perhaps
still ongoing) trial and further searching did not reveal additional
information about this trial (Rule 2003).
See Characteristics of excluded studies and Figure 2.
Risk of bias in included studies
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We assessed risk of bias of included studies according to six specific
domains using theCochrane ’Risk of bias’ assessment tool (Higgins
2011) (Figure 3; Figure 4).
Figure 3. Risk of bias graph for the 10 included studies in the review.
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Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study in the review.
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Most studies were assessed at low or unclear risk of bias. Only
Ballard 2008 was assessed at low risk of bias for all domains. Bergh
2011 was judged to be at high risk of bias in two domains. Cohen-
Mansfield 1999 and van Reekum 2002 were each assessed at high
risk of bias in one domain. The most common unclear risk of
bias domains were selection bias, detection bias, attrition bias and
reporting bias.
See Characteristics of included studies.
Allocation
Randomisation sequence generation was described and adequate
in six trials (Ballard 2008; Bergh 2011; Bridges-Parlet 1997;
Devanand 2012; Ruths 2008; van Reekum 2002) and unclear
in four trials (Ballard 2004; Cohen-Mansfield 1999; Devanand
2011; Findlay 1989).
Allocation concealment was only described in sufficient detail
to assess the risk of bias as low in three studies (Ballard 2008;
Bergh 2011;Devanand 2012). Risk of allocation concealment bias
was unclear in seven studies (Ballard 2004; Bridges-Parlet 1997;
Cohen-Mansfield 1999; Devanand 2011; Findlay 1989; Ruths
2008; van Reekum 2002).
Blinding
All included studies were double-blinded. The overall risk of per-
formance bias was low. All studies adequately described methods
of blinding participants and personnel. We assessed four studies
(Devanand 2011; Findlay 1989; Ruths 2008; van Reekum 2002)
at unclear risk of detection bias; information on blinding of out-
come assessors was not reported. In these trials, there were several
subjective outcomes, so a lack of blinding of outcome assessors
could have had an influence.
Incomplete outcome data
Six trials reported the issue of incomplete outcome data, with no
unequal numbers across the groups andwith adequate reasons pro-
vided for dropouts and losses to follow-up (Ballard 2004; Ballard
2008; Bridges-Parlet 1997; Devanand 2011; Devanand 2012; van
Reekum 2002). In Bergh 2011, attrition bias was judged as high
risk due to the high dropout rate with unequal numbers across the
groups (7 dropouts of 9 participants in the discontinuation group
and no dropouts of 10 participants in the continuation group)
and missing data. We considered the risk of incomplete outcome
data bias to be unclear in three studies (Cohen-Mansfield 1999;
Findlay 1989; Ruths 2008).
Selective reporting
We judged four studies at low risk of selective reporting bias
(Ballard 2004; Ballard 2008; Bridges-Parlet 1997; Ruths 2008).
Findlay 1989 did not describe the primary outcome and was un-
clear if all outcomes were reported. In van Reekum 2002, some
outcomesmentioned in themethods sections of the paper were not
reported in the results. In Bergh 2011, an unpublished study, the
authors reported that they did not perform an observed case anal-
ysis due to the high dropout rate and missing data. In Devanand
2012 the CGI-C data were not fully reported. Devanand 2011
and Devanand 2012 reported numeric data for several continu-
ous outcomes at the time of randomisation into the discontinu-
ation phase, but only dichotomous data at later time points. In
Cohen-Mansfield 1999, outcome data were not reported sepa-
rately for each medication discontinued in the trial (i.e. haloperi-
dol, thioridazine or lorazepam).
Other potential sources of bias
It was unclear if participants in the two groups were similar in
Ruths 2008. In the Findlay 1989 study there was a baseline imbal-
ance between the placebo group and continuation group in one
of the three cognitive/behavioural rating scales used to measure
outcomes. It was unclear if this had an impact on the results.
Effects of interventions
See: Summary of findings for the main comparison
Discontinuation compared to continuation of antipsychotic
medication for behavioural and psychological symptoms in older
people with dementia
We included 10 RCTs with 632 participants. However, although
Cohen-Mansfield 1999 met inclusion criteria, we were unable to
use any data from this study.Cohen-Mansfield 1999 didnot report
outcome data separately for the different medications discontin-
ued in the trial (which included the benzodiazepine lorazepam as
well as the antipsychotics haloperidol and thioridazine). We con-
tacted the study author by for further data, but have not received
a response (Declerck 2009b [pers comm]).
For all outcomes, our conclusions were based on studies that re-
ported quantitative data, or on conclusions made by the study
authors if data were not provided.
The result and the evidence quality for each outcome for the main
comparison (discontinuation compared to continuation of an-
tipsychotic drug use for behavioural and psychological symptoms
in older participants with dementia) are described in Summary of
findings for the main comparison.
Primary outcomes
1. Success of antipsychotic withdrawal
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We defined success of withdrawal as the ability to complete the
study, i.e. no dropout due to worsening of neuropsychiatric symp-
toms (NPS) or no relapse to antipsychotic drugs use during the
trial. This was not reported in any of the included studies. Several
studies reported the number of participants completing and not
completing the study, but did not report the number of partici-
pants who failed to complete the study due to worsening NPS or
the number of participants who restarted antipsychotics. There-
fore, we used the difference between groups in the number of non-
completers of the study as a proxy for our primary outcome. How-
ever, we could not pool data because the studies were too hetero-
geneous clinically and there were considerable discrepancies in the
way the success of antipsychotic withdrawal was measured.
Nine studies (575 participants) reported data relevant to this out-
come (Ballard 2004; Ballard 2008; Bergh 2011; Bridges-Parlet
1997; Devanand 2011; Devanand 2012; Findlay 1989; Ruths
2008; van Reekum 2002).
In seven studies (446 participants) discontinuation of the antipsy-
chotic made little or no difference to the ability of participants
to complete the study (Ballard 2004; Ballard 2008; Bridges-Parlet
1997; Devanand 2011; Findlay 1989; Ruths 2008; van Reekum
2002).
In three studies (149 participants) there was some evidence in
favour of the continuation group (Devanand 2011; Devanand
2012; Bergh 2011). Although Devanand 2011 reported no dif-
ference between groups in the numbers of participants leaving
the study group early due to symptomatic relapse (a worsening
of psychosis, agitation or aggression), the study also reported that
time to a symptomatic relapse was shorter in the discontinuation
group than in the continuation group. Devanand 2012 reported
a higher rate of participants leaving the study group early due to
symptomatic relapse in the discontinuation group compared with
the continuation group and that discontinuation led to increased
risk of symptomatic relapse (increase in the NPI-core score at 4
months and 8months follow-up). Bergh 2011 reported a very high
dropout rate (7 of 9 participants) in the discontinuation group
compared to no dropouts (among 10 participants) in the contin-
uation group.
We assessed the overall quality of the evidence for this outcome to
be low, downgraded one level for indirectness, as not all included
studies directly measured the outcome of our interest, and one
level for risk of reporting bias. Several studies did not report the
number of participants who failed to complete the study due to
worsening NPS or the number of participants who relapsed to
antipsychotic use.
In Ballard 2008, we extracted data from the study flow diagram on
the same proxy outcome as reported in the pilot study of Ballard
2004 i.e. the number of participants not completing the study
(based on intention-to-treat (ITT) analysis). In this study, there
was a high number of participants not completing the study: 45/
82 participants (56%) in the discontinuation group and 43/83
(51%) participants in the continuation group. Three participants
in the discontinuation group and four in the continuation group
did not complete the study because their behavioural condition
deteriorated. No difference between groups was reported. No data
were reported for relapse to antipsychotic use.
Ballard 2004 reported the number of non-completers of the study
based on ITT analysis and the proportion of participants devel-
oping pronounced behavioural symptoms. About a third (14/46,
30%) participants in the discontinuation group and 14/54 (26%)
participants in the continuation group did not complete the study
(P = 0.62). Six of 46 participants in the discontinuation and 5/
54 participants in the continuation group did not complete the
study due to behavioural deterioration (P = 0.55). In this study,
there was no difference in completion rates between groups. No
data were reported for relapse to antipsychotic use.
In Bergh 2011 there was a high dropout rate and imbalance be-
tween the discontinuation and continuation groups: 7/9 partici-
pants in the discontinuation group and 0/10 participants in the
continuation group failed to complete the study. This could be
interpreted as failure of completing the study in the discontinu-
ation group due to worsening NPS. The study authors reported
that results were inconclusive.
Bridges-Parlet 1997 reported the numbers of participants com-
pleting the four-week trial, the number of non-completers of the
study due to increased NPS and also the number of participants
relapsing to antipsychotic use. Two of 22 participants (9%) in the
discontinuation group and 0/14 participants in the continuation
group failed to complete the study. There was no difference in suc-
cessful completion between groups (Chi² > 0.05). One non-com-
pleter experienced a pronounced increase in behavioural symp-
toms and was reverted to antipsychotic drug use.
Devanand 2011 reported the total number of participants not
completing the study, the rate of leaving the study group early
due to symptomatic relapse, and the time to symptomatic relapse.
Therewas a higher rate of participants leaving the study group early
due to symptomatic relapse in the discontinuation group (8/10,
80%) compared to the continuation group (4/10, 40%), but the
difference in relapse rates between the groups was not statistically
significant (Chi² =3.3, P =0.07). Therewas, however, a statistically
significantly shorter time to relapse in the discontinuation group:
mean 5.8 weeks (SD 6.7) in the discontinuation group compared
to mean 8.0 weeks (SD 6.7) in the continuation group (Chi²
= 4.1, P = 0.04). The severity of agitation or aggression in the
open haloperidol treatment phase of the study did not predict the
likelihood of symptomatic relapse in the discontinuation trial.
Devanand 2012 reported the total number of participants not
completing the study and the rate of participants leaving the study
early due to symptomatic relapse (an increase in the NPI-core
score of 30% or more). During the first 16 weeks of the study (N
= 110), 27/40 participants in the discontinuation group and 30/
70 participants in the continuation group did not complete the
study. The rate of participants leaving the study early due to symp-
tomatic relapse (including relapse, imminent relapse, or mortality)
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was higher in the discontinuation group (24/40, 60%) than in the
continuation group (23/70, 33%) (P = 0.004). The discontinu-
ation group had an increased risk of leaving the study early due
to symptomatic relapse compared with the continuation group
(hazard ratio (HR) 1.94, 95% CI 1.09 to 3.45, P = 0.02). Crude
(unstratified) rates of relapse at four months were 6.5 and 3.0 per
100 patient-weeks of follow-up for the discontinuation and con-
tinuation groups, respectively. During the subsequent 16 weeks
(N = 40), 13/27 participants did not complete the study in the
discontinuation group and 3/13 participants did not complete the
study in the continuation group. The rate of participants leaving
the study early due to symptomatic relapse was higher in the dis-
continuation group (13/27, 48%) than in the continuation group
(2/13, 15%) (HR 4.88, 95% CI 1.08 to 21.98, P = 0.02). At eight
months, crude rates of relapse were 4.3 and 1.1 per 100 patient-
weeks of follow-up for the discontinuation and the continuation
groups respectively. The total number of participants completing
the eight months discontinuation trial was very low: 10/40 par-
ticipants in the discontinuation group and 10/32 participants in
the continuation group. No difference was reported by the study
authors.
In Findlay 1989, all 36 participants (18 in each group) completed
the four week study.We therefore assumed that no participants left
the study early due to worsening NPS or relapsed to antipsychotic
use.
The main outcome measure in Ruths 2008 was successful antipsy-
chotic discontinuation, i.e. still off antipsychotics in the discon-
tinuation group at the end of the one month study. In the discon-
tinuation group 23/27 participants were still off antipsychotics.
Four participants did not complete the study in the discontinu-
ation group (4/27) and three participants did not complete the
study in the continuation group (3/28) (P = 0.7). There were two
non-completers in the discontinuation group due to behavioural
deterioration.
van Reekum 2002 reported that 10/17 participants stopped the
allocated treatment early in the discontinuation group and 6/17
stopped early in the continuation group (ITT analysis). The dif-
ference in the rate of early stopping between the groups was not
significant (RR 1.57, 95%CI 0.76 to 3.26), nor was the difference
in number of participants stopping early due to exacerbation of
NPS (4/17 in the discontinuation group, 3/17 in the continuation
group, P > 0.1.) There were no data on relapse to antipsychotic
use.
2. Behavioural and psychological symptoms
Seven studies (519 participants) contributed data for this outcome
(Ballard 2004; Ballard 2008; Bergh 2011; Bridges-Parlet 1997;
Devanand 2012; Ruths 2008; van Reekum 2002).
Two studies (265 participants) used the NPI to assess NPS and
were considered suitable to pool for meta-analysis (Ballard 2004;
Ballard 2008). There was little or no difference in NPS between
groups after three months (negative values favour discontinua-
tion): MD -1.49, 95% CI -5.39 to 2.40; participants = 194; stud-
ies = 2 (Analysis 1.1 and Figure 1). Initially, assessments of theNPI
scores in these two Ballard studies were not made at the same time
(Ballard 2004 assessed at three months and Ballard 2008 assessed
at 1, 3, 6 and 12 months, but data in the publication were only
available for sixmonths).With the permission of Clive Ballard and
the help of Ly-Mee Yu we calculated means and mean differences
from individual participant data of the DART-AD trial for the
NPI score at three months using SPSS software (Declerck 2009c
[pers comm]).
We could not pool data from five studies because they were clin-
ically too heterogeneous (different outcomes, different outcome
scales, different time of follow-up) or reported insufficient data.
However, results from these five studies (254 participants) also
suggested that discontinuation may make little or no difference to
NPS (Bergh 2011; Bridges-Parlet 1997; Devanand 2012; Ruths
2008; van Reekum 2002).
Overall, we considered the quality of evidence relating to this
outcome to be low, downgraded one level for imprecision due to
the wide confidence interval and small number of participants and
one level for risk of reporting bias (study authors’ conclusions were
not supported with reported data in four studies).
Subgroup analyses of Ballard 2004 andBallard 2008 suggested that
the effect of antipsychotic discontinuation may differ depending
on the severity ofNPS at baseline. Ballard 2004 reported that some
participants with less severe NPS (NPI score ≤ 14) may benefit
from discontinuation of antipsychotics in terms of agitation (a
subscore of the NPI). Ballard 2008 and Ballard 2004 suggest that
some participants with more severe NPS (total NPI > 14) may
benefit from continuing antipsychotic treatment.
Behavioural and psychological symptoms measured with
versions of the NPI
Pooled studies
Therewas nodifference between groups in change on theNPI total
score after three months in Ballard 2004 or the key psychiatric/
behavioural factors of agitation, mood and psychosis. Results were
reported for on-treatment-analysis only (i.e. all participants who
completed the study).
In the subgroup of participants with baseline NPI scores at or be-
low the median (≤ 14) there was a trend that the discontinuation
group was less likely to develop pronounced behavioural or psy-
chiatric symptoms (Chi² = 3.6; P = 0.06) although there was no
difference in the total NPI score between groups (Mann-Whitney
U test z = 1.7; P = 0.9). A pronounced behavioural problem was
defined as a score of 8 or above on an individual item of the NPI
(Declerck 2009c [pers comm]). There was a greater reduction of
agitation (a subscore of the NPI) in the discontinuation group:
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1.0 point (SD 3.1) improvement in the discontinuation group
and 1.5 point (SD 2.5) deterioration in the continuation group
(Mann-Whitney U test z = 2.4; P = 0.018).
A subgroup of participants with higher baseline NPI scores (> 14)
were more likely to develop pronounced behavioural problems if
antipsychotics were discontinued (Chi² = 6.8; P = 0.009). There
were no differences in total NPI score (Mann-Whitney U test z =
0.34; P = 0.73) or agitation (Mann-Whitney U test z = 0.82; P =
0.38).
In the Ballard The DART-AD Trial 2008 there was no difference
between groups in the estimated mean change in NPI scores be-
tween baseline and six months. However, there was a significant
difference between groups in the estimated mean change in NPI
scores between baseline and 12 months. Results are reported for
the modified intention-to-treat (mITT) analysis (i.e. only partici-
pants who had at least one dose of treatment were included in the
analysis).
For all participants, there was no clear difference between groups
in the estimated mean change in NPI scores between baseline and
six months: 4.5 points (SD 17.6) deterioration for the discontin-
uation group (N = 53) compared to 1.3 points (SD 15.5) deteri-
oration for the continuation group (N = 56); estimated mean dif-
ference in NPI change (favouring continue treatment) 2.4, 95%
CI -8.2 to 3.5, adjusted for baseline value: P = 0.4.
For participants with baseline NPI ≤ 14, the change in NPI over
six months was very similar between groups (estimated mean dif-
ference in NPI change 0.49, 95% CI -5.63 to 6.60).
For participants with baseline NPI≥ 14, there was no clear differ-
ence between groups in the estimated mean change in NPI scores
between baseline and 6months (estimatedmean difference inNPI
change -5.33, 95% CI -15.82 to 5.17).
For all participants, continuation leads to small advantages at 12
months for those who continued antipsychotics: 11.4 points (SD
17.7) deterioration in the discontinuation group (N = 31) com-
pared to 1.4 points (SD 22.1) deterioration in the continuation
group (N = 28); estimatedmean difference inNPI change (favour-
ing continuation group) -10.9, 95% CI -20.1 to -1.7, adjusted for
baseline: P = 0.02. Over 12 months there was a large amount of
missing data, which could limit the validity of the results.
For participants with baseline NPI≤ 14, there was no clear differ-
ence between groups in the estimated mean change in NPI scores
between baseline and 12 months: estimated mean difference in
NPI change (favouring continuation of treatment) -5.2, 95% CI
-15.8 to 5.4.
For participants with baseline NPI > 14, continuation lead to ad-
vantages at 12 months for those who continued on antipsychotics:
estimated mean difference in NPI change (favouring the contin-
uation group) -16.9, 95% CI -32.5 to -1.2. The study authors
mentioned that the test for interaction (although underpowered)
was not significant (P = 0.2) and therefore concluded there was
no evidence of interaction between treatment group and severity
of symptoms at baseline (Ballard 2008).
Studies that could not be pooled
Bergh 2011 reported NPI-10 as a primary outcome, measuring
10 of the 12 NPI items, but without a score for sleep/nighttime
behaviour and appetite/eating changes. The mean total score for
the NPI-10 decreased by 3.50 (SD 13.53) in the discontinuation
group anddecreased by 5.40 (SD10.78) in the continuation group
(P = 0.76).
Devanand 2012 measured and reported the NPI core score for
both groups at baseline and at the time of randomisation, and
measured but not reported at later time points, although change
in theNPI core score was used to define relapse. The study authors
reported that the total NPI score at baseline did not predict a
relapse during the first 16 weeks of phase B and that the presence
of psychosis at baseline or randomisation did not predict a relapse
after discontinuation of risperidone.
Ruths 2008 used the NPI-Q, which measures severity but not fre-
quency of NPS, as a primary outcome. The NPI-Q scores were
reported for all 55 participants at one month follow-up. Changes
from baseline did not differ significantly between groups for total
NPI-Q scores, or the 12 individual symptoms of the NPI, or the
agitation subscore. There was no difference between groups in the
number of participants whose NPI-Q scores remained stable or
decreased (18/27 in the discontinuation group, 24/28 in the con-
tinuation group, P = 0.18). Participants with behavioural deteri-
oration after antipsychotic cessation used higher daily drug doses
at baseline (P = 0.042).
van Reekum 2002 used the NPI as an outcome but did not report
data in the paper. The study authors reported no conclusions re-
lating to NPI score.
Behavioural and psychological symptoms measured with
other scales
We could not pool data from any of the studies using other scales
to assess behavioural and psychological symptoms.
Bergh 2011 reported depression measured with the CSDD. They
found no evidence of a difference between groups. The mean
change from baseline to 25 weeks on the CSDD was a small dete-
rioration of 5.83 points (SD 36.40) in the discontinuation group
and a small improvement of 5.30 points (SD 11.25) in the con-
tinuation group (P = 0.375).
Bridges-Parlet 1997 concluded there was no difference between
continuation and discontinuation groups in observed instances of
physically aggressive behaviour: discontinuation group 1.27 (SD
3.95) versus continuation group 4.50 (SD 8.83), P > 0.05. Ver-
bally aggressive behaviour was reported not to differ significantly
between groups, although no data were provided to support this
conclusion made by the study authors.
van Reekum 2002 reported no statistically significant difference
in BEHAVE-AD (measuring behaviour) and ROAS (measuring
physical aggression towards themselves or others) scores between
the discontinuation and continuation groups (P > 0.05). The dis-
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continuation group showed more apathy than the continuation
group (P = 0.04). However, not all of the study authors’ conclu-
sions were supported by data reported.
3. Presence of withdrawal symptoms or withdrawal
syndrome in the first four weeks after withdrawal
No studies reported withdrawal symptoms or withdrawal syn-
drome in participants who discontinued antipsychotics.
4. Adverse events
Five studies (381 participants) (Ballard 2008; Bridges-Parlet 1997;
Devanand 2012; Findlay 1989; van Reekum 2002) contributed
data on adverse events. Devanand 2011 reported adverse events
only for the initial phase of open treatment with haloperidol and
not for the discontinuation phase. None of the studies system-
atically reported all adverse and serious adverse events. Studies
reported only a selection of adverse events such as parkinson-
ism, movement disorders, falls, mobility, balance, extrapyramidal
symptoms, heart rate and blood pressure. We could not pool data
because of the diverse ways adverse events were assessed.
Discontinuation maymake little or no difference to adverse events
(Devanand 2012; Ballard 2008; Bridges-Parlet 1997; Findlay
1989; van Reekum 2002). Overall, we considered the quality of
evidence for this outcome to be low, downgraded one level for in-
directness because only a selection of adverse events was systemati-
cally assessed and one level for risk of bias because there was a high
dropout in two studies (Ballard 2008; Devanand 2012) and risk
of reporting bias (no data were provided to support the authors’
conclusions in two studies).
Ballard 2008 measured change in severity of parkinsonism from
baseline to six months using theMUPDRS. There was a small 0.4
point (SD 3.2) improvement in the discontinuation group and a
small 0.8 point (SD 4.1) deterioration in the continuation group.
The study authors reported that this difference was not statistically
significant: estimated mean difference (favouring placebo): 1.1,
95% CI 0.4 to 2.6, adjusted for baseline value: P = 0.1. This may
be due to the small sample size and high dropout.
Bridges-Parlet 1997 reported that three participants in the dis-
continuation group experienced adverse events (2 participants had
behaviour deterioration and 1 had tardive dyskinesia). There were
no adverse events reported for the continuation group.
In Devanand 2012 all adverse events (extrapyramidal signs,
akathisia or restlessness, sedation, insomnia, confusion, agitation-
aggression, falls, nausea or vomiting and other) and serious adverse
events (death, cardiovascular event, neurologic event, agitation-
aggression, pulmonary event, fall or fracture and other) were re-
ported in a separate table, and an expanded version of this table was
provided in the Supplementary appendix.Only this study assessed
falls. A serious adverse event was defined as an adverse event that
resulted in any of the following outcomes: death, a life-threatening
condition, hospital admission or prolongation of hospital stay or
an unexpected event leading to clinically significant disability or
incapacity. There were no differences in rates of serious adverse
events, adverse events and death. There was no difference in ad-
verse events measured with the Simpson-Angus, AIMS, TESS, al-
though comparisons were based on small numbers of participants,
especially during the final 16 weeks and on truncated observation
period for adverse events in the case of participants who had an
early relapse. No data for difference between groups was reported.
Findlay 1989 reported numerical data for mobility, range of mo-
bility, transferring, response to chest pushing and balance and po-
sition sense, vibration sense, reading of a sway for the participants
standing with eyes open, systolic and diastolic blood pressure and
heart rate, lying and standing blood pressure and heart rate, the
sum of the mobility outcomes, balance while standing, balance
on turning head, balance on turning whole body through 360 °.
Only means, ranges and numbers of observations were reported
for each of these outcomes. The study authors concluded that dis-
continuation had no apparent effect on mental function, mobility
or balance, and that the drugs had few side effects.
van Reekum 2002 assessed extrapyramidal signs using ESRS, but
reported results for this outcome only at baseline and not at the
end of the study. The study authors concluded that both groups
scored similarly on the assessment measures. The data to support
this conclusion were not reported.
Secondary outcomes
1. Cognitive function
We included five studies (365 participants) for this outcome (
Ballard 2008; Devanand 2011; Devanand 2012; Findlay 1989;
van Reekum 2002). Outcomemeasures differed across studies and
we could not pool data for this outcome.
Discontinuation may make no difference to cognitive function
(Ballard 2008; Devanand 2011; Devanand 2012; Findlay 1989;
van Reekum 2002). However, one trial found that discontinua-
tion improves measures of verbal fluency (Ballard 2008). Over-
all, we assessed the quality of the evidence for this outcome to be
low, downgraded one level for imprecision (no meta-analysis and
most included studies had few participants) and one level for risk
of reporting bias (no data were provided to support the authors’
conclusions in 4 studies).
Ballard 2008 reported four outcomes measuring aspects of cogni-
tive function. One outcome, the FAS, measuring verbal fluency,
favoured the discontinuation group after sixmonths: the estimated
change in FAS totals between baseline and six months was a 0.6
point (SD 6.2) improvement in the discontinuation group and a
3.2 points (SD 6.6) deterioration in the continuation treatment
group: estimated mean difference (favouring discontinuation) -
4.5, 95% CI -7.3 to -1.7, adjusted for baseline: P = 0.002. For the
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main outcome, the SIB, used to assess overall cognition, there was
no evidence of a difference between groups. Themean change from
baseline to six months was a deterioration of 5.7 points (SD 14.2)
in the discontinuation group and a deterioration of 6.2 points (SD
16.0) in the continuation group (estimated difference -0.4, 95%
CI -6.4 to 5.5, adjusted for baseline: P = 0.9). For the SMMSE,
used to assess overall cognition, there was also no evidence of a
difference between groups. The mean change from baseline to six
months for the SMMSE was a deterioration of 1.0 point (SD 4.2)
in the discontinuation group and a deterioration of 1.8 point (SD
3.6) in the continuation group (estimated MD -1, 95% CI -2.7
to 0.7, adjusted for baseline: P = 0.2). For the STALD (receptive),
used to assess receptive language skills, there was no evidence of a
difference between the continuation and discontinuation groups.
The mean change in STALD scores was 0.3 points (SD 2.1) de-
terioration for the discontinuation group and a 0.5 point (SD
1.7) deterioration for the continuation group: estimatedMD -0.2,
95% CI -1.1 to 0.6, adjusted for baseline value: P = 0.6. For the
STALD (expressive), used to assess expressive language skills, there
was no clear evidence of a difference between the continuation and
discontinuation groups. The mean change in receptive language
scores between baseline and six months was a 0.2 point (SD 2.5)
improvement in the discontinuation group and a 0.6 point (SD
1.8) deterioration in the continuation group: estimated MD -1.0,
95% CI -2.0 to 0.04, adjusted for baseline: P = 0.06.
InDevanand 2011 the study authors reported that cognition mea-
sured by change in MMSE did not differ by treatment group
in phase B. No data were provided to support this conclusion.
MMSE cognitive scores were measured and reported only at base-
line (phase A) and at time of randomisation into phase B, and
measured but not reported at other time points or at the end of
the study.
In Devanand 2012 the study authors reported that the changes in
MMSE and ADAS-cog score did not differ between the continu-
ation and discontinuation groups. Data were not reported to sup-
port these conclusions. Total MMSE and ADAS-cog scores were
measured and reported only at baseline of the open risperidone
treatment and at the time of randomisation into the discontinua-
tion trial and measured but not reported at other time points or
at the end of the study.
Findlay 1989 concluded there was no difference in cognitive func-
tion measured by CAS over a four-week study period. Outcomes
were reported only as means with a range and number of obser-
vations. However, the difference between the discontinuation and
continuation groups at baseline could have influenced the result.
van Reekum 2002 concluded there was no difference between the
continuation and discontinuation groups in cognition, measured
by MMSE and MDRS. Data were not reported to support these
conclusions.
2. Quality of life of participants, carers, families or a
combination
Quality of life was reported in two studies (119 participants)
(Ballard 2004; Bergh 2011). We could not pool data because dif-
ferent outcome measures were used.
There may be no difference in quality of life between groups, but
we considered the quality of the evidence for this outcome to be
low, downgraded one level for imprecision and one level for risk of
bias (high risk of attrition bias and reporting bias in Bergh 2011).
There was no clear evidence of a difference between groups in
well-beingmeasured by Dementia CareMapping in Ballard 2004.
There was a small improvement in well-being (mean -0.18 (SD
1.72)) in the discontinuation group and a slight worsening (mean
0.35 (SD 2.41)) in the continuation group (MD -0.53, 95% CI -
1.42 to 0.36).
Bergh 2011 reported there were no statistically significant differ-
ences in QoL-AD between groups. No data were provided to sup-
port this conclusion.
3. Time, in days, until repeat prescription for any
psychotropic or any antipsychotic agent
Time in days until repeat prescription for any psychotropic or any
antipsychotic agent was reported for a subgroup 30 participants
in one nursing home. Ruths 2008 reported that standing orders
for antidepressants, hypnotic and anxiolyticmedications remained
unchanged for all participants during the intervention, but did not
provide supporting data.We considered this to be very low-quality
evidence, downgraded one level for imprecision (single study with
a small number of participants) and two levels for risk of bias
(unclear risks of selection, detection bias and reporting bias; no
data provided to support conclusion).
4. Use of physical restraint
Use of physical restraint was reported as an outcome in Bridges-
Parlet 1997 (36 participants). The study authors reported no dif-
ference in time being restrained between the discontinuation and
continuation groups, but provided no supporting data. We con-
sidered the quality of this evidence to be very low, downgraded
one level for imprecision (single study with a small number of
participants) and two levels for risk of bias (no data reported to
support conclusion and unclear risk of selection).
5. Mortality
Mortality was reported as an outcome in two studies (275 partic-
ipants) (Ballard 2008; Devanand 2012). We could not pool data
due to heterogeneity of the outcome measures. It was not pos-
sible to draw conclusions about the effect of discontinuation on
mortality because of the very low-quality of the evidence, down-
graded one level for imprecision (small numbers of participants
and events in both studies) and two levels for risk of attrition bias
(high dropout in both studies).
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Ballard reportedmortality data as cumulative probability of survival
at 12, 24 and 36 months in a long-term follow-up for participants
randomised in the 12 month discontinuation trial (Ballard 2008).
In a mITT analysis including participants who received at least
one dose of treatment, there was no evidence of a difference be-
tween groups. The cumulative probability of survival during the
first 12 months was 70% (95% CI 58% to 80%) in the continua-
tion group compared with 77% (95% CI 64% to 85%) in the dis-
continuation group. The small sample size meant a lack of power
to detect differences. The difference between groups in cumula-
tive survival rate became more pronounced after the 12 month
randomised phase of the trial. The cumulative survival rate was
higher in the discontinuation group (71%) compared to the con-
tinuation group (46%) after 24 months follow-up, and also higher
in the discontinuation group (59%) compared to the continua-
tion group (30%) after 36 months follow-up (reported as a signif-
icant difference between groups, no further details reported). Due
to high dropout and uncertainty about the use of antipsychotics,
Ballard 2008 reported that the lower mortality in the discontinu-
ation group should be interpreted with caution. The survival rates
were similar in additional analyses that focused on the participants
who continued their allocated treatment for at least 12 months.
In Devanand 2012 mortality measured after 16 and 32 weeks did
not differ between the continuation and discontinuation groups.
Three deaths (1 in the discontinuation group and 2 in the con-
tinuation group) occurred during the discontinuation trial. There
were small numbers of participants, especially during weeks 16 to
32.
6. Other secondary outcomes
6.1 Global functioning
We included four studies (329 participants) for this outcome (
Ballard 2008; Devanand 2011; Devanand 2012; van Reekum
2002). Outcome measures differed among included studies and
data could not be pooled for this outcome.
Discontinuation may make no difference to global functioning.
Overall, we assessed the quality of the evidence for this outcome to
be low, downgraded one level for imprecision (studies with small
numbers of participants) and one level for risk of reporting bias in
three studies.
In Ballard 2008 global function assessed with the BADLS showed
no clear difference between continuation and discontinuation
groups: there was an improvement in function of 0.2 points (SD
7.2) in the discontinuation group and an improvement of 1.8
points (SD 8.9) in the continuation group. However there was no
difference between groups (estimated MD 1.7, 95% CI -1.2 to
4.6, adjusted for baseline: P = 0.2). For the change on FAST, which
measures global outcome, there were no differences between the
continuation and discontinuation groups in terms of the dementia
stage (P = 0.9).
Devanand 2011 reported no evidence of a difference in BFAS
scores between the continuation and discontinuation groups in
phase B, although the supporting data were not reported.
Devanand 2012 reported no evidence of a difference in physical
function between groups on the Physical Self-Maintenance Scale,
although the supporting data were not reported.
van Reekum 2002 concluded that discontinuation of antipsy-
chotics did not lead to differences between groups on the BDS,
measuring activities of daily living and motivational behaviour.
Supporting data were not provided.
6.2 Sleep
We included two studies (66 participants) for this outcome
(Bridges-Parlet 1997; Ruths 2008). Outcome measures differed
and we could not pool data for this outcome.
Discontinuation may make no difference to sleep (Bridges-Parlet
1997; Ruths 2008). Overall, we assessed the quality of evidence
for this outcome to be low, downgraded one level for imprecision
(only 2 studies with few participants) and one level for risk of bias
(conclusions were from subgroup analyses and there was a risk of
reporting bias in Ruths 2008).
In a subgroup of the Ruths 2008 study, sleep was measured by
actigraphy in 30 participants over four weeks. Abrupt discontinu-
ation of antipsychotics was associated with slightly reduced aver-
age sleep efficiency from 86% to 75% (i.e. 54 minutes less sleep),
but there was no difference between groups (P = 0.29).
In Bridges-Parlet 1997, the study authors reported no difference
in time sleeping between treatment groups. No data were provided
to support the conclusion.
6.3 Clinical global impression
We included three studies (311 participants) for this outcome (
Ballard 2008; Devanand 2012; Findlay 1989).Outcomemeasures
differed among included studies and we could not pool data for
this outcome.
Based on these three studies, we are uncertain whether discontin-
uation improves clinical global functioning. Overall, we assessed
the quality of the evidence for this outcome to be low, downgraded
one level for imprecision (small number of participants) and one
level for risk of reporting bias (data not provided to support con-
clusion in either study).
In Ballard 2008, there was no evidence of differences between
the continuation and discontinuation groups in clinical global
impression rated on the CGI-C (P = 0.9).
Findlay 1989 reported no difference in global impression using
the SandozClinical AssessmentGeriatric Scale (SCAGS). Authors’
conclusions were not supported with extractable data; results were
given only as means, ranges and numbers of observations.
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In Devanand 2012, the CGI-C was also measured at different
times, but assessment at the end of the discontinuation trial was
not reported in the paper, although this score was a criterion of
the predefined threshold score for relapse in the discontinuation
trial. No conclusions were made by the study authors.
Covariables
In a post hoc analysis reported inBallard 2008 (N=100, follow-up
3 months) there was no indication of a difference between partic-
ipants taking typical or atypical antipsychotics. Most participants
were taking risperidone or haloperidol; the number of participants
taking other drugs was too small for any meaningful comparison.
D I S C U S S I O N
Summary of main results
We included 10 studies that included a total of 632 participants.
One new trial was added for this update (19 participants).
Our conclusions for all outcomes were based on studies that re-
ported quantitative data, or on conclusions made by the study
authors if data were not provided.
Pooling was only possible for behavioural outcomes assessed by
Neuropsychiatric Inventory score (NPI) and not possible for all
other outcomes due to the clinical heterogeneity of the studies, and
considerable discrepancies in the ways outcomes were measured.
The results and quality of evidence assessment for each outcome
in the main comparison (discontinuation compared to continua-
tion of antipsychotic drug use for behavioural and psychological
symptoms in older participants with dementia) are described in
Summary of findings for the main comparison.
Primary outcomes
Our predefined outcome success of withdrawal was not reported
in the included studies. Therefore, we used the difference between
groups in the number of non-completers of the study as a proxy
for our primary outcome. Low-quality evidence in seven studies
suggests little or no overall difference in the ability of participants
to complete the study.However, in two studies of participants with
psychosis, aggression or agitation who had responded to antipsy-
chotic treatment, we found theremay be a benefit from continuing
antipsychotics. One small study reported that a high proportion
of participants in the discontinuation group failed to complete the
study.
We found low-quality evidence in two pooled studies and five
non-pooled studies for the outcome behavioural and psychological
symptoms. In the two pooled studies, there was no difference in
NPI scores between groups. In five non-pooled studies, discontin-
uation may make little or no difference in scales measuring overall
behaviour and psychological symptoms between groups. The two
pooled studies performed subgroup analyses according to baseline
NPI-score (≤ 14 or > 14). In one study, some participants with
milder symptoms at baseline were less agitated at three months in
the discontinuation group. Both studies suggest that participants
with more severe neuropsychiatric symptoms (NPS) (total NPI
above 14) may benefit from continuing antipsychotic treatment.
No studies reported withdrawal symptoms.
Low-quality evidence from five studies suggested discontinuation
may make little or no difference in adverse events between groups.
Secondary outcomes
Low-quality evidence from five studies suggested discontinuation
may make no difference to cognitive function. However, one trial
found that discontinuation improved measures of verbal fluency.
Low-quality evidence from two studies indicated there may be no
difference in quality of life between discontinuation and continu-
ation group participants.
It remains unclear if discontinuation reduced time to repeat pre-
scription of any psychotropic or antipsychotic agent (1 study) or
discontinuation increased use of physical restraint (1 study).
We found low-quality evidence that discontinuation may make
no difference to global functioning (4 studies), in sleep (2 studies)
and clinical global functioning (3 studies).
Based on very low-quality evidence from two studies, It was not
possible to draw conclusions about the effect of discontinuation
on mortality.
Overall completeness and applicability of
evidence
The main limitation of this review was the lack of consistency re-
garding study participants (such as the case definition applied and
the severity of dementia of the participants), types and dosages
of antipsychotics used before withdrawal, exclusion criteria, in-
terventions (i.e. method of withdrawal), outcomes, and times of
assessment among the individual studies.
We included all types and grades of dementia severity, regardless of
themethod of diagnosis. This reflects the current situation in clin-
ical practice where many nursing home residents with dementia
are not formally diagnosed. We believe that including all potential
participants will make the review findings as widely applicable as
possible.
It is possible that the profile of the original symptoms (i.e. a spe-
cific cluster of NPS) for which the antipsychotics were prescribed
influenced the assessed outcome. Therefore, it would be useful
to know why the antipsychotics were prescribed. Devanand 2011
and Devanand 2012 tried to overcome this problem by including
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only participants with symptoms of psychosis, agitation or aggres-
sion who had responded to antipsychotic treatment.
Most of the available evidence only applies to nursing home resi-
dents or to people in long-stay psychogeriatric or geriatric wards
(i.e. hospital setting). Only one small pilot study and its larger
subsequent trial included participants living in the community
(outpatients). Therefore, the results of this review may not be ap-
plicable to community settings.
Adverse events, withdrawal symptoms or syndromes, initiation of
other psychoactive drug use after withdrawal and baseline antipsy-
chotic dose were not systematically reported. Consequently, the
effect of these on clinical outcomes is unknown, which is a ma-
jor gap in the evidence. It was not possible to draw conclusions
about the comparative efficacy of a tapered withdrawal schedule
or abrupt withdrawal.
This review assessed the effect of antipsychotic withdrawal only.
The results cannot be extrapolated to other drug types which may
be prescribed for NPS in dementia and which are also potentially
inappropriate or harmful, such as benzodiazepines.
Quality of the evidence
Overall, data on the effect of withdrawal of antipsychotics in older
participants with dementia and NPS remain very sparse. We sum-
marised the quality of evidence for comparisons in Summary of
findings for the main comparison. Evidence for all outcomes was
low- or very low-quality. The reasons for downgrading were im-
precision, risk of bias and indirectness.
Limitations in study design or execution
Many included studies had methodological limitations. Only one
RCTwas assessed at low risk of bias for all domains (Ballard 2008).
In almost half of the studies, there was insufficient information on
random sequence generation or allocation concealment or both.
Participants and personnel were blinded in all studies, but infor-
mation on blinding of outcome assessment was unclear for four
studies, althoughwe thought this was unlikely to seriously alter the
results. One study had a high dropout rate with imbalance between
groups which could influence the results. Three studies were iden-
tified as having a potential risk of reporting bias, although most
results reported were negative, suggesting they were not tending
to favour the reporting of positive results. We judged three studies
to be at high risk of reporting bias, possibly influencing results.
Because of these limitations, we downgraded the level of evidence
by one or two levels for risk of bias.
Mortality outcomes were measured in two studies from four
months to 12 months (Ballard 2008; Devanand 2012). In a long-
term follow-up of 36 months, after the 12 months randomised
discontinuation trial, we were uncertain whether discontinuation
led to a decreasedmortality (Ballard 2008). These two studies were
possibly too short-term to detect an effect of discontinuation of
antipsychotics on mortality rates.
Other limitations of study design were a lack of information about
the indications for antipsychotic use and a lack of systematic re-
porting of adverse events which may be related to antipsychotics
use, such as falls, extrapyramidal symptoms, cognitive dysfunc-
tion, metabolic changes, cardiovascular events and others. Only
one study assessed falls (Devanand 2012).
Inconsistency of results
The two studies that reported our primary outcome NPS and pro-
vided data that could be pooled for meta-analysis, showed consis-
tency of results between the studies. On the whole, the diversity
of the studies and their outcome measures precluded meta-anal-
yses. We therefore summarised evidence in a narrative synthesis,
showing good consistency of conclusions across studies.
Indirectness
We defined success of withdrawal as the ability to complete the
study (i.e. no withdrawal due to worsening of NPS or no relapse
to antipsychotic drugs use during the trial). However none of the
studies included this outcome defined in this way. Therefore, we
used the number of non-completers of the study and the difference
between groups as a proxy for our primary outcome. We down-
graded the quality of evidence for this outcome by one level due
to this indirectness.
Most of the included trials assessed a wide range of neuropsychi-
atric symptoms (anxiety, apathy, depression, delusions, wander-
ing, repetitive vocalisations, shouting, disinhibition, aberrant mo-
tor behaviour and appetite behaviour and many other symptoms).
Two RCTs (Devanand 2011; Devanand 2012) focused on par-
ticipants with psychosis, agitation or aggression. This could limit
generalisability of the results of these studies, although we did not
think this had an impact on the overall conclusions, because this
subgroup was small. We discussed this subgroup separately be-
cause it may be clinically relevant.
We downgraded quality by one level for indirectness when con-
sidering the outcome adverse events because the included studies
measured only a selection of potential adverse events.
Imprecision
All included studies had problems including ’frail’ older partici-
pants (a group with high mortality) and had small sample sizes.
Therefore, the statistical power of the studies was low, and very
few outcomes showed clinical differences between the groups. Be-
cause it was not possible to pool data for most outcomes due to
variability in outcome measures, the potential benefit of a meta-
analysis to produce a more precise effect estimate could not be
realised.
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The effect estimate for the two pooled studies on NPS had a
wide 95% confidence interval which includes the null effect of no
difference between treatments. This means NPS could get either
better or worse after discontinuation.
Publication bias
We conducted a comprehensive search for published and unpub-
lished studies that would have reduced the risk of publication bias.
Funnel plots could not be constructed because we included only
10 studies.
Potential biases in the review process
We searched a wide range of databases with no restriction of lan-
guage. We identified one unpublished study. We may have missed
relevant studies; however, we think it is unlikely that we did not
capture all available RCT evidence in this review.
Three review authors independently conducted all data selection
and extraction; another review author acted as arbiter to minimise
the risk of error and bias.
We pooled two studies that used the same NPI scale, although
assessed at different times. It was unclear whether this difference in
time of assessment had an important impact on the conclusions.
A critical narrative synthesis of the results could introduce bias,
although there was consistency in the effects of the intervention
across studies.
Overall, data on the effect of withdrawal of antipsychotics in older
people with dementia and NPS remain very sparse, and conclu-
sions should be interpreted with caution.
None of the review authors was involved in the included trials or
had conflicts of interest in the field of antipsychotics.
Agreements and disagreements with other
studies or reviews
A systematic review of 10 studies (Pan 2014) found that discontin-
uation of antipsychotics had no effect on behavioural and psycho-
logical symptoms severity, early study termination and mortality.
Pan 2014 did not identify the unpublished study by Bergh 2011.
One cluster RCT (Ballard 2016) in participants with dementia
living in nursing homes found advantages on quality of life if an-
tipsychotic review is combined with non-pharmacological inter-
ventions (social interaction or exercise) compared with antipsy-
chotic review without non-pharmacological interventions. This
reinforces the urgency to establish safe and effective pharmaco-
logical and non-pharmacological alternatives to antipsychotics in
older people with dementia and NPS.
A literature review by Banerjee 2009 revealed an increase in abso-
lute mortality risk of approximately 1% after antipsychotic treat-
ment in older people with dementia.We found insufficient data to
determine whether discontinuation of antipsychotic medication
has any effect on mortality.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is low-quality evidence that antipsychotics may be discon-
tinued in older people with dementia who have been taking these
drugs for at least three months, and that discontinuation may
have little or no important effect on behavioural and psycholog-
ical symptoms. This approach is consistent with the observation
that most behavioural complications of dementia are intermittent
and do not persist for longer than three months. Discontinuation
also may have little or no effect on overall cognitive function, al-
though one study reported an improvement in verbal fluency. It
may make no difference to adverse events and quality of life. We
are uncertain whether discontinuation of antipsychotics leads to a
decrease in mortality at short- or long-term follow-up.
Subgroup analyses in some of the included trials suggest that dis-
continuation may reduce agitation for participants with less severe
neuropsychiatric symptoms (NPS) and continuation may benefit
participants with more severe NPS.
We also found that in two studies, participants with psychosis,
aggression or agitation who had responded well to long-term an-
tipsychotic drug use may benefit from continuation of antipsy-
chotics.
Nevertheless, because of limitations in the quality of the evidence,
further research on the benefits and harms of withdrawing an-
tipsychotics from participants with milder and severe symptoms
is required.
The overall conclusions of the review are unchanged since this
review was published 2013 and the number of available trials is
still low.
Implications for research
The available studies have low statistical power due to lower than
expected recruitment and highmortality in this frail group of older
people. This could explain the absence of a clinically important
effect for several outcomes. However, the sample of participants
included in these studies reflects everyday reality.Conducting trials
in this context of frail older people requires a delicate balance
between methodological rigor and feasibility. Future trials need to
be rigorous in design and delivery, with subsequent reporting to
include a comprehensive description of all aspects of methodology
to enable appraisal and interpretation of results with sufficient
follow-up. A pragmatic trial, designed to evaluate the effectiveness
of interventions in real-life routine practice conditions, may add
significant value.
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None of the included studies addressed acute withdrawal effects
of antipsychotics. Abrupt drug discontinuation may contribute
to observed withdrawal effects and tapering medication may pro-
duce different effects, particularly in participants taking high doses
of antipsychotics at baseline. More studies focusing on different
methods of withdrawal are needed to provide the evidence base
for clinical recommendations.
A focus on the NPS cluster with predominantly psychotic symp-
toms (i.e. hallucinations, irritability, agitation and anxiety) could
be clinically relevant and an appropriate primary outcome for stud-
ies assessing the effect of withdrawal from antipsychotics in par-
ticipants with dementia. It is likely that scales other than the NPI
scale (e.g. the agitation NPI subscore) will correspond better with
this symptom cluster and should, therefore, be used in further tri-
als.
Studies are needed to explore the effects of withdrawal on differ-
ent aspects of cognitive function and to determine whether any
cognitive effects have an impact on the ability of participants to
carry out daily activities.
Characteristics other than low baseline behavioural scores (Ballard
2004), for example, low antipsychotic baseline dose, or no use
of benzodiazepines or antidepressants, may predict beneficial out-
comes after antipsychotic cessation (Meador 1997). Future tri-
als could examine how outcomes for discontinuation of antipsy-
chotics depend on the agent and on drug interactions and con-
comitant drugs. Thus, other psychotropic medications such as
benzodiazepines, should be considered systematically as well.
Important adverse effects such as falls, extrapyramidal symptoms
and involuntary movements are not systematically measured in
most of the available studies. The reduction of adverse events re-
lated to long-term antipsychotic drug use is another potential ben-
efit of discontinuing antipsychotics and should be evaluated more
systematically.
The perceptions and beliefs of carers and families may influ-
ence inclusion of participants in withdraw interventions. Smith
2011 reported that in the Ballard 2008 study, consent was with-
drawn in 16% of the eligible cases before blinding, either by
the participant, the family practitioner or the family. In addi-
tion, Cohen-Mansfield 1999 reported that half of the nursing staff
feared that drug withdrawal would lead to deterioration of be-
haviour. More studies are needed to elicit barriers and enabling
factors and explore their impact on success of the intervention.
Our review reinforces the urgency to establish safe and effective
pharmacological and non-pharmacological alternatives to antipsy-
chotics in older people with dementia and NPS. Meanwhile, ac-
tion is needed in several domains of dementia care to reduce long-
term and potentially inappropriate use of antipsychotics in frail
older people (McCleery 2012).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ballard 2004
Methods Design: double-blind, placebo-controlled study
Duration: 3 months
Participants Country: UK
Centres: 2
Setting: residents of 2 long-term care facilities
Total number of participants: 100 (46 intervention, 54 control)
Analysis: completed at least 1 follow-up randomisation
Gender distribution (F%): 76 % intervention = 76%, control = 87%
Mean age (years): intervention = 83.1 (SD 7.1), control = 83.6 (SD 9.3)
Cognitive function (Mean MMSE): intervention = 5.5 (SD 6.8), control = 5.5 (SD 6.
5)
Total NPI: intervention = 13.3 (SD 9.3), control = 15.7 (SD 8.3)
Inclusion criteria: older participants (aged > 65 years) care facility residents, probable
or possible Alzheimer’s disease by the NINCDS-ADRDA criteria (National Institute of
Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association Criteria), a Clinical Dementia Rating Scale stage 1 or greater and
no severe behavioural symptoms (no individual scores above 7) on the NPI at time of
evaluation, taking neuroleptics (thioridazine, chlorpromazine, haloperidol, trifluoper-
azine or risperidone) for more than 3 months (median prescription time longer than 1
year)
Exclusion criteria: no severe behavioural disturbances, taking neuroleptics for longer
than 3 months, having severe behavioural symptoms (individual scores above 1) and no
severe behavioural symptoms (individual scores above 7 on 1 of the 12 items of the NPI-
scale)
Interventions Intervention 1: abrupt discontinuation of antipsychotics (intervention group)
Intervention 2: continuing antipsychotics (control group)
No dose reduction of tapering
Outcomes Duration of follow-up: 3 months (0, 1 and 3 months)
Outcomes measured: behavioural and psychiatric symptoms (NPI), quality of life
(DCM)
Notes Funding provided by Research into Aging (London, UK) and Age Concern (London,
UK)
Conflicts of interests were not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: method of sequence generation
is not reported
Quote: ”Subjects were then randomised to
neuroleptic (N = 54) or placebo (N = 46)“
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment is not described
Quote: ”...Dispensing was coordinated by
the pharmacy departments at the 2 cen-
tres. Prescriptionswerewrittenprior to ran-
domisation in a twice daily regimen, allo-
cating to each participant the closest dose.
..“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as double-
blinded, unlikely that blinding could have
been broken. Encapsulation of the admin-
istered drugs ensured blinding of partici-
pants and doctors/nurses
Quote: ”The study was conducted using a
double-blind design. All study neuroleptics
were encapsulated by an independent com-
pany tomaintain blind, and dispensing was
coordinated by the pharmacy departments
at the 2 centres. Prescriptions were writ-
ten prior to randomisation in a twice-daily
regimen, allocating to each participant the
closest dose to their pre-existing prescrip-
tion from the doses encapsulated“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: study is described as double-
blinded, unlikely that blinding could have
been broken. Blinding of the outcome
raters is not described
Quote: ”...using a double blind design...the
centre coordinator, blinded to neuroleptic
status, decided whether the patient needed
to be withdrawn from the study to receive
“rescue” medication.“
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Low risk Comment: reasons for dropouts reported
and similar for both groups
Quote: ”All evaluations were undertaken
at baseline. The NPI and DCM assess-
ments were also completed at 1 and 3
month follow-up. Study withdrawals and
the proportion of participants develop-
ing marked (pronounced or manifest) be-
havioural symptoms are described and
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compared between groups using the chi-
square test. Fourteen participants (26%
active treatment, 30% placebo) withdrew
from the study in each group. There were
only 6 withdrawals in the placebo-treated
group (13%) and 5 withdrawals in the ac-
tive treatment group (9%) because of be-
havioural deterioration. Otherwithdrawals
were because of physical health problems
(active group: 3 (6%), placebo group: 3
(7%)), protocol violation (active group:
2 (4%), placebo group: 1(2%)) or with-
drawal of consent (active group: 3 (6%),
placebo group: 2 (4%)). Eighty-two (82%)
of the participants completed at least 1 fol-
low-up evaluation and were included in the
primary outcome analysis. For all partici-
pants who completed at least 1 follow-up
assessment, the last evaluation was carried
forward“
Selective reporting (reporting bias) Low risk Comment: behavioural and psychiatric
symptoms and well-being reported on all
measured time points, cognition was only
assessed at start of the study
Other bias Low risk No other bias
Ballard 2008
Methods Design: randomised, blinded, placebo-controlled parallel 2-group treatment discontin-
uation study
Duration: 12 months
Participants Country: UK
Setting: residents of 5 long-term care facilities
Total number of participants: 165 (82 discontinuation, 83 continuation)
Gender distribution (women %): 75.6 % discontinuation, 77.1% continuation
Mean Age, SD (years): 84.9 (SD 6.1) discontinuation, 84.4 (SD 7.0) continuation
Inclusion criteria: participants lived in a nursing or residential home, patient fulfilled
the NINCDS/ADRDA criteria for possible or probable Alzheimer’s Disease, patient had
either a MMSE score > 6 or a Severe Battery Impairment score > 30, patient was taking
at least 10mg chlorpromazine equivalents of a typical neuroleptic or at least 0.5 mg daily
of risperidone
Exclusion criteria: participants unable to complete primary outcome measures at base-
line assessment, clinician responsible for care or study clinician considered the person
with any physical condition that would have made participation in the trial distressing
or likely to have more physical problems, patient was currently taking thioridazine and
showing a prolonged QTc on electrocardiogram, patient was likely to be unable to take
39Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with
dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ballard 2008 (Continued)
capsules
Interventions Intervention 1: abrupt discontinuation of neuroleptics and switch to placebo (placebo
group)
Intervention 2: continuation of neuroleptics (continuation group)
Three fixeddosages (very low-low-high)were chosen for each of the permittedneuroleptic
drugs and were maintained during the 12 months
Outcomes Duration of follow-up: 12 months
Primary outcome:
Cognitive function: total Severe Impairment Battery (SIB) score (0, 6, 12 months)
Secondary outcomes:
neuropsychiatric symptoms: NPI (0, 6, 12 months)
cognitive function: StandardisedMini-Mental State Examination (SMME) (0, 6months)
adverse effects: Modified Unified Parkinson’s disease Rating Scale (M-UPDRS) (0, 6
months)
FAS test (0, 6 months)
Bristol Activities of Daily Living Scale (BADLS) (0, 6 months)
Sheffield Test for Acquired Language Disorders (STALD)(0, 6 months)
Functional Assessment Staging (FAST)(0, 6 months)
Clinician’s Global Impression of Change (CGIC) (0, 6 months)
Notes Clive Ballard, first author, has received honoraria en research grants from different com-
panies
Study was possible by a grant from the Alzheimer’s Research Trust, Cambridge, UK
There are several factors limiting the generalisability of the interpretation of this trial
First, recruitment focused on participants living in residential care where moderate and
severe dementia usually predominates, and the participants generally are older and frailer
than their counterparts in other settings. Thus, the results are not easily extrapolated to
individuals who are cared for in other community settings
Second, 89% of the participants were taking haloperidol or risperidone, but pharmaco-
logical profiles of neuroleptics differ, so that the study might not adequately represent
the effects of discontinuation of other neuroleptics
Furthermore, polypharmacy is common in residential care, and the study didnot consider
other psychotropic prescriptions
Finally, high participant attrition sharply reduced the statistical power and scope for
analysis of outcomes at 12 months. Imputation procedures and sensitivity analyses es-
tablished robustness of estimates, but they cannot account for type II errors (i.e. false-
negative interpretation)
Individual participant data at three months from was kindly provided by the authors to
allow pooling of the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comments: randomisation was done by
computer random number generator
Quote: ”Randomisation was performed
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centrally at the Centre for Statistics in
Medicine in Oxford (CSMO), using ded-
icated computer software (MINIM). The
randomisationprogramme included amin-
imisation algorithm to ensure balanced al-
location of participants across the interven-
tion groups for important prognostic fac-
tors“
Allocation concealment (selection bias) Low risk Comment: central allocation concealment
Quote: ”The statistician carrying out the
randomisation had no direct contact with
patients and allocation was, therefore, to-
tally independent of patient recruitment.
The clinician responsible for randomisa-
tion of a patient faxed a randomisation
form to the CSMO (or sent e-mail) in ex-
ceptional circumstances) and provided de-
tails appropriate and sufficient for estab-
lishing eligibility. If a person was eligible
and informed consent/assent had been ob-
tained and baseline assessments had been
completed, the patient was randomised
by the statistician either to continue tak-
ing medication or to discontinue (placebo
group). The statistician directly commu-
nicated the allocation to the relevant trial
pharmacy, ensuring concealment.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as double-
blinded, unlikely that blinding could have
been broken
Quote: ”The clinicians, those administer-
ing the trial medication, the carers, the
relatives and the participants themselves,
and those assessing the outcomes were all
blinded to treatment allocation. Each an-
tipsychotic was over-encapsulated to main-
tain the double-blind design. Placebo cap-
sules were identical to the over-encapsu-
lated antipsychotics,..“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: study is described as double-
blinded, unlikely that blinding could have
been broken
Quote: ”... those assessing the outcomes
were blinded to treatment allocation...“
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Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Low risk Comment: flow of participants is included.
Missing data is balanced across groups and
similar reasons
Quote: ”Primary analysis was done per-
formed on patients with complete data at
both baseline and week 26, including those
who did not adhere tot the protocol. To
give a completed data set the imputation
method was used “filling in” missing data
with plausible values. A sensitivity analysis
was used to test the robustness of the SIB
result. This analysis was limited to those
participants for whom the risk of possible
floor and ceiling effects was smallest, i.e.
SIB baseline cut-off values ≥ 40 but ≤ 90.
“
Selective reporting (reporting bias) Low risk Comment: all intended primary and sec-
ondary outcomes are reported in the first
and the follow-up study
Other bias Low risk No other bias
Bergh 2011
Methods Design: randomised double-blind placebo-controlled trial with two sub-studies: the an-
tidepressant discontinuation placebo-controlled study group (Bergh 2012) and the an-
tipsychotic discontinuation placebo controlled study group (Bergh 2011). The antipsy-
chotic discontinuation study (Bergh 2011) met inclusion criteria and was included in
the review.
Duration: 25 weeks
Participants Country: Norway
Setting: residents of 15 nursing homes
Total number of randomised participants: 19 (9 discontinuation, 10 continuation)
Mean age (years): 81.7 discontinuation, 82.6 continuation
Gender distribution (% women): 37.5 discontinuation, 70 continuation
Median CSDD score (range 0 to 38): 5.5 discontinuation, 6 continuation
Median NPI-10 (range 0 to 144): 22 discontinuation, 21 continuation
Inclusion criteria: vascular or Alzheimer dementia, or mixed Alzheimer’s disease/vas-
cular dementia, nursing homes resident for 3 months or more, given risperidone for 3
months or more, Clinical Dementia rating 1, 2 or 3
Exclusion criteria: dementia of other origin, psychiatric disease (schizophrenia, depres-
sion or any severe), life expectancy less than 3 months, acute infection last 10 days,
unstable diabetes mellitus, terminal disease
Interventions Treatment 1: discontinuation risperidone after titrated out over one week
Treatment 2: continuation of risperidone (dose in each patient varied, according to the
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dose the participants were prescribed at inclusion, mean dose at inclusion was 0.92 mg/
d)
Concomitant therapy: all kinds of concomitant therapy were allowed before, during
and after the study
Outcomes Primary outcomes: neuropsychiatric symptoms: changes in Neuropsychiatric Inven-
tory-10 (0 weeks, 25 weeks; range 0 to 120), depressive symptoms of a patient with
dementia: changes in Cornell’s Depression Scale (0 week, 25 weeks; range 0 to 38),
safety analyses: changes on the Unified Parkinson Disease Rating Scale (UPDRS, six-
item version) (0 weeks, 25 weeks)
Secondary outcomes: Quality of life - Alzheimer’s disease (QoL-AD), the Severe Im-
pairment Battery (SIB), the Lawton & Brody’s Physical Self-Maintenance scale (PSMS)
, the Clinical Dementia Rating Scale (CDR)
Notes Sponsor: Innlandet Hospital Trust. There is no conflict of interest of the author reported.
It is unclear if the author received grants. Provider of study drugs is not described
This was an unpublished study. We requested results by email communication with the
author on 8 June 2017 (Van Leeuwen 2017 [pers comm]). We received study results on
10 June 2017. The study arm with antidepressants was published in 2012 as a separate
paper. The antipsychotics discontinuation arm was never published as paper. The study
results were known in 2011 and reported to the Norwegian Medicines Agency. This
study was not included in the 2013 review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: participants randomised cen-
trally
Quote: ”...using computer generated ran-
domisation (1:1) in block of four...“
Allocation concealment (selection bias) Low risk Comment: pharmacist was responsible for
allocation
Quote: ”... patients were allocated to
placebo or active treatment group by cen-
tralized allocation in blocks of four (1:
1) by Sykehusapotekene Gjøvik, who also
kept the randomisation list, computer de-
rived, until the statistical analyses were
completed..“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study was described as double-
blinded, probably blinding will be success-
fully done
Quote: ”Study blinding was maintained
as no other involved partner of the study
knew the randomisation list than Syke-
husapoteket Gjøvik. All statistical analy-
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ses were performed before the randomisa-
tion groups were unblended. The bottles
with active medication and placebo were
identical labelled...replaced by placebo in
a blinded way or replaced by a study drug
containing active medication (same kind,
same dose) as before...“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: probably blinding of assess-
ment outcomes was successfully done. The
study involved 57 study nurses which could
have biased the results
Quote: ”Data collection was done by
research nurses. All statistical analyses
were performed before the randomisation
groups were unblended. A sealed code en-
velope was stored in the patient’s medical
journal at the nursing homes, and could
only be opened in case of medical emergen-
cies as a serious adverse event.“
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
High risk Comment: all randomised participants
(19) are described in the flowchart. Very
high dropout andwithdrawal in the discon-
tinuation group (7/9) suggests high risk of
bias. Dropouts were more frequent in the
ApDG (7/9, 77.8%) than in the ApCG (0/
10, 0.0%) (P = 0.001). The analysis was
based on modified ITT: participants in ef-
ficacy analysis: 16, participants included in
safety analysis: 18. Unpublished data and
high dropouts suggests high risk of attrition
bias
Selective reporting (reporting bias) High risk Comment: protocol was registered in Clin-
icalTrials.gov, outcomemeasurements were
not all reported as per protocol paper. Study
is unpublished, no peer reviewing to valid
results suggests high risk of bias
Quote: ” ... The number of primary end-
points were reduced from three to two:
Cornell Scale of Depression in Dementia
and the Neuropsychiatric Inventory...the
changes were made prior to breaking the
blind, and have limited implications for
study interpretation... no observe case anal-
ysis en no interim analyses as planned in
the protocol.“
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Other bias Low risk No other bias
Bridges-Parlet 1997
Methods Design: double-blind, baseline treatment neuroleptic-controlled pilot study
Duration: 4 weeks
Participants Country: USA
Setting: residents of long-term care facilities
Participants: 36 (22 discontinuation, 14 continuation)
Inclusion criteria: participants with diagnosis of possible or probable Alzheimer’s de-
mentia (criteria were given), participants receiving a neuroleptic (any traditional neu-
roleptic was acceptable) and who had been on a stable dose for 3 months prior to the
study, a history of physically aggressive behaviour according to the referring nursing
supervisor, participants residing in a nursing home, participants on antidepressants were
permitted to participate if medication doses had been stable
Exclusion criteria: participants with primary psychiatric diagnoses, mental retardation
and terminal illness or other recent acute, changes in health status (e.g. recent broken
hip)
Interventions Intervention 1: withdrawal neuroleptics (discontinuation)
Intervention 2: no withdrawal neuroleptics (continuation)
Abrupt withdrawal or tapering off a neuroleptic when baseline dose exceeded the equiv-
alent of 50 mg of chlorpromazine. The tapering was done by dropping the baseline neu-
roleptic dose by half during week 1 and then discontinuing the neuroleptic completely
at the beginning of week 2
Neuroleptic drugs: haloperidol (21), thioridazine (9), thiothixene (3), trifluoperazine (1)
, mesoridazine (1), loxapine (1)
Outcomes Primary outcome: completion of the 4 weeks of study (numbers completing the 4 week
study), behavioural symptoms: change in the amount of observed physically aggressive
behaviour (mean, mean difference) (0, 1, 2, 4 weeks)
Secondary outcomes: use of physical restraint, verbally aggressive behaviour, walking,
amount of time spent sleeping and sitting, verbal aggressiveness, physically aggressive
acts observed by experienced study personnel and by using a portable barcode reader
capable of storing several hours of observation (0, 1, 2, 4 weeks)
Notes Research grant from the Alzheimer’s Association.
There may have been selective recruitment limiting the generalisation of the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: randomisation was done by
random number table
Quote: ”Assignment was based on a prede-
termined sequence such that three patients
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were assigned to withdrawal for every two
not withdrawn. At the end of week 1, sub-
jectswere randomly assigned to eitherwith-
drawal or no withdrawal.“
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment is not described, and may not have
been blinded. Participant groups were well
matched for age, chlorpromazine-equiva-
lent neuroleptic dose and physically aggres-
sive behaviour at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as double-
blinded, unlikely that blinding could have
been broken. Nursing staff was involved
in decision to discontinue the programme.
They were blinded for the treatment allo-
cated, thus outcome assessment may have
been adequately blinded
Quote: ”Patients in both groups received
identical-appearing capsules prepared at
theUniversity ofMinnesotaHospital Phar-
macy. Patients receiving their medication
in crushed form, received in the placebo
group tablets of vitamin C instead of cap-
sules. The patient receiving intramuscular
mesoridazine daily was given intramuscu-
lar saline from a nurse not directly involved
in the patient’s care“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: study is described as dou-
ble-blinded, unlikely that blinding could
have been broken. Participants were di-
rectly observed by study personnel, who
were blinded to treatment assignments and
recording behaviour was done by using a
portable bar-code reader capable of storing
several hours of observation
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Low risk Comment: dropouts were described
Quote: ”Of the 22 patients who were with-
drawn, 20 (91%) completed the 4-week
double-blinded withdrawal. Two patients
were restarted on medication on the rec-
ommendation of the nursing staff; only one
went back on a neuroleptic. Of the 14 pa-
tients not withdrawn, all completed the
4-week trial. Of the 576 observation pe-
riods there were seven in which the bar-
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code reader failed. Handwritten back-up
noteswere used for physically aggressive be-
haviour frequency.“
Selective reporting (reporting bias) Low risk Comment: all intended outcomes were re-
ported
Other bias Low risk No other bias
Cohen-Mansfield 1999
Methods Design: double-blind cross-over study
Duration: seven weeks followed by seven weeks cross-over
Participants Country: USA
Setting: residents of one nursing home
Diagnosis: the diagnosis of dementia was not mentioned
Number of participants: 58
Inclusion criteria: nursing home residents; aged over 70 years; had received at least four
weeks haloperidol, thioridazine or lorazepam for agitation
Exclusion criteria: concomitant administration of other antipsychotic or anti-anxiety
drugs other than low-dose trazodone hydrochloride for sleep, life expectancy less than
three months due to obvious causes as judged by the nursing home staff member respon-
sible for direct care psychiatric diagnosis of a major affective disorder of schizophrenia
according toDSM-III, acute infection within 10 days before entry, expectancy of leaving
the nursing home within three months, uncontrolled hyperglycaemia or hypoglycaemia
Interventions Tapering period: withdrawal of antipsychotic and lorazepam use by tapering to placebo
during a three-week period
Intervention 1: seven weeks of taking placebo followed by seven weeks of taking an-
tipsychotic medication
Intervention 2: seven weeks of taking medication followed by seven weeks of placebo
Antipsychotics: haloperidol, thioridazine
Outcomes Time of measurements: one week after start of dosage tapering (week 1), phase one
tapering (week 3), phase one end point (week 10), phase two tapering (week 13), phase
two end point (week 20)
Primary outcomes: behavioural symptoms (BPRS) (mean), agitation (CMAI) (mean)
Secondary outcomes (mean): adverse effects (AIMS), cognitive function (MMSE),
global impression scale (GCI-S), sleep and activity level ratings
Time of assessment: one week after start of dosage tapering (week 1), phase one tapering
(week 3), phase one end point (week 10), phase two tapering (week 13), phase two end
point (week 20)
Notes Several different analyses were used to assess the robustness of the result. However, it
was not clear if an intention-to-treat analysis was used. We were unable to use any
data from this study. Cohen-Mansfield 1999 did not report outcome data separately for
the different medications discontinued in the trial (which included the benzodiazepine
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lorazepam as well as the antipsychotics haloperidol and thioridazine)
This study was supported by grants AG00547 and AG10172 from theNational Institute
on Aging, Bethesda, MD, USA
No conflicts of interest reported.
Because diagnosis of dementia was not mentioned in the paper, we emailed the first
author (Declerck 2009a [pers comm] on 21 april 2009 to ask her whether the participants
included had dementia and her answer was positive (referring to the MMSE scores)
We have asked the author by email for more results (SDs of the means…) on 1 July
2009, but we have not received any response on our last e-mail (Declerck 2009b [pers
comm]).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of sequence generation
is not described
Quote ”...half the residents were randomly
assigned to have their medication dose ta-
pered during a 3-week period, followed
by receipt of a placebo (the other half
continued their usual medication dosage)
. Residents were randomly assigned to the
placebo versus medication group and strat-
ified both by level of cognitive function and
by psychotropic medication.“
Allocation concealment (selection bias) Unclear risk Comment: allocation is not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as blinded,
unlikely that blinding was broken
Quote: ”Study medications (usual medi-
cation and placebo) were administered as
identical liquids to ensure blindness by the
care team. Only the dispensing pharma-
cist, who was not an employee of the nurs-
ing home, knew which medication was ad-
ministered.The care team, residents, family
caregivers, and research team were blinded
to which group a participant was assigned.
“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: study is described as blinded,
unlikely that blinding was broken
Quote: ”The care team, ... and research
teamwere blinded to which group a partic-
ipant was assigned. Primary outcome data
BPRS was assessed by daytime and evening
nursing staff. “
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Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Unclear risk Comment: rates and reason for dropout
were described.Howeverwewere uncertain
howmany participants discontinued in the
discontinuation or continuation group in
the first part of the study
Quote: ”Twenty-three participants discon-
tinued participation in the study before
completion for the following reasons: death
or dying (3), hospitalisation (1), not eating
or weight loss (3), increased agitation (9)
, lethargy (2), withdrawal of consent (4),
facial asymmetry (1) and fall (3); some had
multiple reasons. For 12 participants, dis-
continuation occurred during the original
drug dosage, for 9 while taking placebo,
and for 2 during titration from drug to
placebo. Most discontinuations (20 of 23)
occurred in the first part of the study, be-
fore the cross-over.“
Selective reporting (reporting bias) High risk Comment: no distinction ismade for num-
ber of withdrawals in each group during
the first part of the trial. it is not clear
how they analyse these outcome. By not
making difference in outcome reporting
between discontinuation of antipsychotics,
namely haloperidol and thioridazine, ver-
sus discontinuation of lorazepam, a benzo-
diazepine, it is impossible to retain robust
conclusions from this withdrawal study
Quote: ”Participants who discontinued the
study were similar in demographic char-
acteristics to those who stayed. Although
their levels of agitation at baseline were
higher than those who stayed in the study,
these differences did not reach statistical
significance. Most withdrawals from the
study occurred in the first part of the study
(no numbers given).“
Other bias Low risk No other bias
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Methods Design: a six-month, randomised, double-blind, placebo-controlled discontinuation trial
(phase B) following response to haloperidol open treatment during 20 weeks (phase A)
Participants Country: USA
Setting: participants living in the community who presented to a memory disorders
clinic or an affiliated behavioural neurology practice group
Total number of participants: 44 participants included in phase A, 22 responders of
phase A were eligible for randomisation in phase B (discontinuation trial), 20 in phase
B (10 discontinuation, 10 continuation)
Gender distribution (female): 77%
Mean (years): 75 (SD 8.0)
Inclusion criteria: aged 50 to 95 years, clinical diagnosis of dementia byDSM-IV criteria
and probable Alzheimer’s disease by NNCDS-ADRA criteria, MMSE range between 5
and 26, current symptoms of psychosis, agitation or aggression
Exclusion criteria: acute unstable medical condition, delirium, alcohol or substance
abuse or dependence during the prior year, clinical evidence of stroke, other dementias
including vascular or Lewy body or frontotemporal dementia, multiple sclerosis, Parkin-
son’s disease, Huntington’s disease, tardive dyskinesia, diagnosis of a psychotic disorder
predating the onset of dementia, antipsychotic medication usage during the 4 weeks
before study entry, and contra-indication to the use of haloperidol
Interventions Phase A: open treatment (20 weeks): 44 participants living in the community with
Alzheimer’s disease and psychosis, agitation or aggression receiving psychotropic medi-
cation had a 1-week washout before entering phase A. During phase A flexible doses of
haloperidol 0.5 to 5mg daily were individually titrated tomaximise therapeutic response
and minimise side effects, especially extrapyramidal side effects. Visits occurred at 0, 2,
4, 8, 12, 16 and 20 weeks
Phase B: discontinuation trial (24 weeks): 20 phase A responders were double-blind ran-
domised to a continuation versus placebo (i.e. discontinuation) group. For participants
randomised to placebo, there was a 2-week double-blind sequential placebo substitution
tapering period to placebo
Outcomes Phase A: the 3 most prominent targets of psychosis, agitation or aggression, scored on
a 7-point scale (0 = absent to 6 = extreme) and tracked during the study. Criteria for
response (primary outcome) were minimum 50% reduction from baseline in the sum
score of these 3 target symptoms, a sum score ≤ 6 on these 3 items (range 0 to 18),
and minimal or greater improvement on the CGI-C score (rated only for symptoms of
psychosis, agitation or aggression)
Phase B
Primary outcome: relapse, assessed at any single time point during phase B. Criteria for
relapse were minimum 50% worsening from the sum score of the 3 target symptoms at
the end of phase A, a sum score ≥ 6 on these 3 items (range 0 to 18), and minimal or
greater worsening on the CGI-C score (rated for psychosis and agitation/aggression)
Secondary outcomes: somatic side effects assessed by the TESS, extrapyramidal signs
assessed by the UPDRS and tardive dyskinesia assessed by the Rockland TD scale.
Cognition was assessed by change in MMSE and impairment in ADL was assessed by
the modified BFAS
Time points of assessment during phase B: 0 (same as end of phase A), 2, 4, 8, 12, 16,
20 and 24 weeks (i.e. 6 months)
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Pretrial: a 1-week washout prior to entering phase A.
Notes Disclosures: authors had financial links with several pharmaceutical companies. Study
supported by NIH grant
The discontinuation trial included only participants who responded to haloperidol. Non-
responders after the first 20 weeks (phase A) were excluded from the discontinuation
phase (B). This limits the generalisability of the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described in the study
Allocation concealment (selection bias) Unclear risk Comment: no description of the blinding
of random allocation
Quote: ”Responders by end-Phase A were
eligible for Phase B, a 24-week, random
assignment (1:1 assignment of haloperidol
and placebo), double-blind, trial of contin-
uation haloperidol (same dose as end-Phase
A) versus switch to placebo.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as double-
blinded, unlikely blinding could have been
broken
Quote: ”Haloperidol and placebo were
made up in identical looking opaque white
capsules.“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome raters is
not described. In these trial, they were sev-
eral subjective outcomes, so a lack of blind-
ing of outcome assessors could had an in-
fluence
The protocol (Devanand 2012a) for the
subsequent study (Devanand 2012) men-
tions: Quote: ”The blind is maintained af-
ter study exit to avoid biasing raters. A
code-break is authorized only if needed in
cases of overdose or medical emergency...
raters remained unaware of the group as-
signments of all patients during the entire
study.“
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Low risk Comment: non-completers data were de-
scribed and balanced between the groups
Attrition at end of phase A fully accounted
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for; quote: ”There were 15 Phase A non-
completers (34%), with all early termina-
tions attributed either to lack of efficacy (n
= 9) or side effects (n = 6).“
Attrition at end of phase B accounted for
and ITT included; quote: ”Twenty of the
21 patients randomised in Phase B to con-
tinuation haloperidol or placebo had at
least one follow-up visit after randomisa-
tion and were included in the Phase B anal-
ysis. Among patients who did not relapse,
reasons for early study termination prior to
24 weeks in Phase B were side effects (n =
2), moving out of the area (n = 1), medical
illness (n = 1) and noncompliance (n = 1).
All data from these patients were included
in the intent-to-treat, last observation car-
ried forward, analyses. “
Selective reporting (reporting bias) Unclear risk Comment: several outcomes were mea-
sured at baseline of the open haloperidol
treatment and at time of the discontinua-
tion period, but no results were reported at
later times of assessment
Other bias Low risk No other bias
Devanand 2012
Methods Phase A: flexible dose risperidone open treatment for 16 weeks
Phase B: six-month, randomised, double-blind, placebo-controlled discontinuation trial,
following response to phase A
Duration: 48 weeks
Participants Country: USA
Setting: outpatients through physician referrals and advertising; and residents of as-
sisted-living facilities (memory clinics (including Alzheimer’s research centres), geriatric
psychiatry clinics and clinics at Veterans’ Affairs medical centres) or nursing home
Total number of participants: 253 participants screened
Phase A: 180 received risperidone, participants who had a response in phase A entered
phase B
Phase B: 110 randomised
Group 1: continue risperidone: 32 participants at start, 13 received risperidone at 16
weeks, 10 completed 48 weeks without relapse
Group 2: continue risperidone for 16 weeks and then placebo: 38 participants at start,
27 received placebo at 16 weeks, 14 completed 48 weeks without relapse
Group 3: start placebo in phase B: 40 participants at start, 13 received placebo at week
16, 10 completed 48 weeks without relapse
Gender distribution at baseline: 59%
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Mean (years) at baseline: 79.6 (SD 7.6)
Inclusion criteria: outpatients or residents of assisted-living facilities or nursing homes,
aged 50 to 95 years, met the criteria for dementia of theDiagnostic and StatisticalManual
of Mental Disorders, 4th edition (DSM-IV) and the criteria for probable Alzheimer’s
disease of the NINCDS-Alzheimer’s Disease and Related Disorders Association, a score
on the Neuropsychiatric Inventory (NPI) of 4 or more at both screening and baseline
on the delusions or hallucinations subscale (psychosis score) or the agitation/aggression
subscale (agitation score) (with scores on all NPI subscales ranging from 0 to 12 and
higher scores indicating more pronounced symptoms), a score of 5 to 26 on the Mini-
Mental State Examination (MMSE, with scores ranging from 0 to 30) in the case of
outpatients, a score of 2 to 26 in the case of nursing home residents (with the lower
range reflecting the greater severity of dementia in nursing homes)
Exclusion criteria: history of stroke, transient Ischaemic attack, or uncontrolled atrial
fibrillation
Interventions ParticipantswithAlzheimer’s disease andpsychosis, agitation or aggression received open-
label treatment with risperidone for 16 weeks. Those who had a response to risperidone
therapywere then randomly assigned, in a double-blind fashion, to one of three regimens:
continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks
followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3)
Phase A: open-label treatment with flexible dose risperidone for 16 weeks, participants
who had a response entered phase B
Phase B: 110 randomised in phase B
Group 1: continue risperidone
Group 2 continue risperidone for 16 weeks and then placebo
Group 3: discontinuation of antipsychotics
Concomitant treatment: quote: ”If washout was not feasible ... stable doses of selective
serotonin-reuptake inhibitors or low-dose trazodone or of sedatives or hypnotic agents
were permitted ... Lorazepam, at a dose of 1 mg or less per day, was permitted if needed.
.. cholinesterase inhibitors and memantine at stable dose were permitted“
Outcomes Primary end point: the time to relapse of psychosis and agitation/aggression during
weeks 0 to 16 of phase B, the time to relapse psychosis and agitation/aggression during
weeks 17 to 32 of phase B
Phase A: participants were considered to have had a response if they had a reduction of
30% or more from baseline on the NPI
score (the sum of the sub-scores for agitation-aggression, hallucinations, and delusions)
and a score of one (verymuch improved) or two (much improved) on the Clinical Global
Impression of Change (CGI-C) scale (which ranges from one to seven, with higher scores
indicating less improvement) for overall psychosis, agitation or aggression
Phase B: participants were considered to have had a relapse if they had an increase in
the NPI core score of 30% or more, or a 5-point increase from the score at the end of
phase A, and a score of six (much worse) or seven (very much worse) on the CGI-C
Secondary outcomes: assessments of extrapyramidal signs, with the use of the Simpson-
Angus scale (which ranges from 0 to 40, with higher scores indicating more extrapyrami-
dal signs), tardive dyskinesia, with the use of the Abnormal Involuntary Movement Scale
(AIMS, which ranges from 0 to 35, with higher scores indicating more severe symp-
toms), general somatic symptoms developing during treatment, as assessed with the use
of the Treatment Emergent Symptoms Scale (TESS, which ranges from 0 to 26, with
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higher scores indicating more somatic symptoms), cognitive status, as assessed with the
use of the MMSE and the Alzheimer’s Disease Assessment Scale (ADAS)-cognitive score
(which ranges from 0 to 70, with higher scores indicating worse cognition), physical
function, as assessed with the use of the Physical Self-Maintenance Scale (PSMS, which
ranges from 1 to 30, with higher scores indicating worse functioning) and adverse events
Notes Outcome symptoms slightly unevenly distributed in randomised groups in phase B: 9%
agitation-aggression in group 1 (continue risperidone) versus 19% in group 2 (switch to
placebo after 16 weeks) and 18% in group 3 (placebo throughout phase B)
High rates of discontinuation of risperidone (38% in phase A; 68% in group 1 and 29%
in group 2)
Funding sources: quote ”...Johnson & Johnson, donated the risperidone tablets and
matching placebo but had no role in the conduct of the study or the analysis or reporting
of the data... Supported by grants from theNational Institutes ofHealth (R01AG021488
and R01 AG17761) and the Department of Veterans Affairs.“
Conflict of interest: not reported in the paper, but included in the Supplementary Ap-
pendix available online (add link). The first author received grants from several pharma-
ceutical companies (inside and outside the submitted work). The discontinuation trial
only included only participants who responded to risperidone. Non-responders after first
16 weeks (phase A) were excluded from the discontinuation phase (B). This limits the
generalisability of the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: block randomisation is de-
scribed
Quote: ”The study statistician prepared
a randomised permuted-blocks procedure,
with blocks of three or six, to balance the
group assignment in each of four (2 × 2)
strata, with stratification within each site
according to the presence or absence of psy-
chosis at baseline and residence (assisted-
living facility or nursing home vs. home).“
Allocation concealment (selection bias) Low risk Comment: central allocation by pharma-
cist
Quote: ”Patients who had a response en-
tered phase B of the study and were ran-
domly assigned...The central pharmacy of
the New York State Psychiatric Institute
maintained the assignment code, and clin-
icians and raters remained unaware of the
group assignments of all patients during the
entire study.“
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as double-
blinded and unlikely that blinding could
have been broken
Quote: ”...double-blind fashion... clini-
cians and raters remained unaware of the
group assignments of all patients during the
entire study ... all tablets identical in ap-
pearance ... Immediately before the end of
phase A, the pharmacy dispensed pre-pack-
aged blister packs of risperidone or placebo
tablets that were identical in appearance for
patients eligible for randomisation in phase
B. The number of tablets the patient was
receiving daily at the end of phase A was
the number he or she received throughout
phase B.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: study is described as double-
blinded and unlikely that blinding could
have been broken. The blind is maintained
after study exit to avoid biasing raters. A
code-break is authorized only if needed in
cases of overdose or medical emergency
Quote: ”...raters remained unaware of the
group assignments of all patients during the
entire study...“
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Low risk Comment: all randomised participants ac-
counted for in the flowchart
Quote: ”The dropout rates did not differ
significantly among the randomised groups
(Fig. 1)“
Selective reporting (reporting bias) Unclear risk Comment: the results for the CGI-C were
not reported in the study, the total NPI
scores and the NPI core score were mea-
sured at baseline (phase A) and at time
of randomisation (phase B), but no results
were reported at later times of assessment
Other bias Low risk No other bias.
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Methods Design: randomised double-blind placebo-controlled trial
Duration: 4 weeks
Participants Country: UK
Setting: residents from one long stay of psychogeriatric ward of hospital
Total number of participants: 36
Gender distribution: 100% women
Mean age (years): 65 years or older
Inclusion criteria: senile dementia, Alzheimer type, according to ICD-9, receiving a
stable dose of between 10 mg and 100 mg of thioridazine per day for at least 2 months
Exclusion criteria: male, multi-infarct dementia and antipsychotic agents other than
thioridazine
Interventions Intervention 1: withdrawal of thioridazine
Intervention 2: continuation of thioridazine
Antipsychotic drug: thioridazine
Pre-trial: tapering to half of the daily dose in the first week and to placebo over the next
week
Post-trial: all participants were restored to half their original dose of thioridazine with
any subsequent alterations beingmade by their regular medical attendant on an empirical
base
Concomitant treatment: chlormethiazole
Outcomes Primary outcomes: cognitive function: CAS (0, 2, 4 weeks), cognitive and behavioural
dysfunction: LPRS (0, 2, 4 weeks), functioning: SCAGS (0, 2, 4 weeks)
Secondary outcomes: systolic BP and heart rate (0, 2, 4 weeks)
Results only given as means, ranges and numbers of observations
Notes Conflict of interest and source of funding were not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: methods of sequence genera-
tion were not described
Quote ”...matching active and placebo
(liquid) formulations of thioridazine were
used, each subject being entered separately
and allocated by a random code to the ac-
tive or placebo group in a double-blind
manner“
Allocation concealment (selection bias) Unclear risk Comment: study described
as ’randomised’, the randomisation process
was not completely successful
Quote: ”...each subject being allocated by
a random code to the active or placebo
group in a double-blind manner ... The
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starting difference in Cognitive Assessment
Scale scores between active-continued and
placebo-substituted groups represents an
artefact of the randomisation process.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study described as ”double
blinded“, unlikely that blinding was been
broken
Quote: ”matching active and placebo (liq-
uid) formulations were used ... During the
first week patients in the ’placebo’ group
received placebo substitution for half of
their daily dose of thioridazine and over
the next week a total substitution. Similar
mock substitutions with thioridazine were
given to the ’active’ group, so that initial
medication was continued but the trial re-
mained double-blind. After four weeks all
patients were restored to half their origi-
nal dose of thioridazine with any subse-
quent alterations being made by their regu-
lar medical attendant on an empirical basis
... as it was not possible to break the code
in the middle of the trial “
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: study is described as double-
blinded, blinding of the outcome assessors
is not described. Assessment was done by
clinicians and nurses with psychiatric train-
ing. In these trial, they were several subjec-
tive outcomes, so a lack of blinding of out-
come assessors could had an influence
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Unclear risk Comment: information of dropouts is not
reported in the study
Selective reporting (reporting bias) Unclear risk Comment: primary outcome is not de-
scribed, it is unclear if a selection of mea-
sured outcomes was reported
Other bias Unclear risk Comment: the randomisation procedure
unfortunately resulted in a baseline imbal-
ance in 1 of the 3 cognitive/behavioural
rating scales (starting difference in cogni-
tive assessment scale (CAS) between active
continued was 4.2 treatment and 9.8 in
the placebo-substituted groups. The author
noted: ”Difference represents an artefact of
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the randomisation process.“ It is unclear if
this has had an impact on outcomes
Ruths 2008
Methods Design: randomised, placebo-controlled, double-blinded study
Duration: 4 weeks
Participants Country: Norway
Setting: residents of 13 nursing homes
Diagnosis: dementia diagnosis according to the clinical criteria of ICD-10
Number of participants: 55 (27 intervention, 28 reference)
Gender distribution (F) (number, %): 20 (74%) intervention, 23 (82%) reference
Mean age (years): 83.6 (SD 8.1) intervention, 84.6 (SD 5.9) reference
Inclusion criteria: older participants, aged 65 years and over, dementia diagnosis accord-
ing to the clinical criteria of ICD-10 residence in the facility for at least 3 months before
inclusion, taking haloperidol, risperidone or olanzapine for nonpsychotic symptoms for
at least 3 months before the study as standing medication in stable doses
Exclusion criteria: participants with antipsychotic use for a primary diagnosis of major
psychotic disorder, mental retardation, terminal illness with life expectancy judged to be
shorter than 3 months and recent major changes in health status
Interventions Intervention group: abrupt discontinuation of antipsychotic medication
Reference group: no discontinuation of antipsychotic medication
Note: same dose of initial daily dose of antipsychotic drugs in intervention group: risperi-
done 1.0 (0.5 to 2.0) mg, haloperidol 1.0 (0.5 to 1.5) mg or olanzapine 5.0 (2.5 to 5.0)
mg
Outcomes Behavioural and psychological symptoms measured by the NPI-Q (second baseline pe-
riod, week 1, week 4). The NPI-Q covers 12 symptoms: delusions, hallucinations, agita-
tion/aggression, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant
motor behaviour (restlessness, e.g. purposeless wandering and inappropriate activity),
sleep problems and eating disorders. Information on participants’ symptoms was ob-
tained by interview with the primary nurse informant. Individual symptoms were scored
as 0 (absent), 1 (mild), 2 (moderate), or 3 (severe), providing an NPI-Q sum score rating
from 0 to 36. Three separate ratings were conducted for all the participant. These ratings
included symptoms occurring during the 7-day period before assessment
Sleep/wake activity was recorded continuously during baseline and intervention (i.e. over
6 weeks) using an Actiwatch portable recorder (second baseline week, week 1, week 4).
The Actiwatch is a small wrist-worn device containing an accelerometer that is optimised
for highly effective sleep-week inference from wrist activity. Actigraphically measured
wrist activity is a feasible and reliable method for sleep/wake evaluation in nursing home
residents. The following actigraphic parameters were calculated: total sleep time, total
wake time, sleep efficiency (proportion of sleep during night window, i.e. 11 pm to 7
am), daytime activity and night-time activity. The ratio of day-to-night-time activity was
calculated and expressed as a light/dark ratio. Mean 24-hours activity and peak times of
activity were calculated. Analyses of sleep/wake activity were based on 3 x 7-day records
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Notes Conflict of interests and funding were not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: method of randomisation is
done computer random number generator
Quote: ”Participants were assigned to an-
tipsychotic drug discontinuation (inter-
vention group) or no discontinuation (ref-
erence group) by means of computer gen-
erated, random, permuted blocks of 4... “
Allocation concealment (selection bias) Unclear risk Comment: allocation concealment was
provided central, no further details were re-
ported
Quote: ”...an independent researcher ...
participants were consecutively assigned to
antipsychotic drug discontinuation or no
discontinuation...“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: blinding of participants and
personnel is described, unlikely that blind-
ing could have been broken
Quote: ”In the intervention group, patients
received inert placebo capsules consisting
of lactose, whereas reference group patients
received identically looking capsules con-
taining continued antipsychotic drug treat-
ment at current dose ... all study medi-
cations were provided by an independent
pharmacy to maintain blindness ... Sealed
envelopes, containing details of study med-
ication for each patient, were available for
the nursing home physicians in case of se-
rious health events.“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: study is described as double-
blinded. Blinding of the assessment inter-
viewers is not described. In these trial, they
were several subjective outcomes, so a lack
of blinding of outcome assessors could had
an influence
Quote: ”NPI rating was based on inter-
views with patient’ prime nurse on her
observations of BPSD the previous week.
The interviews were conducted by spe-
59Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with
dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ruths 2008 (Continued)
cially trained medical students... Sealed en-
velopes... At the completion of the inter-
vention, randomizations codes were bro-
ken.“
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Unclear risk Comments: all 55 participants completed
at least the week one evaluation were in-
cluded in study analysis. No statistical dif-
ference in dropout between intervention
and reference group
Quote: ”Seven patients completed the
study prematurely, due to unblinding for
randomisation code, behavioural deterio-
ration, restless legs or delirium.“
Selective reporting (reporting bias) Low risk Comment: all intended outcomes reported
in accordance with the methods section
Other bias Unclear risk Comment: the selection of participants
may have been biased. It is not clear if the
participating nursing homes participants
are different from non-participating nurs-
ing home patients
van Reekum 2002
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 26 weeks
Participants Country: Canada
Setting: residents of two nursing homes and geriatric chronic care floor of an academic
health science centre
Total number of participants: 34 (17 placebo, 17 active)
Gender distribution (male): 47.1% placebo; 56.3% active
Mean (SD) age, years: 84.4 (SD 4;6) placebo, 82.9 (SD 6.9) active
Inclusion criteria: any form of dementia, receiving antipsychotics for 6 months or
longer, stable behaviour
Exclusion criteria: history of antipsychotic discontinuation having failedwithin the past
6 months, a history of schizophrenia, antipsychotic use for nausea, diagnosis of delirium
(DSM-IV criteria), a global rating scale of 3 on the BEHAVE-AD rating scale at the
time of the screening, 1 week prior to the start of the study or within the 2 weeks of the
pre-trial period
Interventions Placebo group: discontinuation antipsychotics
Active treatment: continuing antipsychotic treatment with the same dose
Antipsychotics: risperidone, thioridazine, loxapine, perphenazine, haloperidol, olanza-
pine, nozinan
Note: pre-trial period: 2-week pre-trial period and a 2 week dose reduction period by
tapering (dose reduction with original medication halved for the first week of the dose
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reduction period and the remaining dose halved for the second week)
Concomitant medication: lorazepam 0.5 mg to 1 mg every 8 hours on a per need basis
for agitation
Outcomes Behavioural outcome measures: BEHAVE-AD, the NPI and the ROAS (each visit: 15
times)
Cognitive functioning: MMSE (0, 4, 8, 12, 14, 16, 20, 24 weeks), MDRS (0, 24 weeks)
Functional level: BDS, ADL and motivational behaviour subscale (0, 4, 8, 12, 14, 16,
20, 24 weeks)
Extrapyramidal signs: ESRS (0, 4, 8, 12, 14, 16, 20, 24 weeks)
Clinical impression of severity of behavioural disturbance: CGI (all visits). The CGI
quantified the clinical impression of severity of behavioural disturbance on a 7-point,
verbally anchored scale. The degree of change from baseline was also ranked on a similar
scale
All outcome data were obtained by a trained research assistant upon interview of the
prime nurse or the subject as appropriate for the instrument
Notes Funding source and conflict of interests were not reported in study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: participants randomly assigned
to treatment by random number table
Quote: ”A random number table was used
to allocate subjects to receive either contin-
ued antipsychotic treatment at the current
dose or to receive identical placebo“
Allocation concealment (selection bias) Unclear risk Comment: no reference made to the
method in which allocation concealment
was ensured
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: study is described as ”double
blind“ and unlikely blinding could have
been broken
Quote: ”A randomised double blind
placebo controlled study design was used ..
. During all study periods, medications, in-
cluding placebo, were placed into identical
capsules to maintain blindness.“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: study is described as double-
blinded, blinding of the research team is
not described. In these trial, they were sev-
eral subjective outcomes, so a lack of blind-
ing of outcome assessors could had an in-
fluence
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Quote: ”All outcome datawere obtained by
a trainee research assistant upon interview
of the prime nurse or the subject as appro-
priate for the instrument... if the clinical
staff observed significant behavioural wors-
ening that they thought warranted early
withdrawal from the study, the ware asked
to contact the research team immediately
and the outcome measures were repeated at
that time.“
Incomplete outcome data (attrition bias)
NPI (Neuro Psychiatric Inventory) and
DCM (Dementia Care Mapping)
Low risk Comment: rates and reasons for dropouts
were reported. Analysis is done by inten-
tion-to-treatment principle
Quote: ”The total number of subjects who
were withdrawn from the study early was
10/17 in the placebo group and 6/17 in the
active treatment group. The difference in
the rate of early study withdrawal was not
statistically significant. Subjects were with-
drawn due to medical illness (3), death (3),
extrapyramidal symptoms (3), and exacer-
bations of behavioural problems (4 in the
placebo and 3 in the active group).“
Selective reporting (reporting bias) High risk Comments: some data of the continuation
and the discontinuation group for several
outcomes is not completely given in nu-
merical results but only in descriptive fig-
ures. NPS assessed by NPI, aggression as-
sessed by the ROAS, extrapyramidal signs
assessed by the ESRS, cognitive function-
ing assessed byMMSE and functional out-
come assessed by the BDS were not re-
ported in the paper
Other bias Low risk No other bias.
ADL: activities of daily living; BDS: Blessed Dementia Scale; BEHAVE-AD: Behavioural Pathology in Alzheimer’s disease; BFAS:
Blessed Functional Activity Scale; BP: blood pressure; BPRS: Brief Psychiatric Rating Scale; CAS: Cognitive Assessment Scale; CGI:
Clinical Global Impression; CGI-C: Clinical Global Impression-Change; CMAI: Cohen-Mansfield Agitation Inventory; DCM:
Dementia Care Mapping; DSM-III: Diagnostic and Statistical Manual of Mental Disorders - 3th Edition; DSM-IV: Diagnostic and
Statistical Manual of Mental Disorders - 4th Edition; ESRS: Extrapyramidal Symptom Rating Scale; LPRS: London Psychogeriatric
Rating Scale; MDRS: Mattis Dementia Rating Scale; MMSE: Mini-Mental State Examination; NIH: National Institutes of Health;
NPI: Neuropsychiatric Inventory; NPQ-I: Neuropsychiatric Inventory Questionnaire; NPS: neuropsychiatric symptoms; RCT:
randomised controlled trial; SCAGS: Sandoz Clinical Assessment Geriatric Scale; SIB: Severe Impairment Battery; TESS: Treatment
Emergent Symptom Scale; ROAS: Retrospective Overt Aggression Scale; UPDRS: Unified Parkinson’s Disease Rating Scale.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Azermai 2013 Not an RCT but a clinical trial without a suitable control group
Ballard 2015 Intervention was discontinuation of memantine
Bergh 2012 Intervention was discontinuation of antidepressants
Devanand 2013 Commentary
Garner 2015 Commentary
Gill 2013 Commentary
Gnjidic 2013 Commentary
Horwitz 1995 Not a clinical trial, but a naturalistic study
Ling 2013 Commentary
Lolk 2014 Commentary
McLennan 1992 This trial reports a primary outcome (prolactin response to withdrawal of thioridazine assessed in the Findlay
1989 cohort), which has no relationship with the neuropsychiatric symptom in which we were interested
Patel 2017 Not an RCT; post hoc analysis of Devanand 2012
Power 2013 Commentary
Renard 2014 Commentary
Rule 2003 This reference probably refers to the registration of a discontinuation study which has not been published until
now (no more information found on this reference)
Wessels 2010 This trial was not a discontinuation trial
Westbury 2011 This trial was a follow-up study and not a discontinuation trial
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Discontinuation versus continuation of long-term antipsychotic drug use (continuous data,
analysis method mean difference)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Behavioural assessment 2 194 Mean Difference (IV, Fixed, 95% CI) -1.49 [-5.39, 2.40]
Analysis 1.1. Comparison 1 Discontinuation versus continuation of long-term antipsychotic drug use
(continuous data, analysis method mean difference), Outcome 1 Behavioural assessment.
Review: Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia
Comparison: 1 Discontinuation versus continuation of long-term antipsychotic drug use (continuous data, analysis method mean difference)
Outcome: 1 Behavioural assessment
Study or subgroup Discontinuation Continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ballard 2004 36 -1.3 (9.4) 46 0.2 (12) 70.9 % -1.50 [ -6.13, 3.13 ]
Ballard 2008 54 2.04 (18.2) 58 3.52 (20.78) 29.1 % -1.48 [ -8.70, 5.74 ]
Total (95% CI) 90 104 100.0 % -1.49 [ -5.39, 2.40 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours discontinuation Favours continuation
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Table 1. Antipsychotic drug classes
Phenothiazines with aliphatic side chain
Phenothiazines with piperazine structure
Fhenothiazines with piperidine structure
Butyrophenone derivatives
Indole derivatives
Thioxanthene derivatives
Diphenylbutylpiperidine derivatives
Diazepines, Oxazepines and Thiazepines
Benzamides
Other antipsychotics
Table 2. Antipsychotic drugs with defined daily doses
Phenothiazines with aliphatic side-chain
N05AA01 Chlorpromazine 0.3 g per os
N05AA02 Levomepromazine 0.3 g per os
N05AA03 Promazine 0.3 g per os
N05AA04 Acepromazine 0.1 g per os
N05AA05 Triflupromazine 0.1 g per os
N05AA06 Cyamemazine
N05AA07 Chlorproethazine
Phenothiazines with piperazine structure
N05AB01 Dixyrazine 50 mg per os
N05AB02 Fluphenazine 10 mg per os
N05AB03 Perphenazine 30 mg per os
N05AB04 Prochlorperazine 0.1 g per os
N05AB05 Thiopropazate 60 mg per os
N05AB06 Trifluoperazine 20 mg per os
N05AB07 Acetophenazine 50 mg per os
N05AB08 Thioproperazine 20 mg per os
N05AB09 Butaperazine 10 mg per os
N05AB10 Perazine 0.1 g per os
N05AB20 Homophenazine
Phenothiazines with piperidine structure
N05AC01 Periciazine 50 mg per os
N05AC02 Thioridazine 0.3 g per os
N05AC03 Mesoridazine 0.2 g per os
N05AC04 Pipotiazine 10 mg per os
Butyrophenone derivatives
N05AD01 Haloperidol 8 mg per os
N05AD02 Trifluperidol 2 mg per os
N05AD03 Melperone* 0.3 g per os
N05AD04 Moperon 20 mg per os
N05AD05 Pipamperone 0.2 g per os
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Table 2. Antipsychotic drugs with defined daily doses (Continued)
N05AD06 Bromperidol 10 mg per os
N05AD07 Benperidol 1.5 mg per os
N05AD08 Droperidol
N05AD09 Fluanisone
N05AE Indole derivatives
N05AE01 Oxypertine 0.12 g per os
N05AE02 Molindone 50 mg per os
N05AE03 Sertindole* 16 mg per os
N05AE04 Ziprasidone* 80 mg per os
Thioxanthene derivatives
N05AF01 Flupentixol 6 mg per os
N05AF02 Clopenthixol 0.1 g per os
N05AF03 Chlorprothixene 0.3 g per os
N05AF04 Tiotixene 30 mg per os
N05AF05 Zuclopenthixol 30 mg per os
Diphenylbutylpiperidine derivatives
N05AG01 Fluspirilene
N05AG02 Pimozide 4 mg per os
N05AG03 Penfluridol 6 mg per os
Diazepines, Oxazepines and Thiazepines
N05AH01 Loxapine 0.1 g per os
N05AH02 Clozapine* 0.3 g per os
N05AH03 Olanzapine* 10 mg per os
N05AH04 Quetiapine* 0.4 g per os
Benzamides
N05AL01 Sulpiride 0.8 g per os
N05AL02 Sultopride 1.2 g per os
N05AL03 Tiapride 0.4 g per os
N05AL04 Remoxipride 0.3 g per os
N05AL05 Amisulpride* 0.4 g per os
N05AL06 Veralipride
N05AL07 Levosulpiride 0.4 g per os
Other antipsychotics
N05AX07 Prothipendyl 0.24 g per os
N05AX08 Risperidone* 5 mg per os
N05AX09 Clotiapine 80 mg per os
N05AX10 Mosapramine*
N05AX11 Zotepine* 0.2 g per os
N05AX12 Aripiprazole* 15 mg per os
N05AX13 Paliperidone*
*atypical antipsychotics
* Atypical antipsychotic agents.
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Table 3. Characteristics of included studies
Study IDI Setting Duration Ran-
domised
number
Discon-
tinuation
group
Continua-
tion
group
Discon-
tinuation
schedule
Control Be-
havioural
inclusion
criteria
Notes
Ballard
2004
Residents
in long-
term care
facilities
3 months 100 46 54 Abrupt Typical AP
a
or risperi-
done
NPIb
not higher
than 7
Ballard
2008
Residents
in long-
term care
facilities
6 months
12 months
165 82 83 Abrupt Typical
and
risperi-
done
NRc
Bergh
2011
Residents
in nursing
homes
25 weeks 19 9 10 Ta-
pering over
2 week
Risperi-
done
NRc Unpub-
lished
study
Bridges-
Parlet
1997
Residents
in long-
term care
facilities
1 month 36 22 14 Abrupt +
ta-
pering over
2 weeks
Typical AP
a
Physically
aggressive
partici-
pants iden-
tified by
nurse
supervisors
Cohen-
Mansfield
1999
Residents
in nursing
homes
7 weeks
followed
by 7 weeks
cross-over
58 29 29 Ta-
pering over
3 weeks
Typical AP
a +
lorazepam
NRc Cross-over
study
Devanand
2011
Residents
in the
commu-
nity
6 months
(primary
analysis)
12 months
20 10 10 Abrupt +
ta-
pering over
2 weeks
Haloperi-
dol
Current
symptoms
of psy-
chosis, ag-
itation or
aggression
Partici-
pants had a
response to
haloperi-
dol
open treat-
ment for
20 weeks
Devanand
2012
Residents
in the
commu-
nity and
nursing
homes
4 months
8 months
110 70 40 Abrupt +
ta-
pering over
2 week
Risperi-
done
NPIb score
higher
than 4 on
psychosis
or
agitation/
aggression
subscale
Partic-
ipants had
a response
to risperi-
done
open treat-
ment for
16 weeks
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Table 3. Characteristics of included studies (Continued)
Findlay
1989
Residents
in nursing
homes
1 month 36 18 18 Ta-
pering over
1 week
Thiori-
dazine
NRc
Ruths
2008
Residents
in nursing
homes
1 month 55 27 28 Abrupt Haloperi-
dol risperi-
done,
olanzapine
All partic-
ipants re-
gardless in-
dividual
symptoms
van
Reekum
2002
Residents
in nursing
homes
26 weeks 34 17 17 Ta-
pering over
2 weeks
Typical AP
a
Stable be-
haviour
a AP: antipsychotic drug.
b NPI: Neuropsychiatric Inventory.
c NR: not reported.
A P P E N D I C E S
Appendix 1. Initial search: 9 February 2009
Source Date range searched Hits retrieved
MEDLINE (PubMed) Up to 9 Feb 2009 108
Embase (Ovid SP) Up to 10 Feb 2009 37
PsycINFO (Ovid SP) Up to 10 Feb 2009 20
CINAHL (Ovid SP) Up to 11 Feb 2009 16
LILACS (Bireme) Up to 9 Feb 2009 0
CDCIG SR* Searched 9 Feb 2009 163
CENTRAL (Cochrane Library) Issue 1 2009 75
ISTP Conference Proceedings
portal.isiknowledge.com/portal.cgi
Up to 11 Feb 2009 105
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(Continued)
Australian Digital Theses Program
adt.caul.edu.au/
Searched 12 Feb 2009 0
Canadian Theses and Dissertations
www.collectionscanada.ca/thesescanada/
index-e.html
Searched 12 Feb 2009 0
WHO ICTRP Searched 11 Feb 2009 4
Current Controlled trials:
MetaRegister of Controlled trials (mRCT)
www.controlled-trials.com/
Searched 11 Feb 2009 1
ISRCTN Register Searched 12 Feb 2009 0
Nederlands Trial Register
www.trialregister.nl/trialreg/index.asp
Searched 12 Feb 2009 0
ClinicalTrials.gov www.ClinicalTrials.gov Included in WHO portal //
IPFMA Clinical Trials Register
www.ifpma.org/clinicaltrials.html
Searched 12 Feb 2009 0
UMIN Japan Trial Register
www.umin.ac.jp/ctr/
Searched 12 Feb 2009 0
OPENsigle Searched 12 Feb 2009 0
Appendix 2. Updated search: 11 March 2011
Source Search strategy Hits retrieved
1. ALOIS (www.medicine.ox.ac.uk/alois) Antipsychotic OR neuroleptic OR APSY 126
2. MEDLINE In-process and other non-
indexed citations and MEDLINE 1950 to
11 March 2011 (Ovid SP)
1. antipsychotic*.ti,ab.
2. ”anti-psychotic*“.ti,ab.
3. Antipsychotic Agents/
4. neuroleptic*.ti,ab.
5. phenothiazines.ti,ab.
6. Phenothiazines/
7. butyrophenones.ti,ab.
8. Butyrophenones/
9. risperidone.ti,ab.
10. Risperidone/
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(Continued)
11. Risperdal*.ti,ab.
12. olanzapine.ti,ab.
13. (Zyprexa* or Zalasta* or Zolafren* or
Olzapin* or Oferta* or Zypadhera*).ti,ab
14. haloperidol.ti,ab.
15. Haloperidol/
16. (Aloperidin* or Bioperidolo* or Broto-
pon* or Dozic* or Duraperidol*).ti,ab
17. prothipendyl.ti,ab.
18. methotrimeprazine.ti,ab.
19. Methotrimeprazine/
20. (Nosinan* or Nozinan* or Levo-
prome*).ti,ab.
21. clopenthixol.ti,ab.
22. Clopenthixol/
23. (Sordinol* or clopentixol).ti,ab.
24. flupenthixol.ti,ab.
25. Flupenthixol/
26. (flupentixol or depixol* or fluanxol*).
ti,ab.
27. clothiapine.ti,ab.
28. metylperon.ti,ab.
29. melperon.ti,ab.
30. droperidol.ti,ab.
31. Droperidol/
32. (Droleptan* or Dridol* or Inapsine* or
Xomolix*).ti,ab.
33. pipamperone.ti,ab.
34. Dipiperon*.ti,ab.
35. benperidol.ti,ab.
36. Benperidol/
37. Anquil*.ti,ab.
38. bromperidol.ti,ab.
39. Bromidol*.ti,ab.
40. fluspirilene.ti,ab.
41. Fluspirilene/
42. (Redeptin* or Imap*).ti,ab.
43. pimozide.ti,ab.
44. Pimozide/
45. orap*.ti,ab.
46. penfluridol.ti,ab.
47. Penfluridol/
48. (Semap* or Micefal*).ti,ab.
49. sulpiride.ti,ab.
50. Sulpiride/
51. veralipride.ti,ab.
52. (Agreal* or Agradil*).ti,ab.
53. levosulpiride.ti,ab.
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(Continued)
54. sultopride.ti,ab.
55. (Barnetil* or Barnotil* or Topral*).ti,
ab.
56. aripiprazole.ti,ab.
57. (Abilify* or Aripiprex*).ti,ab.
58. clozapine.ti,ab.
59. Clozapine/
60. (Clozaril* or Azaleptin* or Leponex*
or Fazaclo* or Froidir* or Denzapine* or
Zaponex* or Klozapol* or Clopine*).ti,ab
61. quetiapine.ti,ab.
62. (Seroquel* or Ketipinor*).ti,ab.
63. thioridazine.ti,ab.
64. Thioridazine/
65. (Mellaril* or Novoridazine* or Thio-
ril*).ti,ab.
66. or/1-65
67. exp Dementia/
68. Delirium/
69. Wernicke Encephalopathy/
70. Delirium, Dementia, Amnestic, Cog-
nitive Disorders/
71. dement*.mp.
72. alzheimer*.mp.
73. (lewy* adj2 bod*).mp.
74. deliri*.mp.
75. (chronic adj2 cerebrovascular).mp.
76. (”organic brain disease“ or ”organic
brain syndrome“).mp
77. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
78. ”benign senescent forgetfulness“.mp.
79. (cerebr* adj2 deteriorat*).mp.
80. (cerebral* adj2 insufficient*).mp.
81. (pick* adj2 disease).mp.
82. (creutzfeldt or jcd or cjd).mp.
83. huntington*.mp.
84. binswanger*.mp.
85. korsako*.mp.
86. or/67-85
87. 66 and 86
88. (discontinu* or withdraw* or cessat* or
reduce* or reducing or reduct* or taper* or
stop*).ti,ab
89. 87 and 88
90. randomized controlled trial.pt.
91. controlled clinical trial.pt.
92. randomized.ab.
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93. placebo.ab.
94. drug therapy.fs.
95. randomly.ab.
96. trial.ab.
97. groups.ab.
98. or/90-97
99. (animals not (humans and animals)).
sh.
100. 98 not 99
101. 89 and 100
102. (2009* or 2010* or 2011*).ed.
103. 101 and 102
3. Embase
1980 to 2011 week 12 (Ovid SP)
1. antipsychotic*.ti,ab.
2. ”anti-psychotic*“.ti,ab.
3. Antipsychotic Agents/
4. neuroleptic*.ti,ab.
5. phenothiazines.ti,ab.
6. Phenothiazines/
7. butyrophenones.ti,ab.
8. Butyrophenones/
9. risperidone.ti,ab.
10. Risperidone/
11. Risperdal*.ti,ab.
12. olanzapine.ti,ab.
13. (Zyprexa* or Zalasta* or Zolafren* or
Olzapin* or Oferta* or Zypadhera*).ti,ab
14. haloperidol.ti,ab.
15. Haloperidol/
16. (Aloperidin* or Bioperidolo* or Broto-
pon* or Dozic* or Duraperidol*).ti,ab
17. prothipendyl.ti,ab.
18. methotrimeprazine.ti,ab.
19. Methotrimeprazine/
20. (Nosinan* or Nozinan* or Levo-
prome*).ti,ab.
21. clopenthixol.ti,ab.
22. Clopenthixol/
23. (Sordinol* or clopentixol).ti,ab.
24. flupenthixol.ti,ab.
25. Flupenthixol/
26. (flupentixol or depixol* or fluanxol*).
ti,ab.
27. clothiapine.ti,ab.
28. metylperon.ti,ab.
29. melperon.ti,ab.
30. droperidol.ti,ab.
31. Droperidol/
32. (Droleptan* or Dridol* or Inapsine* or
178
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Xomolix*).ti,ab.
33. pipamperone.ti,ab.
34. Dipiperon*.ti,ab.
35. benperidol.ti,ab.
36. Benperidol/
37. Anquil*.ti,ab.
38. bromperidol.ti,ab.
39. Bromidol*.ti,ab.
40. fluspirilene.ti,ab.
41. Fluspirilene/
42. (Redeptin* or Imap*).ti,ab.
43. pimozide.ti,ab.
44. Pimozide/
45. orap*.ti,ab.
46. penfluridol.ti,ab.
47. Penfluridol/
48. (Semap* or Micefal*).ti,ab.
49. sulpiride.ti,ab.
50. Sulpiride/
51. veralipride.ti,ab.
52. (Agreal* or Agradil*).ti,ab.
53. levosulpiride.ti,ab.
54. sultopride.ti,ab.
55. (Barnetil* or Barnotil* or Topral*).ti,
ab.
56. aripiprazole.ti,ab.
57. (Abilify* or Aripiprex*).ti,ab.
58. clozapine.ti,ab.
59. Clozapine/
60. (Clozaril* or Azaleptin* or Leponex*
or Fazaclo* or Froidir* or Denzapine* or
Zaponex* or Klozapol* or Clopine*).ti,ab
61. quetiapine.ti,ab.
62. (Seroquel* or Ketipinor*).ti,ab.
63. thioridazine.ti,ab.
64. Thioridazine/
65. (Mellaril* or Novoridazine* or Thio-
ril*).ti,ab.
66. or/1-65
67. exp dementia/
68. Lewy body/
69. delirium/
70. Wernicke encephalopathy/
71. cognitive defect/
72. dement*.mp.
73. alzheimer*.mp.
74. (lewy* adj2 bod*).mp.
75. deliri*.mp.
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76. (chronic adj2 cerebrovascular).mp.
77. (”organic brain disease“ or ”organic
brain syndrome“).mp
78. ”supranuclear palsy“.mp.
79. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
80. ”benign senescent forgetfulness“.mp.
81. (cerebr* adj2 deteriorat*).mp.
82. (cerebral* adj2 insufficient*).mp.
83. (pick* adj2 disease).mp.
84. (creutzfeldt or jcd or cjd).mp.
85. huntington*.mp.
86. binswanger*.mp.
87. korsako*.mp.
88. CADASIL.mp.
89. or/67-88
90. 66 and 89
91. (discontinu* or withdraw* or cessat* or
reduce* or reducing or reduct* or taper* or
stop*).ti,ab
92. 90 and 91
93. randomized controlled trial/
94. randomi?ed.ab.
95. controlled clinical trial/
96. placebo.ab.
97. randomly.ab.
98. trial.ab.
99. groups.ab.
100. or/93-99
101. 92 and 100
102. (2009* or 2010* or 2011*).em.
103. 101 and 102
4. PsycINFO
1806 to March week 3 2011 (Ovid SP)
1. antipsychotic*.ti,ab.
2. ”anti-psychotic*“.ti,ab.
3. neuroleptic*.ti,ab.
4. phenothiazines.ti,ab.
5. butyrophenones.ti,ab.
6. risperidone.ti,ab.
7. Risperidone/
8. Risperdal*.ti,ab.
9. olanzapine.ti,ab.
10. (Zyprexa* or Zalasta* or Zolafren* or
Olzapin* or Oferta* or Zypadhera*).ti,ab
11. haloperidol.ti,ab.
12. Haloperidol/
13. (Aloperidin* or Bioperidolo* or Broto-
pon* or Dozic* or Duraperidol*).ti,ab
14. prothipendyl.ti,ab.
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15. methotrimeprazine.ti,ab.
16. (Nosinan* or Nozinan* or Levo-
prome*).ti,ab.
17. clopenthixol.ti,ab.
18. (Sordinol* or clopentixol).ti,ab.
19. flupenthixol.ti,ab.
20. (flupentixol or depixol* or fluanxol*).
ti,ab.
21. clothiapine.ti,ab.
22. droperidol.ti,ab.
23. (Droleptan* or Dridol* or Inapsine* or
Xomolix*).ti,ab.
24. pipamperone.ti,ab.
25. Dipiperon*.ti,ab.
26. benperidol.ti,ab.
27. bromperidol.ti,ab.
28. Bromidol*.ti,ab.
29. fluspirilene.ti,ab.
30. (Redeptin* or Imap*).ti,ab.
31. pimozide.ti,ab.
32. Pimozide/
33. orap*.ti,ab.
34. penfluridol.ti,ab.
35. (Semap* or Micefal*).ti,ab.
36. sulpiride.ti,ab.
37. Sulpiride/
38. veralipride.ti,ab.
39. levosulpiride.ti,ab.
40. sultopride.ti,ab.
41. (Barnetil* or Barnotil* or Topral*).ti,
ab.
42. aripiprazole.ti,ab.
43. (Abilify* or Aripiprex*).ti,ab.
44. clozapine.ti,ab.
45. Clozapine/
46. (Clozaril* or Azaleptin* or Leponex*
or Fazaclo* or Froidir* or Denzapine* or
Zaponex* or Klozapol* or Clopine*).ti,ab
47. quetiapine.ti,ab.
48. (Seroquel* or Ketipinor*).ti,ab.
49. thioridazine.ti,ab.
50. Thioridazine/
51. (Mellaril* or Novoridazine* or Thio-
ril*).ti,ab.
52. (discontinu* or withdraw* or cessat* or
reduce* or reducing or reduct* or taper* or
stop*).ti,ab
53. or/1-51
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54. 52 and 53
55. exp Dementia/
56. exp Delirium/
57. exp Huntingtons Disease/
58. exp Kluver Bucy Syndrome/
59. exp Wernickes Syndrome/
60. exp Cognitive Impairment/
61. dement*.mp.
62. alzheimer*.mp.
63. (lewy* adj2 bod*).mp.
64. deliri*.mp.
65. (chronic adj2 cerebrovascular).mp.
66. (”organic brain disease“ or ”organic
brain syndrome“).mp
67. ”supranuclear palsy“.mp.
68. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
69. ”benign senescent forgetfulness“.mp.
70. (cerebr* adj2 deteriorat*).mp.
71. (cerebral* adj2 insufficient*).mp.
72. (pick* adj2 disease).mp.
73. (creutzfeldt or jcd or cjd).mp.
74. huntington*.mp.
75. binswanger*.mp.
76. korsako*.mp.
77. (”parkinson* disease dementia“ or
PDD or ”parkinson* dementia“).mp
78. or/55-77
79. 54 and 78
80. (2009* or 2010* or 2011*).up.
81. 79 and 80
5. CINAHL (EBSCO host) S1 (MH ”Dementia+“)
S2 (MH ”Delirium“) or (MH ”Delir-
ium, Dementia, Amnestic, Cognitive Dis-
orders“)
S3 (MH ”Wernicke’s Encephalopathy“)
S4 TX dement*
S5 TX alzheimer*
S6 TX lewy* N2 bod*
S7 TX deliri*
S8 TX chronic N2 cerebrovascular
S9 TX ”organic brain disease“ or ”organic
brain syndrome“
S10 TX ”normal pressure hydrocephalus“
and ”shunt*“
S11 TX ”benign senescent forgetfulness“
S12 TX cerebr* N2 deteriorat*
S13 TX cerebral* N2 insufficient*
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S14 TX pick* N2 disease
S15 TX creutzfeldt or jcd or cjd
S16 TX huntington*
S17 TX binswanger*
S18 TX korsako*
S19 S1 or S2 or S3 or S4 or S5 or S6 or S7
or S8 or S9 or S10 or S11 or S12 or S13 or
S14 or S15 or S16 or S17 or S18
S20 TX ”cognit* impair*“
S21 TX ”cognit* defect*“
S22 (MH ”Cognition Disorders+“)
S23 TX MCI
S24 TX ACMI
S25 TX ARCD
S26 TX SMC
S27 TX CIND
S28 TX BSF
S29 TX AAMI
S30 AB MD
S31 AB LCD
S32 AB QD OR ”questionable dementia“
S33 TX AACD
S34 TX MNCD
S35 TX ”N-MCI“ or ”A-MCI“ or ”M-
MCI“
S36 TX ”preclinical AD“
S37 TX ”pre-clinical AD“
S38 TX ”preclinical alzheimer*“ or ”pre-
clinical alzheimer*“
S39 TX aMCI OR MCIa
S40 TX ”CDR 0.5“ or ”clinical dementia
rating scale 0.5“
S41 TX ”GDS 3“ OR ”stage 3 GDS“
S42 TX ”global deterioration scale“ AND
”stage 3“
S43 TX ”Benign senescent forgetfulness“
S44 TX ”mild neurocognit* disorder*“
S45 TX prodrom* N2 dement*
S46 TX ”age-related symptom*“
S47 TX cognit* N2 deficit*
S48 TX cognit* N2 deteriorat*
S49 TX cognit* N2 declin*
S50 TX cognit* N2 degenerat*
S51 TX cognit* N2 complain*
S52 TX cognit* N2 disturb*
S53 TX cognit* N2 disorder*
S54 TX memory N2 episod* or TX mem-
ory N2 los* or TX memory N2 impair* or
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TX memory N2 complain*
S55 TX memory N2 disturb* or TX mem-
oryN2disorder* or TX cerebr*N2 impair*
or TX cerebr* N2 los*
S56 TX cerebr* N2 complain* or TX
cerebr* N2 deteriorat* or TX cerebr* N2
disorder* or TX cerebr* N2 disturb*
S57TXmental*N2 declin* or TXmental*
N2 los* or TX mental* N2 impair* or TX
mental* N2 deteriorat*
S58 TX ”pre-clinical dementia“ or TX
”preclinical dementia“
S59 S20 or S21 or S22 or S23 or S24 or
S25 or S26 or S27 or S28 or S29 or S30 or
S31 or S32 or S33 or S34 or S35 or S36 or
S37 or S38 or S39 or S40 or S41 or S42 or
S43 or S44 or S45 or S46 or S47 or S48 or
S49 or S50 or S51 or S52 or S53 or S54 or
S55 or S56 or S57 or S58
S60 S19 or S59
6. ISIWeb of Knowledge - all databases (in-
cludes: Web of Science (1945 to present);
BIOSIS Previews (1926 to present);MED-
LINE (1950 to present); Journal Citation
Reports)
#1 Topic=(antipsychotic* OR neurolep-
tic* OR phenothiazines OR butyrophe-
nones OR risperidone OR olanzapine OR
haloperidol OR prothipendyl OR meth-
otrimeprazine OR clopenthixol OR flu-
penthixol)
#2 Topic=(clothiapine OR melperon OR
droperidol OR pipamperone OR benperi-
dol OR bromperidol OR fluspirilene OR
pimozide OR penfluridol OR sulpiride)
#3 Topic=(veralipride OR levosulpiride
OR sultopride OR aripiprazole OR cloza-
pine OR quetiapine OR thioridazine)
#4 Topic=(discontinu* or withdraw* or
cessat* or reduce* or reducing or reduct* or
taper* or stop*)
#5 #3 OR #2 OR #1
#6 #5 AND #4
#7 Topic=(dementia OR alzheimer* OR
”lew* bod*“ OR ”parkinson disease de-
mentia“ OR VAD OR PDD)
#8 #7 AND #6
#9 Topic=(randomly OR randomized OR
randomised OR placebo* OR trial OR
RCT)
#10 #9 AND #8
#11 Topic=(#10) AND Year Published=
(2009-2011)
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7. LILACS (Bireme) antipsychotic OR antipsychotics OR neu-
roleptic OR neuroleptics [Words] and
dementia OR demenc$ OR alzheimer$
[Words] and 2009 OR 2010 OR 2011
[Country, year publication]
17
8. CENTRAL (Cochrane Library) (Issue 1,
January 2011)
#1 ”anti-psychotic*“
#2 antipsychotic*:ti,ab
#3 MeSH descriptor Antipsychotic Agents
explode all trees
#4 neuroleptic*:ti,ab
#5 phenothiazines OR butyrophenones
OR risperidone OR Risperdal* OR olan-
zapine
#6 Zyprexa* OR Zalasta* OR Zolafren*
OROlzapin* OROferta* OR Zypadhera*
#7 haloperidol
#8 Aloperidin* OR Bioperidolo* OR Bro-
topon* OR Dozic* OR Duraperidol*
#9 prothipendyl OR methotrimeprazine
OR Nosinan* OR Nozinan* OR Levo-
prome*
#10 clopenthixol OR Sordinol* OR
clopentixol OR flupenthixol OR flupen-
tixol OR depixol* OR fluanxol*
#11 clothiapine OR metylperon OR
melperon OR droperidol OR Droleptan*
OR Dridol* OR Inapsine* OR Xomolix*
#12 pipamperone OR Dipiperon* OR
benperidol OR Anquil* OR bromperidol
OR Bromidol* OR fluspirilene OR Re-
deptin* OR Imap*
#13 pimozide OR orap* OR penfluridol
OR Semap* OR Micefal*
#14 sulpiride OR veralipride OR Agreal*
OR Agradil* OR levosulpiride OR sulto-
pride
#15 Barnetil* OR Barnotil* OR Topral*
#16 aripiprazole OR Abilify* OR Arip-
iprex*ORclozapineORClozaril*ORAza-
leptin* OR Leponex* OR Fazaclo* OR
Froidir* OR Denzapine* OR Zaponex*
OR Klozapol*
#17 quetiapine OR Seroquel* OR
Ketipinor*
#18 thioridazine OR Mellaril* OR
Novoridazine* OR Thioril*
#19 (#1 OR #2 OR #3 OR #4 OR #5 OR
46
79Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with
dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#6 OR #7 OR #8 OR #9 OR #10 OR #
11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18)
#20 Dement*
#21 Deliri*
#22 alzheimer*
#23 ”organic brain disease“ OR ”organic
brain syndrome“
#24 creutzfeldt OR jcd OR cjd
#25 huntington*
#26 binswanger*
#27 korsako*
#28 ”parkinson* disease dementia*“ OR
PDD
#29 ”lew* bod*“ OR DLB OR LDB OR
LBD
#30 MeSH descriptor Dementia explode
all trees
#31 (#20 OR #21 OR #22 OR #23 OR #
24 OR #25 OR #26 OR #27 OR #28 OR
#29 OR #30)
#32 (#19 AND #31), from 2009 to 2011
9. Clinicaltrials.gov (
www.clinicaltrials.gov)
Search 1: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewy OR DLB OR
AD OR LBD | antipsychotic OR neu-
roleptic OR risperidone OR olanzapine
OR haloperidol OR prothipendyl OR
clopenthixol | received from01/01/2009 to
03/31/2011
Search 2: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewy OR DLB OR
AD OR LBD | clothiapine OR droperi-
dol OR pipamperone OR benperidol OR
bromperidol OR fluspirilene OR pimozide
| received from 01/01/2009 to 03/31/2011
Search 3: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewyORDLBORAD
OR LBD | penfluridol OR sulpiride OR
veraliprideOR levosulpirideOR sultopride
9 + 0 + 2 = 11
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OR aripiprazole OR clozapine OR queti-
apine OR thioridazine | received from 01/
01/2009 to 03/31/2011
10. ICTRP Search Portal (apps.who.int/
trialsearch) (includes: Australian New
Zealand Clinical Trials Registry; Clinical-
Trials.gov; ISRCTN;Chinese Clinical Trial
Registry; Clinical Trials Registry - India;
Clinical Research Information Service - Re-
public of Korea; German Clinical Trials
Register; Iranian Registry of Clinical Tri-
als; Japan Primary Registries Network; Pan
African Clinical Trial Registry; Sri Lanka
Clinical Trials Registry; Netherlands Na-
tional Trial Register)
Search 1: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewy OR DLB OR
AD OR LBD | antipsychotic OR neu-
roleptic OR risperidone OR olanzapine
OR haloperidol OR prothipendyl OR
clopenthixol | received from01/01/2009 to
03/31/2011
Search 2: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewy OR DLB OR
AD OR LBD | clothiapine OR droperi-
dol OR pipamperone OR benperidol OR
bromperidol OR fluspirilene OR pimozide
| received from 01/01/2009 to 03/31/2011
Search 3: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewyORDLBORAD
OR LBD | penfluridol OR sulpiride OR
veraliprideOR levosulpirideOR sultopride
OR aripiprazole OR clozapine OR queti-
apine OR thioridazine | received from 01/
01/2009 to 03/31/2011
13
TOTAL before de-duplication 776
TOTAL after de-duplication and first-assess 70
Appendix 3. Top-up searches: June 2012, November 2012, March 2017, January 2018
Source Search strategy Hits retrieved
1. ALOIS (www.medicine.ox.ac.uk/alois)
[Date of most recent search: 10 January
2018]
Antipsychotic OR neuroleptic OR APSY Jun 2012: 58
Nov 2012: 1
Mar 2017: 0
Jan 2018: 0
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2. MEDLINE In-process and other non-
indexed citations and MEDLINE 1950-
present (Ovid SP)
[Date of most recent search: 10 January
2018]
1. antipsychotic*.ti,ab.
2. ”anti-psychotic*“.ti,ab.
3. Antipsychotic Agents/
4. neuroleptic*.ti,ab.
5. phenothiazines.ti,ab.
6. Phenothiazines/
7. butyrophenones.ti,ab.
8. Butyrophenones/
9. risperidone.ti,ab.
10. Risperidone/
11. Risperdal*.ti,ab.
12. olanzapine.ti,ab.
13. (Zyprexa* or Zalasta* or Zolafren* or
Olzapin* or Oferta* or Zypadhera*).ti,ab
14. haloperidol.ti,ab.
15. Haloperidol/
16. (Aloperidin* or Bioperidolo* or Broto-
pon* or Dozic* or Duraperidol*).ti,ab
17. prothipendyl.ti,ab.
18. methotrimeprazine.ti,ab.
19. Methotrimeprazine/
20. (Nosinan* or Nozinan* or Levo-
prome*).ti,ab.
21. clopenthixol.ti,ab.
22. Clopenthixol/
23. (Sordinol* or clopentixol).ti,ab.
24. flupenthixol.ti,ab.
25. Flupenthixol/
26. (flupentixol or depixol* or fluanxol*).
ti,ab.
27. clothiapine.ti,ab.
28. metylperon.ti,ab.
29. melperon.ti,ab.
30. droperidol.ti,ab.
31. Droperidol/
32. (Droleptan* or Dridol* or Inapsine* or
Xomolix*).ti,ab.
33. pipamperone.ti,ab.
34. Dipiperon*.ti,ab.
35. benperidol.ti,ab.
36. Benperidol/
37. Anquil*.ti,ab.
38. bromperidol.ti,ab.
39. Bromidol*.ti,ab.
40. fluspirilene.ti,ab.
41. Fluspirilene/
Jun 2012: 60
Nov 2012: 28 (plus suppl search hits)
Mar 2017: 284
Jan 2018: 63
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42. (Redeptin* or Imap*).ti,ab.
43. pimozide.ti,ab.
44. Pimozide/
45. orap*.ti,ab.
46. penfluridol.ti,ab.
47. Penfluridol/
48. (Semap* or Micefal*).ti,ab.
49. sulpiride.ti,ab.
50. Sulpiride/
51. veralipride.ti,ab.
52. (Agreal* or Agradil*).ti,ab.
53. levosulpiride.ti,ab.
54. sultopride.ti,ab.
55. (Barnetil* or Barnotil* or Topral*).ti,
ab.
56. aripiprazole.ti,ab.
57. (Abilify* or Aripiprex*).ti,ab.
58. clozapine.ti,ab.
59. Clozapine/
60. (Clozaril* or Azaleptin* or Leponex*
or Fazaclo* or Froidir* or Denzapine* or
Zaponex* or Klozapol* or Clopine*).ti,ab
61. quetiapine.ti,ab.
62. (Seroquel* or Ketipinor*).ti,ab.
63. thioridazine.ti,ab.
64. Thioridazine/
65. (Mellaril* or Novoridazine* or Thio-
ril*).ti,ab.
66. or/1-65
67. exp Dementia/
68. Delirium/
69. Wernicke Encephalopathy/
70. Delirium, Dementia, Amnestic, Cog-
nitive Disorders/
71. dement*.mp.
72. alzheimer*.mp.
73. (lewy* adj2 bod*).mp.
74. deliri*.mp.
75. (chronic adj2 cerebrovascular).mp.
76. (”organic brain disease“ or ”organic
brain syndrome“).mp
77. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
78. ”benign senescent forgetfulness“.mp.
79. (cerebr* adj2 deteriorat*).mp.
80. (cerebral* adj2 insufficient*).mp.
81. (pick* adj2 disease).mp.
82. (creutzfeldt or jcd or cjd).mp.
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83. huntington*.mp.
84. binswanger*.mp.
85. korsako*.mp.
86. or/67-85
87. 66 and 86
88. (discontinu* or withdraw* or cessat* or
reduce* or reducing or reduct* or taper* or
stop*).ti,ab
89. 87 and 88
90. randomized controlled trial.pt.
91. controlled clinical trial.pt.
92. randomized.ab.
93. placebo.ab.
94. drug therapy.fs.
95. randomly.ab.
96. trial.ab.
97. groups.ab.
98. or/90-97
99. (animals not (humans and animals)).
sh.
100. 98 not 99
101. 89 and 100
102. (2011* or 2012*).ed.
103. 101 and 102
3. Embase
1980 to 2018 January 09 (Ovid SP)
[Date of most recent search: 10 January
2018]
1. antipsychotic*.ti,ab.
2. ”anti-psychotic*“.ti,ab.
3. Antipsychotic Agents/
4. neuroleptic*.ti,ab.
5. phenothiazines.ti,ab.
6. Phenothiazines/
7. butyrophenones.ti,ab.
8. Butyrophenones/
9. risperidone.ti,ab.
10. Risperidone/
11. Risperdal*.ti,ab.
12. olanzapine.ti,ab.
13. (Zyprexa* or Zalasta* or Zolafren* or
Olzapin* or Oferta* or Zypadhera*).ti,ab
14. haloperidol.ti,ab.
15. Haloperidol/
16. (Aloperidin* or Bioperidolo* or Broto-
pon* or Dozic* or Duraperidol*).ti,ab
17. prothipendyl.ti,ab.
18. methotrimeprazine.ti,ab.
19. Methotrimeprazine/
20. (Nosinan* or Nozinan* or Levo-
prome*).ti,ab.
21. clopenthixol.ti,ab.
Jun 2012: 109
Nov 2012: 35 (plus suppl search hits)
Mar 2017: 533
Jan 2018: 133
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22. Clopenthixol/
23. (Sordinol* or clopentixol).ti,ab.
24. flupenthixol.ti,ab.
25. Flupenthixol/
26. (flupentixol or depixol* or fluanxol*).
ti,ab.
27. clothiapine.ti,ab.
28. metylperon.ti,ab.
29. melperon.ti,ab.
30. droperidol.ti,ab.
31. Droperidol/
32. (Droleptan* or Dridol* or Inapsine* or
Xomolix*).ti,ab.
33. pipamperone.ti,ab.
34. Dipiperon*.ti,ab.
35. benperidol.ti,ab.
36. Benperidol/
37. Anquil*.ti,ab.
38. bromperidol.ti,ab.
39. Bromidol*.ti,ab.
40. fluspirilene.ti,ab.
41. Fluspirilene/
42. (Redeptin* or Imap*).ti,ab.
43. pimozide.ti,ab.
44. Pimozide/
45. orap*.ti,ab.
46. penfluridol.ti,ab.
47. Penfluridol/
48. (Semap* or Micefal*).ti,ab.
49. sulpiride.ti,ab.
50. Sulpiride/
51. veralipride.ti,ab.
52. (Agreal* or Agradil*).ti,ab.
53. levosulpiride.ti,ab.
54. sultopride.ti,ab.
55. (Barnetil* or Barnotil* or Topral*).ti,
ab.
56. aripiprazole.ti,ab.
57. (Abilify* or Aripiprex*).ti,ab.
58. clozapine.ti,ab.
59. Clozapine/
60. (Clozaril* or Azaleptin* or Leponex*
or Fazaclo* or Froidir* or Denzapine* or
Zaponex* or Klozapol* or Clopine*).ti,ab
61. quetiapine.ti,ab.
62. (Seroquel* or Ketipinor*).ti,ab.
63. thioridazine.ti,ab.
64. Thioridazine/
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65. (Mellaril* or Novoridazine* or Thio-
ril*).ti,ab.
66. or/1-65
67. exp dementia/
68. Lewy body/
69. delirium/
70. Wernicke encephalopathy/
71. cognitive defect/
72. dement*.mp.
73. alzheimer*.mp.
74. (lewy* adj2 bod*).mp.
75. deliri*.mp.
76. (chronic adj2 cerebrovascular).mp.
77. (”organic brain disease“ or ”organic
brain syndrome“).mp
78. ”supranuclear palsy“.mp.
79. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
80. ”benign senescent forgetfulness“.mp.
81. (cerebr* adj2 deteriorat*).mp.
82. (cerebral* adj2 insufficient*).mp.
83. (pick* adj2 disease).mp.
84. (creutzfeldt or jcd or cjd).mp.
85. huntington*.mp.
86. binswanger*.mp.
87. korsako*.mp.
88. CADASIL.mp.
89. or/67-88
90. 66 and 89
91. (discontinu* or withdraw* or cessat* or
reduce* or reducing or reduct* or taper* or
stop*).ti,ab
92. 90 and 91
93. randomized controlled trial/
94. randomi?ed.ab.
95. controlled clinical trial/
96. placebo.ab.
97. randomly.ab.
98. trial.ab.
99. groups.ab.
100. or/93-99
101. 92 and 100
102. (2011* or 2012*).em.
103. 101 and 102
4. PsycINFO
1806 to January week 1 2018 (Ovid SP)
[Date of most recent search: 10 January
2018]
1. antipsychotic*.ti,ab.
2. ”anti-psychotic*“.ti,ab.
3. neuroleptic*.ti,ab.
4. phenothiazines.ti,ab.
5. butyrophenones.ti,ab.
Jun 2012: 70
Nov 2012: 58 (plus suppl search hits)
Mar 2017: 281
Jan 2018: 73
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6. risperidone.ti,ab.
7. Risperidone/
8. Risperdal*.ti,ab.
9. olanzapine.ti,ab.
10. (Zyprexa* or Zalasta* or Zolafren* or
Olzapin* or Oferta* or Zypadhera*).ti,ab
11. haloperidol.ti,ab.
12. Haloperidol/
13. (Aloperidin* or Bioperidolo* or Broto-
pon* or Dozic* or Duraperidol*).ti,ab
14. prothipendyl.ti,ab.
15. methotrimeprazine.ti,ab.
16. (Nosinan* or Nozinan* or Levo-
prome*).ti,ab.
17. clopenthixol.ti,ab.
18. (Sordinol* or clopentixol).ti,ab.
19. flupenthixol.ti,ab.
20. (flupentixol or depixol* or fluanxol*).
ti,ab.
21. clothiapine.ti,ab.
22. droperidol.ti,ab.
23. (Droleptan* or Dridol* or Inapsine* or
Xomolix*).ti,ab.
24. pipamperone.ti,ab.
25. Dipiperon*.ti,ab.
26. benperidol.ti,ab.
27. bromperidol.ti,ab.
28. Bromidol*.ti,ab.
29. fluspirilene.ti,ab.
30. (Redeptin* or Imap*).ti,ab.
31. pimozide.ti,ab.
32. Pimozide/
33. orap*.ti,ab.
34. penfluridol.ti,ab.
35. (Semap* or Micefal*).ti,ab.
36. sulpiride.ti,ab.
37. Sulpiride/
38. veralipride.ti,ab.
39. levosulpiride.ti,ab.
40. sultopride.ti,ab.
41. (Barnetil* or Barnotil* or Topral*).ti,
ab.
42. aripiprazole.ti,ab.
43. (Abilify* or Aripiprex*).ti,ab.
44. clozapine.ti,ab.
45. Clozapine/
46. (Clozaril* or Azaleptin* or Leponex*
or Fazaclo* or Froidir* or Denzapine* or
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Zaponex* or Klozapol* or Clopine*).ti,ab
47. quetiapine.ti,ab.
48. (Seroquel* or Ketipinor*).ti,ab.
49. thioridazine.ti,ab.
50. Thioridazine/
51. (Mellaril* or Novoridazine* or Thio-
ril*).ti,ab.
52. (discontinu* or withdraw* or cessat* or
reduce* or reducing or reduct* or taper* or
stop*).ti,ab
53. or/1-51
54. 52 and 53
55. exp Dementia/
56. exp Delirium/
57. exp Huntingtons Disease/
58. exp Kluver Bucy Syndrome/
59. exp Wernickes Syndrome/
60. exp Cognitive Impairment/
61. dement*.mp.
62. alzheimer*.mp.
63. (lewy* adj2 bod*).mp.
64. deliri*.mp.
65. (chronic adj2 cerebrovascular).mp.
66. (”organic brain disease“ or ”organic
brain syndrome“).mp
67. ”supranuclear palsy“.mp.
68. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
69. ”benign senescent forgetfulness“.mp.
70. (cerebr* adj2 deteriorat*).mp.
71. (cerebral* adj2 insufficient*).mp.
72. (pick* adj2 disease).mp.
73. (creutzfeldt or jcd or cjd).mp.
74. huntington*.mp.
75. binswanger*.mp.
76. korsako*.mp.
77. (”parkinson* disease dementia“ or
PDD or ”parkinson* dementia“).mp
78. or/55-77
79. 54 and 78
80. (2011* or 2012*).up.
81. 79 and 80
5. CINAHL (EBSCO host)
[Date of most recent search: 10 January
2018]
S1 (MH ”Dementia+“)
S2 (MH ”Delirium“) or (MH ”Delir-
ium, Dementia, Amnestic, Cognitive Dis-
orders“)
S3 (MH ”Wernicke’s Encephalopathy“)
S4 TX dement*
S5 TX alzheimer*
Jun 2012: 71
Nov 2012: 51 (plus suppl search hits)
Mar 2017: 26
Jan 2018: 8
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S6 TX lewy* N2 bod*
S7 TX deliri*
S8 TX chronic N2 cerebrovascular
S9 TX ”organic brain disease“ or ”organic
brain syndrome“
S10 TX ”normal pressure hydrocephalus“
and ”shunt*“
S11 TX ”benign senescent forgetfulness“
S12 TX cerebr* N2 deteriorat*
S13 TX cerebral* N2 insufficient*
S14 TX pick* N2 disease
S15 TX creutzfeldt or jcd or cjd
S16 TX huntington*
S17 TX binswanger*
S18 TX korsako*
S19 S1 or S2 or S3 or S4 or S5 or S6 or S7
or S8 or S9 or S10 or S11 or S12 or S13 or
S14 or S15 or S16 or S17 or S18
S20 TX ”cognit* impair*“
S21 TX ”cognit* defect*“
S22 (MH ”Cognition Disorders+“)
S23 TX MCI
S24 TX ACMI
S25 TX ARCD
S26 TX SMC
S27 TX CIND
S28 TX BSF
S29 TX AAMI
S30 AB MD
S31 AB LCD
S32 AB QD OR ”questionable dementia“
S33 TX AACD
S34 TX MNCD
S35 TX ”N-MCI“ or ”A-MCI“ or ”M-
MCI“
S36 TX ”preclinical AD“
S37 TX ”pre-clinical AD“
S38 TX ”preclinical alzheimer*“ or ”pre-
clinical alzheimer*“
S39 TX aMCI OR MCIa
S40 TX ”CDR 0.5“ or ”clinical dementia
rating scale 0.5“
S41 TX ”GDS 3“ OR ”stage 3 GDS“
S42 TX ”global deterioration scale“ AND
”stage 3“
S43 TX ”Benign senescent forgetfulness“
S44 TX ”mild neurocognit* disorder*“
S45 TX prodrom* N2 dement*
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S46 TX ”age-related symptom*“
S47 TX cognit* N2 deficit*
S48 TX cognit* N2 deteriorat*
S49 TX cognit* N2 declin*
S50 TX cognit* N2 degenerat*
S51 TX cognit* N2 complain*
S52 TX cognit* N2 disturb*
S53 TX cognit* N2 disorder*
S54 TX memory N2 episod* or TX mem-
ory N2 los* or TX memory N2 impair* or
TX memory N2 complain*
S55 TX memory N2 disturb* or TX mem-
oryN2disorder* or TX cerebr*N2 impair*
or TX cerebr* N2 los*
S56 TX cerebr* N2 complain* or TX
cerebr* N2 deteriorat* or TX cerebr* N2
disorder* or TX cerebr* N2 disturb*
S57TXmental*N2 declin* or TXmental*
N2 los* or TX mental* N2 impair* or TX
mental* N2 deteriorat*
S58 TX ”pre-clinical dementia“ or TX
”preclinical dementia“
S59 S20 or S21 or S22 or S23 or S24 or
S25 or S26 or S27 or S28 or S29 or S30 or
S31 or S32 or S33 or S34 or S35 or S36 or
S37 or S38 or S39 or S40 or S41 or S42 or
S43 or S44 or S45 or S46 or S47 or S48 or
S49 or S50 or S51 or S52 or S53 or S54 or
S55 or S56 or S57 or S58
S60 S19 or S59
S61 EM 2011
S62 EM 2012
S63 S61 OR S62
S64 S60 AND S63
6. ISIWeb of Knowledge - all databases (in-
cludes: Web of Science (1945 to present);
BIOSIS Previews (1926 to present);MED-
LINE (1950 to present); Journal Citation
Reports)
[Date of most recent search: 10 January
2018]
#1 Topic=(antipsychotic* OR neurolep-
tic* OR phenothiazines OR butyrophe-
nones OR risperidone OR olanzapine OR
haloperidol OR prothipendyl OR meth-
otrimeprazine OR clopenthixol OR flu-
penthixol)
#2 Topic=(clothiapine OR melperon OR
droperidol OR pipamperone OR benperi-
dol OR bromperidol OR fluspirilene OR
pimozide OR penfluridol OR sulpiride)
#3 Topic=(veralipride OR levosulpiride
OR sultopride OR aripiprazole OR cloza-
pine OR quetiapine OR thioridazine)
#4 Topic=(discontinu* or withdraw* or
Jun 2012: 56
Nov 2012: 260 (plus suppl search hits)
Mar 2017: 290
Jan 2018: 48
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cessat* or reduce* or reducing or reduct* or
taper* or stop*)
#5 #3 OR #2 OR #1
#6 #5 AND #4
#7 Topic=(dementia OR alzheimer* OR
”lew* bod*“ OR ”parkinson disease de-
mentia“ OR VAD OR PDD)
#8 #7 AND #6
#9 Topic=(randomly OR randomized OR
randomised OR placebo* OR trial OR
RCT)
#10 #9 AND #8
7. LILACS (Bireme)
[Date of most recent search: 10 January
2018]
antipsychotic OR antipsychotics OR neu-
roleptic OR neuroleptics [Words] and
dementia OR demenc$ OR alzheimer$
[Words]
Jun 2012: 6
Nov 2012: 1
Mar 2017: 0
Jan 2018: 0
8. CENTRAL (Cochrane Library) (Issue 1,
2018)
[Date of most recent search: 10 January
2018]
#1 ”anti-psychotic*“
#2 antipsychotic*:ti,ab
#3 MeSH descriptor Antipsychotic Agents
explode all trees
#4 neuroleptic*:ti,ab
#5 phenothiazines OR butyrophenones
OR risperidone OR Risperdal* OR olan-
zapine
#6 Zyprexa* OR Zalasta* OR Zolafren*
OROlzapin* OROferta* OR Zypadhera*
#7 haloperidol
#8 Aloperidin* OR Bioperidolo* OR Bro-
topon* OR Dozic* OR Duraperidol*
#9 prothipendyl OR methotrimeprazine
OR Nosinan* OR Nozinan* OR Levo-
prome*
#10 clopenthixol OR Sordinol* OR
clopentixol OR flupenthixol OR flupen-
tixol OR depixol* OR fluanxol*
#11 clothiapine OR metylperon OR
melperon OR droperidol OR Droleptan*
OR Dridol* OR Inapsine* OR Xomolix*
#12 pipamperone OR Dipiperon* OR
benperidol OR Anquil* OR bromperidol
OR Bromidol* OR fluspirilene OR Re-
deptin* OR Imap*
#13 pimozide OR orap* OR penfluridol
OR Semap* OR Micefal*
#14 sulpiride OR veralipride OR Agreal*
OR Agradil* OR levosulpiride OR sulto-
pride
Jun 2012: 13
Nov 2012: 2 (plus suppl search hits)
Mar 2017: 105
Jan 2018: 96
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#15 Barnetil* OR Barnotil* OR Topral*
#16 aripiprazole OR Abilify* OR Arip-
iprex*ORclozapineORClozaril*ORAza-
leptin* OR Leponex* OR Fazaclo* OR
Froidir* OR Denzapine* OR Zaponex*
OR Klozapol*
#17 quetiapine OR Seroquel* OR
Ketipinor*
#18 thioridazine OR Mellaril* OR
Novoridazine* OR Thioril*
#19 (#1 OR #2 OR #3 OR #4 OR #5 OR
#6 OR #7 OR #8 OR #9 OR #10 OR #
11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18)
#20 Dement*
#21 Deliri*
#22 alzheimer*
#23 ”organic brain disease“ OR ”organic
brain syndrome“
#24 creutzfeldt OR jcd OR cjd
#25 huntington*
#26 binswanger*
#27 korsako*
#28 ”parkinson* disease dementia*“ OR
PDD
#29 ”lew* bod*“ OR DLB OR LDB OR
LBD
#30 MeSH descriptor Dementia explode
all trees
#31 (#20 OR #21 OR #22 OR #23 OR #
24 OR #25 OR #26 OR #27 OR #28 OR
#29 OR #30)
#32 (#19 AND #31)
9. Clinicaltrials.gov (
www.clinicaltrials.gov)
[Date of most recent search: 10 January
2018]
Search 1: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewy OR DLB OR
AD OR LBD | antipsychotic OR neu-
roleptic OR risperidone OR olanzapine
OR haloperidol OR prothipendyl OR
clopenthixol
Search 2: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewy OR DLB OR
AD OR LBD | clothiapine OR droperi-
Jun 2012: 2 + 0 + 2 = 4
Nov 2012: 0 (plus suppl search hits)
Mar 2017: 1
Jan 2018: 0
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dol OR pipamperone OR benperidol OR
bromperidol OR fluspirilene OR pimozide
Search 3: Advanced search: discontinueOR
withdraw OR cessation OR reduce or re-
ducing OR reduction OR taper OR stop
| dementia OR alzheimer OR alzheimers
OR alzheimer’s OR lewyORDLBORAD
OR LBD | penfluridol OR sulpiride OR
veraliprideOR levosulpirideOR sultopride
OR aripiprazole OR clozapine OR queti-
apine OR thioridazine
10. ICTRP Search Portal (apps.who.int/
trialsearch) (includes: Australian New
Zealand Clinical Trials Registry; Clinical-
Trilas.gov; ISRCTN;Chinese Clinical Trial
Registry; Clinical Trials Registry - India;
Clinical Research Information Service - Re-
public of Korea; German Clinical Trials
Register; Iranian Registry of Clinical Tri-
als; Japan Primary Registries Network; Pan
African Clinical Trial Registry; Sri Lanka
Clinical Trials Registry; Netherlands Na-
tional Trial Register)
[Date of most recent search: 10 January
2018]
Search 1: Advanced search: dementia OR
alzheimer OR alzheimers OR alzheimer’s
OR lewy OR DLB OR AD OR LBD |
antipsychotic OR neuroleptic OR risperi-
done OR olanzapine OR haloperidol OR
prothipendyl OR clopenthixol
Search 2: Advanced search: dementia OR
alzheimer OR alzhimers OR alzheimer’s
OR lewy OR DLB OR AD OR LBD |
clothiapine OR droperidol OR pipamper-
one OR benperidol OR bromperidol OR
fluspirilene OR pimozide
Search 3: Advanced search: dementia OR
alzheimer OR alzheimers OR alzheimer’s
OR lewy OR DLB OR AD OR LBD |
penfluridol OR sulpiride OR veralipride
OR levosulpiride OR sultopride OR arip-
iprazole OR clozapine OR quetiapine OR
thioridazine
Jun 2012: 7 + 1 + 4 = 13
Nov 2012: 0 (plus suppl search hits)
Mar 2017: 20
Jan 2018: 3
TOTAL before de-duplication and first-assessment Jun 2012: 454
Nov 2012: 436 (plusNov suppl search hits)
Mar 2017: 1540
Jan 2018: 424
TOTAL after de-duplication and first-assessment by CDCIG Information specialists
based on tiles and abstarcts
Jun 2012: 11
Nov 2012: 20
Mar 2017: 75
Jan 2018: 26
Supplementary search of additional antipsychotics not covered in previous searches (all dates)
MEDLINE In-process and other non-in-
dexed citations and MEDLINE 1950 to
present (Ovid SP)
1. exp Dementia/
2. Delirium/
3. Wernicke Encephalopathy/
4. Delirium, Dementia, Amnestic, Cogni-
tive Disorders/
194
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5. dement*.mp.
6. alzheimer*.mp.
7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. (”organic brain disease“ or ”organic
brain syndrome“).mp
11. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
12. ”benign senescent forgetfulness“.mp.
13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.
16. (creutzfeldt or jcd or cjd).mp.
17. huntington*.mp.
18. binswanger*.mp.
19. korsako*.mp.
20. or/1-19
21. amisulpiride.ti,ab.
22. Chlorpromazine/
23. chlorpromazine.ti,ab.
24. Promazine/
25. promazine.ti,ab.
26. Trifluoperazine/
27. trifluoperazine.ti,ab.
28. Prochlorperazine/
29. prochlorperazine.ti,ab.
30. or/21-29
31. 20 and 30
32. randomized controlled trial.pt.
33. controlled clinical trial.pt.
34. randomized.ab.
35. placebo.ab.
36. drug therapy.fs.
37. randomly.ab.
38. trial.ab.
39. groups.ab.
40. or/32-39
41. 31 and 40
Embase
1980 to 2012 August 03 (Ovid SP)
1. exp dementia/
2. Lewy body/
3. delirium/
4. Wernicke encephalopathy/
5. cognitive defect/
6. dement*.mp.
7. alzheimer*.mp.
8. (lewy* adj2 bod*).mp.
9. deliri*.mp.
425
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10. (chronic adj2 cerebrovascular).mp.
11. (”organic brain disease“ or ”organic
brain syndrome“).mp
12. ”supranuclear palsy“.mp.
13. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
14. ”benign senescent forgetfulness“.mp.
15. (cerebr* adj2 deteriorat*).mp.
16. (cerebral* adj2 insufficient*).mp.
17. (pick* adj2 disease).mp.
18. (creutzfeldt or jcd or cjd).mp.
19. huntington*.mp.
20. binswanger*.mp.
21. korsako*.mp.
22. CADASIL.mp.
23. or/1-22
24. amisulpride/
25. amisulpiride.ti,ab.
26. chlorpromazine/
27. Chlorpromazine.ti,ab.
28. promazine/
29. promazine.ti,ab.
30. trifluoperazine/
31. trifluoperazine.ti,ab.
32. prochlorperazine/
33. prochlorperazine.ti,ab.
34. or/24-33
35. 23 and 34
36. randomized controlled trial/
37. controlled clinical trial/
38. randomi?ed.ab.
39. placebo.ab.
40. randomly.ab.
41. trial.ab.
42. groups.ab.
43. (”double-blind*“ or ”single-blind*“).ti,
ab.
44. or/36-43
45. 35 and 44
PsycINFO
1806 to July week 5 2012 (Ovid SP)
1. exp Dementia/
2. exp Delirium/
3. exp Huntingtons Disease/
4. exp Kluver Bucy Syndrome/
5. exp Wernickes Syndrome/
6. exp Cognitive Impairment/
7. dement*.mp.
8. alzheimer*.mp.
9. (lewy* adj2 bod*).mp.
27
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10. deliri*.mp.
11. (chronic adj2 cerebrovascular).mp.
12. (”organic brain disease“ or ”organic
brain syndrome“).mp
13. ”supranuclear palsy“.mp.
14. (”normal pressure hydrocephalus“ and
”shunt*“).mp.
15. ”benign senescent forgetfulness“.mp.
16. (cerebr* adj2 deteriorat*).mp.
17. (cerebral* adj2 insufficient*).mp.
18. (pick* adj2 disease).mp.
19. (creutzfeldt or jcd or cjd).mp.
20. huntington*.mp.
21. binswanger*.mp.
22. korsako*.mp.
23. (”parkinson* disease dementia“ or
PDD or ”parkinson* dementia“).mp
24. or/1-23
25. amisulpiride.ti,ab.
26. Chlorpromazine/
27. chlorpromazine.ti,ab.
28. Promazine/
29. promazine.ti,ab.
30. Trifluoperazine/
31. trifluoperazine.ti,ab.
32. Prochlorperazine/
33. prochlorperazine.ti,ab.
34. or/25-33
35. 24 and 34
36. randomized.ab.
37. placebo.ab.
38. randomly.ab.
39. trial.ab.
40. groups.ab.
41. ”control group“.ab.
42. (”double-blind*“ or ”single-blind*“).ti,
ab.
43. exp Clinical Trials/
44. or/36-43
45. 35 and 44
Total for supplementary searches 646
Total for pre-publication and supplementary search 1100
Total post first assess and de-duplication 33
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Appendix 4. Abbreviations
ADAS Alzheimer’s Disease Assessment Scale (ADAS)
AIMS Abnormal Involuntary Movement Scale
BADLS Bristol Activities of Daily Living Scale
BCRS Brief Cognitive Rating Scale
BDS Blessed Dementia Scale
BEHAVE-AD Behavioural Pathology in Alzheimer’s disease Rating Scale
BFAS Blessed Functional Activity Scale
BPRS Brief Psychiatric Rating Scale
CAS Cognitive Assessment Scale
CDR Clinical Dementia Rating Scale
CERAD Consortium to Establish a Registry for Alzheimer’s Disease
CGI-C Clinical Global Impression-Change
CMAI Cohen-Mansfield Agitation inventory
CUSPAD Columbia University Scale for Psychopathology in Alzheimer’s Disease
DCM Dementia Care Mapping
DSM-III Diagnostic and Statistical Manual of Mental Disorders, 3th Edition
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
ESRS Extrapyramidal Symptom Rating Scale
FAS F-A-S scale, assessing phonemic verbal fluency
FAST Functional Assessment Staging
FDA Food and Drug Administration
ICD-9 International Statistical Classification of Diseases and Related Health Problems, Ninth Revision
ICD-10 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision
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LPRS London Psychogeriatric Rating Scale Score
MDRS Mattis Dementia Rating Scale
mITT modified intention-to-treat
MMSE Mini-Mental State Examination
M-UPDRS Modified Unified Parkinson’s Disease Rating Scale
NINCDS-ADRDA National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association
NPI Neuropsychiatric Inventory Score
NPS Neuropsychiatric symptoms
PAB Physical Aggressive Behaviour
PSMS Physical Self-Maintenance Scale
QoL Quality of life
ROAS Retrospective Overt Aggression scale
RTD Rockland Tardive Dyskinesia
SCAGS Sandoz Clinical Assessment Geriatric Scale
SIB Severe Impairment Battery
SMMSE Standardised Mini-Mental State Examination
STALD Sheffield Test for Acquired Language Disorder = STALD receptive and STALD expressive skill
TESS Treatment Emergent Symptom Scale
UPDRS Unified Parkinson’s Disease Rating Scale
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WH A T ’ S N E W
Last assessed as up-to-date: 10 January 2018.
Date Event Description
11 January 2018 New citation required but conclusions have not changed One new study was added. Background and methods
were updated in line with MECIR standards, GRADE
assessment incorporated. Conclusions unchanged. New
lead author
10 January 2018 New search has been performed Top up searches were performed for this review on 3
March 2017 and 11 January 2018. One new study was
identified for inclusion in the review
H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 3, 2013
Date Event Description
28 March 2013 Amended Text errors and author affiliations corrected
C O N T R I B U T I O N S O F A U T H O R S
2018 update
EVL: lead author for the review; searched for and selected trials, obtained copies of trial reports and correspondence, ’risk of bias’ table,
entry of data into RevMan and into GRADEpro, did grading, interpretation of data analyses and drafting review.
MP: selection of included studies and interpretation of data analyses, contributed to the text.
MVD: selection of included studies, interpretation of data analyses, grading and ’risk of bias’ table, contributed to the text and text
editing.
ADS: interpretation data analyses and grading, contributed to the text.
RVDS: interpretation of data analyses, contributed to the text.
TD: performed previous work that was used in the current review: obtaining copies of trial reports, extraction of data and interpretation
of data analyses. Contributed to the text.
TC: arbiter in the selection of trials, interpretation of data analyses and grading, contributed to the text.
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D E C L A R A T I O N S O F I N T E R E S T
Ellen Van Leeuwen: none known
Mirko Petrovic: none known
Mieke L van Driel: none known
An IM De Sutter: none known
Robert Vander Stichele: none known
Tom Declercq: none known
Thierry Christiaens: none known
S O U R C E S O F S U P P O R T
Internal sources
• No internal financial support received for this review, Other.
External sources
• No external funding support received for this review, Other.
• NIHR, UK.
This update was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the
Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Changes between the 2009 protocol and the 2013 review
Of the nine included studies, only Ruths 2008 established the dementia diagnosis according to DSM-IV or ICD-10. Findlay 1989
used ICD-9 criteria. Devanand 2011 and Devanand 2012 used the clinical diagnoses of dementia by DSM-IV criteria and probable
Alzheimer’s disease by NINCDS/ADRDA criteria. All other studies included older participants with dementia diagnosed in another
way: Ballard 2008 and Ballard 2004 used new NINCDS/ADRDA criteria for possible or probable Alzheimer’s disease, van Reekum
2002 and Bridges-Parlet 1997 included participants with dementia without any specification (diagnostic criteria unclear). The author
of Cohen-Mansfield 1999 stated in her email (Declerck 2009a [pers comm]) that ”she was quite sure all participants had dementia“.
All studies included, since they all studied participants with dementia. Devanand 2011 and Devanand 2012 included participants aged
50 to 95 years. The Ballard 2008 and Devanand 2012 trials did not report schizophrenia in the exclusion criteria, therefore it may be
possible that some participants with dementia and schizophrenia are included in these trials.
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Changes between the 2009 protocol and this update
Ellen Van Leeuwen joined the review author team in 2017.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [adverse effects; ∗therapeutic use]; Dementia [∗psychology]; Mental Disorders [∗drug therapy]; Psychomotor
Agitation [∗drug therapy]; Randomized Controlled Trials as Topic; Recurrence
MeSH check words
Aged; Humans
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